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Summary 
Antibodies represent an indispensable part of the human immune defense against various 
diseases. They are either generated by the immune system upon acute infection or active 
vaccination, or are applied as passive vaccine or targeted therapeutic. In the immune defense 
against malaria, antibodies either directly inhibit invasion of the parasite into its host cells, or 
recruit immune effector cells, e. g. monocytes or polymorphonuclear neutrophils (PMNs). 
In malaria research, the stimulation of PMNs is determined in antibody-dependent 
respiratory burst (ADRB) assays, mostly using solid-phase immobilized antigens (sADRB) 
instead of merozoites (mADRB). In this thesis, the corresponding neutrophilic ADRB 
responses in these two assays were functionally dissected, resulting in distinct dependencies 
on Fcγ-receptors (FcγRs) and cellular localizations of the generated reactive oxygen species 
(ROS). Conclusively, the assay setup must be chosen carefully to meet the final application. 
In case of P. falciparum merozoites, the mADRB assay represents the situation in the blood 
circulation the closest and should therefore be applied in further studies instead of the 
commonly used sADRB assay. 
Next, A strategy was set up to efficiently screen new isolated antibodies for their 
antimalarial functionality, focusing on direct growth inhibition and PMN stimulation. Two 
isotypes (IgG1, IgA2m(2)) of a known antibody were expressed in Nicotiana benthamiana 
and HEK293-6E cells, whereby, in general, higher yields were obtained from the N. 
benthamiana plants. The IgG1 isotype was superior to the IgA2m(2) isotype in inhibiting 
parasite growth and should accordingly be used to screen for this application. In contrast, the 
IgA2m(2)-induced ADRB is more efficient and independent from the Fc N-glycan structure, 
and thus should be used to study this functionality. Finally, FcR crosslinking was verified to 
be crucial for the efficient stimulation of PMNs. This can be achieved by using a polyclonal 
antibody preparation, directed against abundant target antigens and well accessible epitopes. 
Finally, antimalarial fusion proteins were evaluated as new therapeutic protein class 
against P. falciparum. The serine protease Granzyme B (Gb) was fused to the MSP4-specific 
scFv “2.44”, which had been previously isolated for this prupose, to facilitate a co-import of 
Gb into the erythrocyte during the invasion step. The final antimalarial fusion protein Gb-
2.44(scFv) showed a cross-strain invasion-dependent antimalarial activity, which was 
superior to the activity of Gb alone or malaria-unrelated Gb-scFv fusion proteins. 
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Zusammenfassung 
Antikörper sind ein essentieller Bestandteil des humanen Immunsystems gegen diverse 
Krankheiten. Sie werden entweder vom Immunsystem in Reaktion auf aktive Impfungen oder 
akute Infektionen gebildet, oder als passive Impfstoffe oder Therapeutika verabreicht. In der 
Immunantwort gegen Malaria können Antikörper entweder die Wirtszellinvasion inhibieren, 
oder Immunzellen (Monozyten, polymorphonukleäre Neutrophile (PMNs)) rekrutieren. 
In der Malariaforschung wird die Stimulierung von PMNs in „antibody-dependent 
respiratory burst“ (ADRB) Versuchen untersucht, wobei meist Festphasen-immobilisierte 
Antigene (engl. „solid-phase“) (sADRB) anstelle von Merozoiten (mADRB) benutzt werden. 
In dieser Arbeit wurden die entsprechenden ADRB Antworten analysiert. Die sADRB und 
mADRB Antworten unterschieden sich in ihrer Abhängigkeit von den Fcγ-Rezeptoren (FcγR) 
und der zellulären Lage der generierten reaktiven Sauerstoffspezies (ROS). Dementsprechend 
muss der experimentelle Aufbau passend zur finalen Anwendung gewählt werden, welche P. 
falciparum Merozoiten betreffend der mADRB anstelle des bisher genutzten sADRBs ist. 
Als nächstes wurde eine Strategie entwickelt, um neu isolierte Antikörper effizient auf 
ihre Funktionalität hinsichtlich der Invasionsinhibition oder der Rekrutierung von PMNs zu 
untersuchen. Zwei Isotypen (IgG1, IgA2m(2)) eines bekannten Antikörpers wurden in 
Nicotiana benthamiana Pflanzen und HEK293-6E Zellen exprimiert, wobei die Pflanzen die 
Antikörper zuverlässig mit höheren Ausbeuten exprimiert haben. Der IgG1-Isotyp war dem 
IgA2m(2)-Isotyp hinsichtlich direkter Invasionsinhibition überlegen, und sollte daher für die 
Evaluierung dieser Anwendung genutzt werden. Im Gegensatz dazu war die IgA2m(2)-
vermittelte Stimulation von PMNs effizienter und unabhängig von der Fc N-Glykanstruktur, 
weswegen diese Funktionalität mittels IgA2m(2) besser evaluiert werden kann. Letztendlich 
wurde gezeigt, dass das Verlinken der FcγR unerlässlich ist, um PMNs effizient zu 
stimulieren. Dies kann mittels einer polyklonalen Antikörperpräparation erreicht werden, 
welche gegen häufige Antigene und gut zugängliche Epitope gerichtet sind. 
Zuletzt wurden Antikörper-basierte Fusionsproteine als mögliche therapeutische 
Proteinklasse gegen P. falciparum evaluiert. Die Serinprotease Granzyme B (Gb) wurde 
hierfür an das MSP4-spezifische scFv „2.44“ fusioniert. Dieses Fusionsprotein zeigte eine 
stammübergreifende, invasionsabhängige Wirkung gegen P. falciparum, welche gegenüber 
sowohl Gb als auch nicht P. falciparum-spezifischer Gb-scFv Fusionsproteine erhöht war.
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I. Introduction 
I.1 Malaria 
I.1.1 Epidemiology 
The vector-borne tropical disease malaria belongs to the infectious diseases with highest 
morbidity and mortality, along with the acquired immune deficiency syndrome (AIDS) and 
tuberculosis. In 2013, it caused ~584,000 deaths, most of them (78%) in children below the 
age of five years in sub-Saharan Africa [10, 11]. Symptoms of mild malaria include fever, 
headache, chills or diaphoresis, while severe forms can lead to cerebral malaria (sequestration 
of parasites into the brain), pulmonary edema, acute renal failure, severe anemia and/or 
bleeding. Among the six human-infective species (Plasmodium vivax, P. ovale curtisi, P. 
ovale wallikeri, P. malariae, P. knowlesi and P. falciparum), which are transmitted by the 
female Anopheles mosquito, Plasmodium falciparum causes the severest forms of malaria 
[12, 13]. 
Until now, there is no vaccine on the market against this devastating disease. The most 
advanced vaccine is RTS,S, the only vaccine candidate which has reached clinical trial phase 
III so far [14], and will probably receive recommendation by the World Health Organization 
(WHO) in 2015. It aims to inhibit invasion of the sporozoites into the hepatocytes, but only 
achieved up to 50% vaccine efficacy in children, and only up to 30% in infants [15]. 
Treatment of malaria has become complicated due to rising resistances against the commonly-
used medication such as chloroquine, mefloquine or sulfadoxine. Today, P. falciparum 
malaria is treated with artemisinin-based combination therapies, against which also drug 
resistant strains are emerging [16]. Altogether, these facts show that new strategies for 
prevention or treatment are urgently required [17-19]. 
 
I.1.2 The life cycle of P. falciparum 
The main challenge in targeting the parasite is its very complex life cycle comprising several 
stages in two hosts (Figure 1). Plasmodium sporozoites are injected into the skin and enter 
hepatocytes, where they develop to hepatic schizonts, which leave the liver as membrane-
enclosed parasite-filled structures, so-called “merosomes” [20]. After arrival in the blood 
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stream, these release 10,000-30,000 merozoites, which invade erythrocytes and develop from 
merozoites to ring-stage parasites, trophozoites and schizonts. After schizont rupture, 20-30 
merozoites are released into the blood stream to infect new erythrocytes again. Trophozoites 
may also develop into gametocytes which can be taken up by the mosquito again. Inside the 
mosquito midgut, the parasite undergoes sexual replication and is able to cross the midgut 
epithelium as ookinete. The now-built oocyst forms sporozoites, which move to the salivary 
glands of the mosquito after rupture of the oocyst, ready to be transmitted again [21, 22]. 
 
 
Figure 1 The life cycle of P. falciparum. 
The life cycle starts with the injection of P. falciparum sporozoites into the skin. While undergoing several 
changes in morphology, these move through the liver, enter the blood stream, where they cause most of the 
clinical symptoms. After development of some blood-stage trophozoites to gametocytes, these can be taken up 
by a female Anopheles mosquito where they develop to sporozoites to be transmitted again, thus completing the 
cycle. Illustration modified from [22]. 
 
During this life cycle, antibodies can interfere at three main stages: 1) in the pre-
erythrocytic stage, they are able to block invasion of sporozoites into hepatocytes; 2) in the 
asexual erythrocytic replication cycle, they are able to control blood stage parasitemia [23]; 3) 
in the sexual replication cycle, they can prevent gametocyte-fertilization and thus the 
transmission of the parasite to the mosquito (Figure 1).  
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I.2 Antibody-based strategies to control P. falciparum blood 
stage infection  
Antibodies play a significant role in the immune defense against a blood stage malaria 
infection. It has been shown that the transfer of antibodies from semi-immune individuals 
reduced parasite load in infected children [24, 25]. During blood-stage development of P. 
falciparum, three main modes of action apply to malaria-specific antibodies: 1) inhibition of 
merozoite invasion into erythrocytes by blocking of important epitopes during the invasion 
process; 2) opsonization of merozoites for clearance by the innate immune system; 3) 
opsonization of infected erythrocytes to prevent sequestration (Figure 2). 
 
 
Figure 2 Modes of action of antimalarial antibodies during blood-stage infection. 
Antimalarial antibodies may either block invasion of the merozoite into the erythrocyte (1), opsonize merozoites 
for clearance by the innate immune system (2) or block the adherence of infected erythrocytes to the vessel walls 
and therewith prevent sequestration (3). Illustration modified from [23]. 
 
Antibodies which prevent erythrocyte sequestration do not directly interfere with the 
development of blood stage malaria infection, but enable clearance of the parasites through 
the spleen. To control blood stage parasitemia, antibodies can inhibit the invasion of 
merozoites into erythrocytes, but this growth inhibitory activity alone does not always 
correlate with protection from the disease [26]. Therefore, other potential mechanisms are 
worth being investigated. From the 1990s on, monocytes have been postulated as potential 
antimalarial effector cells recruited by merozoite-opsonizing antibodies in antibody-
dependent cellular inhibition (ADCI) assays [27, 28]. Additionally, polymorphonuclear 
neutrophil granulocytes (PMNs) have recently emerged as promising antimalarial immune 
cells, whose antibody-mediated stimulation correlates with protection from the disease [29].
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I.2.1 PMNs as antimalarial effector cells 
PMNs are the most abundant white blood cells representing ~70% of the human white blood 
cell count. In a healthy environment, PMNs remain resting in the blood stream. Upon 
infection with a pathogen, they are attracted by chemokines, migrate through the blood vessel 
wall to the site of infection or inflammation and encounter the invading microbes by 
antimicrobial effects, such as degranulation which results in the release of antimicrobial 
proteins and proteases, phagocytosis, as well as the generation of cytokines, chemokines and 
reactive oxygen species (ROS). These effects can be activated, among others, by engagement 
of constant antibody fragment-receptors (FcR) by use of antibodies. PMNs constitutively 
express two low-affinity FcγRs, namely CD16(b)/FcγRIII(b) (~135,000 FcγRIII(b)/PMN) and 
CD32(a)/FcγRII(a) (~31,000 FcγRII(a)/PMN), but they can also express the high-affinity 
CD64/FcγRI after stimulation with GM-CSF, for example. PMNs also express CD89/FcαRI 
(~66,000 FcαRI/PMN). FcR crosslinking is crucial for CD16(b), CD32(a) and CD89 to 
activate cellular mechanisms because of their low affinity for monomeric antibodies [30-34]. 
There is also early evidence that PMNs may play a role in the human immune defense 
against malaria. The activity of PMNs against malaria parasites has been demonstrated in 
vitro [35], and their phagocytic activity has been observed in vivo [36]. More recently, clinical 
protection from malaria was shown to correlate with antibody-dependent respiratory burst 
(ADRB)-activity of PMNs [29]. In the field of malaria, two to three closely related ADRB 
assays represent the major experimental procedures for the assessment of antibody-mediated 
stimulation of PMNs. These differ in the presentation of the antibodies: one assay uses 
antibodies bound to solid-phase coated antigen [37], another uses antibodies bound to purified 
merozoites [29], and yet another uses directly coated antibodies [38, 39] to determine antigen-
independent PMN stimulation. The ADRB itself comprises three major steps: binding of an 
antibody to its target antigen or its attachment directly to the bottom of a polystyrene plate, 
FcR engagement, and thereby induction of the neutrophilic ADRB. Throughout this thesis, 
the stimulation of PMNs was analyzed by measuring the generation of reactive oxygen 
species (ROS, i. e. O2•- at first, and further H2O2, HO•, HOCl), which are visualized by the 
membrane-permeable luminescence amplifier luminol (Figure 5, II.2.7.2). This assay has 
been used to study the reactivity of naturally-acquired antibodies [29] as well as potential 
protective effects of recombinantly produced ones [38]. 
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I.2.1.1 Recombinant antibodies and their implications for therapeutic use 
In the field of malaria, potential protective effects of recombinant antibodies in cooperation 
with PMNs, as outlined in chapter I.2.1, have been investigated using two isotypes, IgG and 
IgA [37, 38, 40]. 
IgG1 is the most prevalent isotype in the human blood stream and of approved 
therapeutic antibodies [41]. Especially for their application as effector-cell recruiting 
mediator, the choice of the most suitable expression host is critical. Antibodies can be 
expressed in a wide variety of expression systems such as plants, yeasts, insect cells or 
mammalian cells [42]. One of the main differences between all these expression systems is 
their distinct N-glycosylation pattern (Figure 3).  
 
 
Figure 3 N-glycan profile of the human IgG-Fc and recombinant proteins depending on the expression 
host. 
A: N-glycan profile of native human IgG [43]. The nomenclature of sugars is according to the Nomenclature 
Committee [44]. Linkages from: http://www.imgt.org/IMGTeducation/IMGTlexique/G/Glycosylation.html 
(accessed March 2nd, 2015). 
B: N-glycan profile of soluble CD16(a) or interleukin-17A expressed in human embryonic kidney 293 
(HEK293) cells [45, 46]. The most abundant type is shown whereas underrepresented patterns are shown in the 
black box. 
C. N-glycan profile of soluble CD16(a) expressed in Chinese hamster ovary (CHO) cells [46]. The most 
abundant type is shown whereas underrepresented patterns are shown in the black box. 
D: N-glycan profile of Nicotiana benthamiana plants. Glycan-linkages which differ from those in humans are 
highlighted in red. Drawn is the expected complex glycan structure of an apoplast-targeted antibody [47, 48]. 
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Because binding of IgG to any FcγR heavily depends on the N-glycan structure at the single 
conserved glycosylation site in the IgG-Fc, asparagine residue #297 (Asn297) [49], the 
expression host is of major importance for an efficient effector cell stimulation. Out of these 
expression systems, three routinely applied types at Fraunhofer IME are N. benthamiana 
plants (or plant suspension cells) for transient or stable expression of recombinant proteins, 
CHO cells for stable expression, and HEK293 cells for transient expression.  
IgA is the second prevalent isotype in the blood stream, and its usage has two main 
advantages: IgA is superior to IgG in the induction of the neutrophilic ADRB [39], and the N-
glycan profile is not critical for binding of IgA to CD89 [50]. A therapeutic drawback of IgA 
is its reduced plasma half-life of 1 week, compared to 1-3 weeks for IgG.  
Both isotypes, however, are able to induce a neutrophilic ADRB response and 
phagocytosis, e. g. of bacteria (Escherichia coli, Streptococcus pneumonia, Staphylococcus 
aureus)  or fungi (Candida albicans) [50]. But especially for experimental screenings, the IgA 
isotype may be preferential for the evaluation of PMN-stimulatory functionality because of its 
enhanced capacity of inducing the neutrophilic ADRB [38].  
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I.2.2 Antibody-fusion proteins 
Another, rather exploratory strategy for antibody-based therapeutic approaches may be the 
use of antibody-fusion proteins. Currently, these are intensively investigated predominantly 
for the specific elimination of cancer cells, and some antibody-drug conjugates (ADCs) are 
already in clinical trials or have received approval from the US Food and Drug 
Administration (FDA) [51, 52]. In general, these proteins consist of antibodies or derivatives 
thereof as highly-specific targeting molecule, which is either chemically conjugated to a 
chemical compound (ADC) or genetically fused to an effector domain belonging to one of 
several protein classes from distinct origins (bacterial or plant-originated toxin: immunotoxin 
(IT); human effector molecule: cytolytic fusion protein (CFP)). Genetic fusion of the protein-
based effector moiety may be preferred over chemical coupling, because this approach 
ensures stoichiometry and site-directed conjugation [52]. But so far, none of these fusion 
proteins has received FDA-approval, underlining the necessity for further research using these 
innovative therapeutic agents. The bacterial toxins “Pseudomonas aeruginosa exotoxin A” or 
“Corynebacterium diphteriae toxin” inhibit the eukaryotic protein biosynthesis by ADP-
ribosylation of the eucaryotic elongation factor 2, while some plant-derived toxins like ricin 
or saporin inhibit ribosomal activity [53]. The main drawback of these effector domains is 
their immunogenicity due to their non-human origin. This challenge is nowadays overcome 
with the screening of human effector molecules for targeted therapeutic approaches. Some 
promising alternatives are: 1) the ribonuclease Angiogenin, which cleaves tRNA and thus also 
inhibits the protein biosynthesis [54]; 2) the microtubule-associated protein MAP, which 
stabilizes the microtubuli during cell proliferation and therewith inhibits it efficiently [55]; or 
3) the serine protease Granzyme B (Gb) [56] (I.2.2.1). Independent from the type of effector 
domain, the main targeting route remains similar. The ADC, IT or CFP binds to its target 
receptor on the cell surface by the antibody-derived binding moiety, is rapidly internalized by 
receptor-mediated endocytosis and the effector domain is released into the cytosol. Here, the 
effector domain kills the malignant cell by an effector domain-dependent mode of action [52, 
53].  
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I.2.2.1 Granzyme B: Targeting an enzyme with potential antimalarial activity 
to the parasite 
Of all the introduced effector domains one deserves special attention in the field of malaria: 
the serine protease Gb. In humans, Gb is secreted by natural killer (NK) cells or cytotoxic T-
lymphocytes together with the pore-forming protein perforin against virus-infected cells. Gb 
enters the cell through this pore and cleaves e. g. pro-caspases 3, 7, 8 and 10, or Bid into their 
active forms, finally inducing DNA-fragmentation and apoptosis [57, 58]. 
With regard to malaria, NK cells have been shown to lyse P. falciparum-infected 
erythrocytes [59]. Moreover, increased levels of circulating Gb are found in naturally infected 
individuals [60] and in co-cultures of NK cells and P. falciparum. In these co-cultures, 
specific eryptosis of infected erythrocytes via a perforin-independent pathway has been 
shown [61]. However, until now a direct proof of the antimalarial activity of Gb is missing. 
The possibility of using antibodies or fragments thereof for the delivery of antimalarial 
molecules has also been raised [62], but merozoites lack internalizing receptors which are 
targeted by ADCs, ITs or CFPs against e. g. cancer cells. Thus, the targeting mechanism 
needs to be distinct. It has been demonstrated that transferrin-toxin fusions can be guided to 
the parasite by its transferrin receptor. This receptor is expressed on the surface of infected 
erythrocytes only and is internalized after binding of transferrin [63]. Although some authors 
claim to have identified and characterized this receptor [64, 65], others argue that iron uptake 
by the parasite is nonspecific and that the P. falciparum transferrin receptor remains elusive 
[66]. Therefore, another strategy was investigated in this PhD thesis: some of the merozoite 
surface proteins (MSPs), namely MSP1, MSP2, MSP4 and MSP8, remain attached to the 
membrane during invasion and are not shed like the majority of the plasmodial surface 
proteins [67]. Furthermore, several of these MSPs contain immunogenic epidermal growth 
factor (EGF)-like domains [68-71] which serve as ideal targets for the generation of specific 
antibodies, because they are rather conserved among strains and even species [72]. Recently, 
MSP2 and MSP4 were shown to be imported into newly-infected erythrocytes [67]. Boyle et 
al. presented that MSP2 is rapidly degraded whereas MSP4 is imported without processing, 
remaining intact for up to 5 h in the infected erythrocyte. Thus, MSP4-specific antibodies or 
fragments thereof are attractive candidates to guide Gb to the parasite by co-import during the 
invasion step, remaining bound to MSP4. 
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I.3 Objectives of this PhD thesis 
The objectives of this PhD thesis are the characterization and functional modification of 
antimalarial antibodies for potential therapeutic or preventive use. The objectives are split in 
three main strategies (Figure 4). 
 
Figure 4 Flow chart summarizing the objectives of this PhD thesis. 
This PhD thesis is divided into the three main working strategies: The functional dissection of the neutrophilic 
ADRB, functional characterization of recombinant monoclonal antimalarial antibodies, and the targeted delivery 
of antimalarial compounds by example of Gb and a PfMSP4-specific scFv. 
 
The first strategy is the functional dissection of the neutrophilic ADRB by using the two 
predominant assays utilized for the evaluation of antibody-induced stimulation of PMNs in 
malaria research, which use antibodies bound to either solid-phase immobilized antigens [37] 
or to merozoites [29], and the corresponding assays have been named sADRB or mADRB 
assay in this thesis (Figure 5). The experimental procedures of these assays have been 
established before in my master thesis [73]. The suitability of either assay for the evaluation 
of antimalarial functionalities of antibodies should be determined in three main steps: 1) 
identification of the major contributing FcγR; 2) determination of the predominant cellular 
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location of the generated ROS; 3) evaluation of the preferred anti-merozoite mode of action in 
the mADRB assay. These experiments should be performed with naturally-acquired 
antibodies from malaria-exposed semi-immune individuals from Kumasi (Ghana). 
The second objective of this PhD thesis is the functional characterization of monoclonal 
antimalarial antibodies with major focus on direct growth inhibitory properties and especially 
the stimulation of PMNs. This PhD thesis is embedded in the Fraunhofer Future Foundation 
Project “Innovative Technologies to Manufacture Ground-breaking Biopharmaceutical 
Products in Microbes and Plants”. One of the main aims of this project is the isolation of 
malaria-specific human antibodies for therapeutic or preventive use. Therefore, a well 
mapped-out strategy for the assessment of their antimalarial functionality is needed. This 
work flow should be set up by evaluation of IgG1 and IgA2m(2) as isotypes, as well as N. 
benthamiana or HEK293-6E cells as transient expression hosts, for their suitability of 
mediating antimalarial functionalities. Both expression systems distinguish themselves by 
their high-yield expression of functional proteins in low periods of time [74-77], which is 
finally needed for the functional characterization of antibodies, although CHO cells are 
routinely used for the production of biopharmaceuticals [42] and have the closest identity 
with the native human N-glycan profile (Figure 3). By using the apical membrane antigen 1 
(AMA1)-specific “4G2” antibody [78], four different antibody variants (two isotypes from 
two expression hosts) should be evaluated concerning antigen recognition, direct growth 
inhibitory properties and induction of the neutrophilic ADRB. 
The third objective comprises the functional modification of antimalarial antibodies for 
the targeted delivery of potential antimalarial effector molecules to the parasite. This aim 
should be achieved by generating a potent scFv-based fusion protein. As outlined, especially 
Gb is of major interest because Gb has been suggested as a potential antimalarial effector 
molecule (I.2.2.1). Thus, the direct antimalarial effect of Gb should be verified at first. Next, a 
suitable antibody targeting the chosen antigen, PfMSP4, should be isolated and characterized 
based on the established screening protocol developed in the second project objective. 
Afterwards, its scFv-derivative should be genetically fused to Gb and respective Gb-scFv 
fusion protein should be expressed in HEK293-6E cells. Finally, the suitability of such an 
antimalarial fusion protein for potential therapeutic approaches should be assessed with 
special focus on the enhanced antimalarial activity of this Gb-scFv fusion protein. 
Material and Methods
 
 
 
 
 
11 
 
II. Material and Methods 
II.1 Material 
II.1.1 Chemicals and consumables 
Chemicals and consumables were purchased from Planta Düngemittel GmbH (Regenstauf), 
Roche (Karlsruhe), BD Biosciences (Heidelberg),  Sigma-Aldrich (Taufkirchen), B. Braun 
Melsungen AG (Melsungen), Bio-Rad (München), Carl Roth (Karlsruhe), Dianova 
(Hamburg), eurofins Genomics (Ebersberg), Greiner Bio One (Frickenhausen), Labomedic 
(Bonn), Life Technologies GmbH (Invitrogen®, Molecular Probes®, Gibco®, GeneArt®; 
Darmstadt), Macherey-Nagel (M&N, Düren), EMD Merck Millipore (Biochrom; Berlin), 
New England Biolabs (NEB, Frankfurt am Main), Qiagen (Hilden), , Agilent Technologies 
(Santa Clara, CA, USA), SARSTEDT AG & Co. (Nümbrecht), Sartorius (Göttingen), Thermo 
Fisher Scientific (Schwerte), VWR (Langenfeld), eBioscience (Frankfurt), R&D Systems 
(Minneapolis, MN, USA), Corning Inc. (New York, NY, USA), Lonza (Basel, Switzerland), 
PAN Biotech (Aidenbach), Organotechnie (La Cournuve, France), Polyplus (Illkirch Cedex, 
France), Calbiochem (now EMD Millipore, Berlin), Immunology Consultants Laboratory, 
Inc. (Portland, OR, USA), Vector Laboratories (Burlingame, CA, USA), Abd Serotec 
(Düsseldorf), eBioscience (Frankfurt), Immunostep (Salamanca, Spain), GE Healthcare 
(PAA, BiacoreTM; Uppsala, Sweden), Jackson ImmunoResearch (JIR; West Grove, PA, 
USA), ATCC (Manassas, VA, USA), Santa Cruz Biotechnologies Inc. (Heidelberg). 
 
II.1.2 Oligonucleotides, plasmids and DNA sequences 
All primers were ordered from eurofins Genomics and are listed in the appendix (VII.2). 
Plasmids used were pTRA(k)t (based on pTRAc [79]), kindly provided by Holger 
Spiegel (Fraunhofer IME, Aachen), pTT5(SH8Q2) (based on pTT [80], obtained through a 
material transfer agreement from the Canadian National Research Counsil). 
pTT5SH8Q2_EGbR201K-scFv was generated by Lea Hein (Institute for Applied Medical 
Engineering AME, Aachen). Plasmid maps are listed in the appendix (VII.5).  
DNA sequences encoding for the V regions of the AMA1-specific antibody „4G2“ [78], 
or encoding for the human IgA2m(2) antibody constant region (without tailpiece for 
dimerization) were ordered from GeneArt®, and are listed in the appendix (VII.6). 
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II.1.3 Enzymes, reaction kits and purification matrices 
All enzymes (Table 1), kits (Table 2) and matrices (Table 3) were used as suggested by the 
manufacturer unless stated otherwise in the corresponding method. 
 
Table 1 Enzymes 
Enzyme Company 
Taq polymerase Invitrogen 
High Fidelity Taq polymerase Roche 
Restriction enzymes and appropriate reaction buffers NEB 
Quick T4 DNA ligase and appropriate reaction buffers NEB 
Phosphatidylinositol-specific phospholipase C (Pi-PLC) Molecular Probes® 
Catalase (CAT) Sigma-Aldrich 
Superoxide dismutase (SOD) Sigma-Aldrich 
Remove-iTTM Endo S NEB 
Recombinant Enterokinase (rEK) Novagen / Merck Millipore 
Granzyme B standard for activity assay Calbiochem 
 
Table 2 Reaction kits 
Reaction kit Company 
NucleoSpin® Plasmid  M&N 
NucleoSpin® Gel and PCR Clean-up  M&N 
NucleoSpin® RNA  M&N 
NucleoBond® Xtra Midi Plus M&N 
QIAamp DNA Blood Mini Qiagen 
SuperScript® III First-Strand Synthesis System for RT-PCR Invitrogen 
Mouse Immunoglobulin Isotyping ELISA BD Pharmingen (BD Biosciences) 
QuikChange Lightning Agilent Technologies 
 
Table 3 Purification matrices 
Matrix Company 
Ni-NTA agarose  Qiagen or Thermo Fisher Scientific 
MabSelectTM sepharose GE Healthcare 
Protein A agarose Roche 
CaptureSelect™ Human IgA Affinity Matrix  Invitrogen 
 
II.1.4 Substrates and antibodies 
All substrates and antibodies used in this PhD thesis are listed in Table 4 and Table 5.  
 
Table 4 Substrates 
Substrate Enzyme Company Application Readout 
NBT/BCIP Alkaline phosphatase Carl Roth Immunoblot Immunoblot 
pNPP* Alkaline phosphatase Sigma Aldrich ELISA A405 nm 
TMB** Peroxidase Invitrogen ELISA A450 nm 
NBT/BCIP: nitro-blue tetrazolium and 5-bromo-4-chloro-3’-indolyphosphate; pNPP: para-nitrophenylphosphate 
* After appropriate incubation time, the absorbance at 405 nm (A405 nm) was detected using the Epoch 
spectrophotometer (II.1.9). 
** After an appropriate incubation time, the reaction of TMB was stopped with 50 µl of 1 M HCl before the 
A450 nm was determined using the Epoch spectrophotometer (II.1.9). 
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Table 5 Antibodies 
Name Conjugate Abbreviation Company Application (dilution or concentration) 
Goat anti-human Ig  GαH-Ig Invitrogen IgG1-quantification ELISA (2 µg/ml) 
Goat anti-human IgG, 
Fc-specific PO GαH-IgGFC
PO JIR ELISA (1:5000 - 9000) 
Human IgG standard  huIgG JIR IgG1-quantification ELISA (2 µg/ml - 0.5 ng/µl) 
Goat anti-human IgG, 
κLC-specific AP GαH-IgκLC
AP Sigma-Aldrich ELISA (1:5000) 
Mouse anti-Granzyme 
B - MαGb 
Santa Cruz 
Biotech; Clone 2C5
ELISA (1:500), 
immunoblot (1:5000) 
Goat anti-mouse IgG, 
H+L-specific AP GαM-IgGH+L
AP Dianova Immunoblot (1:5000) 
Goat anti-human IgG Alexa Fluor® 647 GαH-IgG
647 JIR IFA (1:100) 
Goat anti-human IgG Cy3 GαH-IgGCy3 JIR IFA (1:1000) 
Goat anti-human IgA Alexa Fluor® 647 GαH-IgA
647 JIR IFA (1:200) 
Goat anti-mouse IgG FITC GαM-IgGFITC JIR IFA (1:100) 
Goat anti-mouse IgG Alexa Fluor® 488 GαM-IgG
488 Invitrogen IFA (1:100) 
Goat anti-rabbit IgG Alexa Fluor® 488 GαR-IgG
488 JIR IFA (1:200) 
Goat anti-rabbit IgG Alexa Fluor® 594 GαR-IgG
594 JIR IFA (1:400) 
IgG from 3rd bleed of 
Rabbit #93, anti-
PfAMA1 [6] 
- Rα-AMA193, 3rd 
Alexander Boes 
(Fraunhofer IME) Co-stain in IFA (50 µg/ml) 
Mouse anti-MSP1 - 5.2 ATCC [81] Co-stain in IFA (20 µg/ml) 
Mouse IgM anti-
PfHRP2  MPFM-55A 
Immunology 
Consultants 
Laboratory, Inc 
PfHRP2 ELISA (1 µg/ml) 
Mouse IgG anti-
PfHRP2 PO MPFG-55P 
Immunology 
Consultants 
Laboratory, Inc 
PfHRP2 ELISA (0.05 µg/ml)
Mouse anti-human 
CD32, clone 6C4  MαH-CD32 eBioscience 
CD32(a) blocking on PMNs 
(0.5 µg/105 PMNs) 
Mouse anti-human 
CD16 FITC MαH-CD16
FITC Immunostep 
FcR-profiling of PMNs by 
flow cytometry (1:100) 
Mouse anti-human 
CD32 
Alexa Fluor® 
647 MαH-CD32
647 Abd Serotec 
Mouse anti-human 
CD64 FITC MαH-CD64
FITC Abd Serotec 
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II.1.5 Media, buffers and solutions 
All growth media, buffers and solutions (Table 6) were prepared according to Sambrook and 
Green unless stated otherwise [82]. Growth media were autoclaved for 20 min at 121°C. 
Instable components (e. g. sugars, mineral salts) were sterilized by 0.22-µm filtration. 
 
Table 6 Media, buffers and solutions 
Medium/buffer/solution Component Concentration 
LB(Amp) medium (pH 7.0) 
 
 
 
Peptone 
Yeast extract 
NaCl 
(Ampicillin) 
1% (w/v) 
0.5% (w/v) 
1% (w/v) 
(100 µg/ml) 
LB(Amp) agar (pH 7.0) LB(Amp) medium 
Agar 
 
1.5% (w/v) 
2x TYG(Amp) medium (pH 7.0) Peptone 
Yeast extract 
NaCl 
Glucose 
(Ampicillin) 
1.6% (w/v) 
1% (w/v) 
0.5 (w/v) 
1% (w/v) 
(100 µg/ml) 
SOC medium (pH 7.0) Peptone 
Yeast extract 
NaCl 
KCl 
MgCl2 
Glucose 
2% (w/v) 
0.5% (w/v) 
0. 5% (w/v) 
2.5 mM 
10 mM 
20 mM 
YEB+(KCR) medium (pH 7.4) 
 
 
 
 
 
 
  
Beef extract 
Yeast extract 
Peptone 
Sucrose 
MgSO4 
(Kanamycin) 
(Carbenicillin) 
(Rifampicin) 
0.5% (w/v) 
0.1% (w/v) 
0.5% (w/v) 
0.5% (w/v) 
0.05% (w/v) 
(25 µg/ml) 
(50 µg/ml) 
(25 µg/ml) 
YEB+KCR agar (pH 7.4) YEB+KCR medium 
Agar 
 
1.25% (w/v) 
A. tumefaciens freezing medium (pH 7.4) YEB+ medium 
Glycerol 
50% (v/v) 
50% (v/v) 
2x infiltration medium (pH 5.6) Glucose 
Saccharose 
Ferty Mega 2 
0.4% (w/v) 
10% (w/v) 
0.1% (w/v) 
Extraction buffer (pH 8.0) PBS 
Sodium disulfite 
 
10 mM 
E. coli Comp buffer A (pH 5.8) Sodium-acetate 
MnCl2 
CaCl2 
Glycerol 
30 mM 
50 mM 
10 mM 
15% (v/v) 
E. coli Comp buffer B (pH 6.8) MOPS 
CaCl2 
RbCl 
Glycerol 
30 mM 
75 mM 
10 mM 
15% (v/v) 
Coating buffer (pH 9.0) Na2CO3 
NaHCO3 
0.1 M 
0.1 M 
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1x PBS(T) (pH 7.4) NaCl 
KCl 
Na2HPO4 
KH2PO4 
(Tween-20) 
137 mM 
2.7 mM 
10 mM 
1.76 mM 
(0.1% (v/v)) 
PBS/BSA PBS 
BSA 
 
2% (w/v) 
PBS/M PBS 
Skimmed milk powder 
 
2% (w/v) 
1x TGS (pH 8.6) Tris 
Glycine 
SDS 
25 mM 
192 mM 
0.1% (w/v) 
5x denaturing reducing protein loading buffer 
(In 5x denaturing non-reducing protein loading 
buffer the β-mercaptoethanol is replaced by H2O.) 
Tris-HCl (pH 6.8) 
Glycerol 
SDS 
Bromophenol blue 
β-mercaptoethanol 
62.5 mM 
30% (v/v) 
4% (w/v) 
0.05% (w/v) 
10% (v/v) 
Coomassie staining solution Methanol 
Coomassie G-250 
Glacial acetic acid 
50% (v/v) 
0.25% (w/v) 
9% (v/v) 
Coomassie destaining solution Methanol 
Glacial acetic acid 
10% (v/v) 
10% (v/v) 
Immunoblot transfer buffer TGS 
Methanol 
 
20% (v/v) 
1x TAE  Tris 
Glacial acetic acid 
EDTA 
40 mM 
5.7% (v/v) 
10 mM 
6x Orange G DNA loading buffer Glycerol (15% v/v) 
Orange G 
60% (v/v) 
2 µg/ml 
EGb storage buffer (pH 7.5) TrisHCl 
NaCl 
20 mM 
50 mM 
Gb activity test buffer (pH 7.4) NaCl 
HEPES 
DTT 
EDTA 
Glycerol 
CHAPS 
100 mM 
50 mM 
10 mM 
1 mM 
10% (v/v) 
0.1% (w/v) 
HBS-EP HEPES 
NaCl 
EDTA 
Tween-20 
10 mM 
150 mM 
3 mM 
0.005% (v/v) 
MCM (malaria cell culture medium) (pH 7.4) RPMI 
HEPES 
L-Glutamin 
10x AlbumaxII 
Gentamycin 
 
24 mM 
1 mM 
1x 
50 µg/ml 
SAG-mannitol  Sodium chloride 
Adenine-HCl 
Glucose 
D-Mannitol 
0.88% (w/v) 
0.0215% (w/v) 
0.9% (w/v) 
0.525% (w/v) 
Glycerolyte Glycerol 
Sodium lactate 
KCl 
NaH2PO4 
57% (v/v) 
1.6% (w/v) 
0.03% (w/v) 
25 mM 
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10x AlbumaxII RPMI (powder) 
HEPES 
NaHCO3 
Gentamycin 
AlbumaxII 
Hypoxanthin 
Glucose 
1.043% (w/v) 
24 mM 
0.2% (w/v) 
25 µg/ml 
5% (w/v) 
0.2 mM 
0.2% (w/v) 
pLDH buffer (pH 8.0) 
 
 
Add directly before use: 
TrisHCl 
Sodium-L-lactate 
Triton X-100 
NBT 
APAD 
Diaphorase 
100 mM 
0.56% (w/v) 
0.25% (v/v) 
200 µg/ml 
50 µg/ml 
1 U/ml 
70% Percoll 10x RPMI 
Percoll 
Sorbitol (133 mg/ml in PBS) 
10% (v/v) 
70% (v/v) 
20% (v/v) 
IMAC binding/washing buffer (pH 8.0) NaCl 
NaH2PO4 
300 mM 
50 mM 
IMAC elution buffer (pH 8.0) NaCl 
NaH2PO4 
Imidazole 
300 mM 
50 mM 
500 mM 
 
Protein A / MabSelectTM binding/washing buffer 
(pH 7.4) 
Na2HPO4 
NaCl 
20 mM 
150 mM 
Protein A / MabSelectTM elution buffer (pH 2.5-3.0) Sodium citrate 100 mM 
Protein A / MabSelectTM CIP buffer NaOH NaCl 
100 mM 
1 M 
CaptureSelect IgA binding/washing buffer (pH 7.4) PBS  
CaptureSelect IgA elution buffer (pH 3.0) Glycine 100 mM 
Neutralization buffer (pH 9.0) TrisHCl 1 M 
Storage buffer of purification matrices PBS 
Ethanol 
 
20% (v/v) 
IFA blocking and dilution buffer  PBS 
BSA (IgG-free, Invitrogen) 
Saponin 
 
0.5% (w/v) 
0.01% (w/v) 
Complete Freestyle F17 medium Freestyle F17 medium 
GlutaMAXTM 
Hypoxanthine/Thymidine 
 
4 mM 
1x (from 50x) 
 
II.1.6 Bacterial strains 
Escherichia coli DH5α (genotype F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyr A96 relA1) (Invitrogen) was used for cloning 
purposes. 
Agrobacterium tumefaciens strain GV3101 PMP90RK [GmR, KmR, RifR] [83] was used 
to infiltrate N. benthamiana plants for the expression of recombinant full-size antibodies. A. 
tumefaciens:pTRAc_p19si expressing the transcriptional silencer “p19” [84, 85] was kindly 
provided by Dr. Thomas Rademacher (Fraunhofer IME, Aachen). 
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II.1.7 Patient plasma and provided proteins 
Plasma samples from semi-immune voluntary donors have been collected by Dr. Rolf Fendel 
and Dr. Otchere Addai-Mensah (both Fraunhofer IME, Aachen) in January 2011 in 
accordance with the Helsinki Declaration on Scientific Research. Study approval was 
received from the regional Committee on Human Research Publication and Ethics (CHRPE) 
of The Kwame Nkrumah University of Science and Technology (Kumasi, Ghana). 
Three diversity covering variants of AMA1, DiCo1-3 [86], were produced in Pichia 
pastoris in the GMP facility of Fraunhofer IME, Aachen (Dr. Stephan Hellwig, Dr. Jürgen 
Drossard). Permission to use these proteins was given by Dr. Bart Faber (BPRC, Rijswijk, 
The Netherlands). A 1:1:1 mixture was used throughout this thesis with one exception: The 
affinity of 4G2IgG1 was determined using the P. falciparum 3D7-strain AMA1, expressed in 
N. benthamiana and kindly provided by Alexander Boes (Fraunhofer IME, Aachen). 
H10IgG1, a human monoclonal antibody specific for the carcinoembryonic antigen was 
stably expressed in CHO-DG44 cells (H10IgG1CHO) by Dr. Anne Höhne (by birth Peuscher) 
[87] and was kindly provided by Holger Spiegel (both Fraunhofer IME, Aachen). 
The fusion protein mE-ERH, which consists of the EGF-like domains of MSP1, MSP4 
and MSP8 (1st and 2nd EGF-like domain), was expressed in N. benthamiana and kindly 
provided by Alexander Boes (Fraunhofer IME, Aachen). 
EGb (Gb fused to an N-terminal protective peptide and recombinant enterokinase (rEK) 
cleavage site (ECS)) was expressed in HEK293-T cells and kindly provided by Dr. Sonja 
Schiffer (Institute for Applied Medical Engineering AME, Aachen) [88]. 
 
II.1.8 Mammalian cell lines 
HEK293-6E cells, which were obtained through a material transfer agreement from the 
Canadian National Research Counsil, were used for the expression of recombinant proteins. 
Eight murine hybridoma cell lines (2.44, 2.48, 2.6, 2.7, 2.29, 2.68, 2.47, 2.8) producing 
antibodies specific for the EGF-like domain of PfMSP4 (PfMSP4EGF) (amino acids 201-247) 
were kindly provided by Alexander Boes (Fraunhofer IME, Aachen). These were generated 
by fusion of spleen cells from mE-ERH-immunized (II.1.7) BALB/c mice with the murine 
myeloma cell line Sp2/0-Ag14 (ATCC, CRL-1581) and subsequent limiting dilution method 
[3]. Hybridoma cell lines were cultivated in ISF-1 medium (Biochrom). 
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II.1.9 Equipment and software 
Autoclaves Varioclav H+P 135S (H+P Labortechnik GmbH, Oberschleißheim) 
Systec HX-430 (Systec, Wettenberg) 
Balances TE64, TE3102S (Sartorius, Göttingen) 
BiacoreTM BiacoreTM T200 (GE Healthcare, Freiburg) 
Software: BiacoreTM T200 Evaluation Software V1 
Centrifuges Avanti J25 I (Beckmann Coulter, Krefeld) 
Multifuge1s/-3s-R, Biofuge PrimoR (Heraeus Holding GmbH, Hanau) 
Centrifuge 5415D, Centrifuge 5415R (Eppendorf, Hamburg) 
Microfuge (Carl Roth, Karlsruhe) 
Rotina 420R (Hettich, Tuttlingen) 
Cell counter Casy Cell Counter (Schärfe Systems, Reutlingen); 
Hemacytometer (Marienfeld, Lauda-Königshofen) 
Centrifugal concentrators Vivaspin® concentrator VS15RH2, VS02H2 and VS060 (Sartorius, Göttingen) 
Cryopreservation module StrataCooler Cryo Preservation Module (Thermo Fisher Scientific, Schwerte) 
DNA Sequencer ABI Prism 3730 Capillar Sequencer (Applied Biosystems, Foster City, USA) 
Electrophoreses apparatus Mini-PROTEAN 3 Electrophoresis System, PowerPac HC and Basic, Sub-Cell 
GT Systems (Biorad, München) 
Electroporator Multiporator® (Eppendorf, Hamburg) 
Flow Cytometer BD FACSVerseTM (Heidelberg) 
Software: BD Facsuite 
Gel documentation system Gel Doc™ XR+ System (Biorad, München) 
Software: Image LabTM; 
CanoScan 9000F MARKII (Canon, Krefeld) 
Ice machine Icematic F200 (Castel Mac SpA, Castelfranco Veneto, Italy) 
Incubation shaker AJ118- 2 (Infors HT, Bottmingen, Switzerland) 
Magnetic stirrer IKA®RCT basic RCT-B (IKA, Staufen) 
Microbiological safety cabinet Biowizard 2 MSC (Kojair Tech Oy, Vilppula, Finnland) 
Microplate reader Tecan GENios Pro (Tecan, Männedorf, Switzerland)  
Software: Magellan  
Epoch multi-volume spectrophotometer system (BioTek, Bad Friedrichshall) 
Software: Gen5  
Microwave OMV330D-M (OK) 
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Microscope Leica Microscope DM 2000, Leica DM IL and 
Leica TCS SP8 Confocal Microscope (Leica, Wetzlar) 
Software: LAS AF  
Milli-Q®-System Aquinta Ls with MemTap1, 0.2 µm PES (Membra-Pure, Bodenheim) 
pH-meter PB-11 (Sartorius, Göttingen) 
Photometer Take3 micro-volume plate (BioTek, Bad Friedrichshall) 
BioPhotometer (Eppendorf, Hamburg) 
Pipettes Single channel pipettes: Discovery Pro DP10, DP20, DP200, DP1000 (HTL 
Lab Solutions, Warsaw, Poland) 
8-channel manual pipettors: Discovery Pro DP8-10, DP8-200 (HTL Lab 
Solutions, Warsaw, Poland) 
8-channel motorized pipettor: Research® pro-8 50-1200 µl (Eppendorf, 
Hamburg) 
Pipettor Biohit midi plus (Sartorius, Göttingen); 
Finnipipette Pipet Controller (Thermo Fisher Scientific, Schwerte) 
PCR thermal cycler Primus 96 Plus Thermal Cycler (eurofins Genomics, Ebersberg)  
PCR working station UV Airclean Workstation UVC/T-M-AR (LTF Labortechnik, Wasserburg) 
Shaker Multi-flask shaker VKS 75 B (Edmund Bühler, Tübingen) 
Software (additional) Aida Image Analyzer 4.27.039 (Raytest, Straubenhardt)  
Adobe Photoshop CS5.1 (Version 12.1 x64Adobe) 
CLC Main Workbench 6 (CLC bio, Aarhus, Denmark) 
GraphPad Prism® 5.0 (GraphPad Software Inc., La Jolla, USA) 
Microsoft Office 2010 (Microsoft, Redmond, USA)) 
NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc) 
SignalP 4.1 Server (http://www.cbs.dtu.dk/services/SignalP) 
Suspension mixer CMV suspension mixer (Fröbel Labortechnik GmbH, Lindau) 
Timer Rotilabo®-Signal-Timer (Roth, Karlsruhe) 
Thermomixer Thermomixer®comfort/compact (Eppendorf, Hamburg) 
Vortexer Vortex-Genie 2 (Scientific Industries, New York, USA) 
Water bath TW20 (Julabo, Seelbach) 
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II.2 Methods 
II.2.1 Recombinant DNA technology 
Molecular biological methods were performed as described by Sambrook and Green [82]. 
 
II.2.1.1 Agarose gelelectrophoreses and extraction of DNA from agarose gels 
DNA fragments after polymerase chain reaction (PCR) or after restriction digest (II.2.1.4, 
II.2.1.5) and plasmids (II.1.2) were separated on a 0.8-1.2% (w/v) agarose gel containing 
300 ng/ml ethidium bromide at 120-140 V for 30 min, depending on their size. If preparative 
gels were run, the desired bands were cut out of the gel using a scalpel and the DNA was 
extracted using the NucleoSpin® Gel and PCR Clean-up kit (Table 2, II.1.3). 
 
II.2.1.2 Determination of DNA concentration 
The concentration of purified DNA (II.2.1.1, II.2.2.4) was determined using the Epoch micro-
volume spectrophotometer (II.1.9) with a Take3 micro-volume plate. 
 
II.2.1.3 V-region rescue 
V-region rescue was performed as described previously [3]. RNA was extracted from 
5 x 106 hybridoma cells using the NucleoSpin®RNA II kit (Table 2, II.1.3). cDNA was 
synthesized using the SuperScript® III First-Strand Synthesis System for RT-PCR (Table 2, 
II.1.3) using oligodT-primers provided by the kit. This cDNA served as template for the 
amplification of antibody V regions [89] by PCR (II.2.1.4) using the High Fidelity Taq 
polymerase system (Table 1, II.1.3). PCR products were purified after agarose 
gelelectrophoreses (II.2.1.1) and sequenced (II.2.1.6). Obtained sequences were analyzed 
using the IMGT/V-quest [90] and NCBI nucleotide BLAST [91] tools. Vh- and Vl-gene 
families were identified, as well as the most probable sequence start of the Vh gene according 
to the closest germ-line sequence. The Vh-forward primer binds in the framework region, thus 
introducing nucleotide mutations, which were corrected using germ-line adapted cloning 
primers (VII.4). 
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II.2.1.4 PCR and colony PCR 
PCR is a standard technique for the amplification of DNA fragments [92]. In this PhD thesis, 
a PCR was performed to amplify fragments for subsequent cloning (II.2.1.5) or to analyze 
transformed bacteria for the presence of a desired plasmid (colony PCR) (Table 7). 
 
Table 7 Composition of a standard PCR and a colony PCR reaction 
Component Volume for standard PCR Volume for colony PCR 
10x reaction buffer 2.5 µl 2 µl 
Taq polymerase 0.25 µl 0.2 µl 
MgCl2 (50 mM) 0.75 µl 0.8 µl 
dNTPs (10 mM each) 0.5 µl 0.4 µl 
Forward primer (10 pmol/µl) 0.5 µl 0.4 µl 
Reverse primer (10 pmol/µl) 0.5 µl 0.4 µl 
Template  0.5 µl One picked colony 
Nuclease-free H2O 19.5 µl 15.8 µl 
Total volume 25 µl 20 µl 
 
DNA fragments were amplified with specifically designed oligonucleotide primers 
(II.1.2) by repetitive denaturation, annealing of primers and elongation steps (Table 8) using a 
Primus 96 Plus thermal cycler (II.1.9). Amplified fragments were analyzed by agarose 
gelelectrophoreses and extracted from the gels, if necessary (II.2.1.1). 
 
Table 8 Incubation scheme of a PCR reaction 
Step Temperature Duration Repetition 
Initial denaturation 94°C 5 min (standard PCR) 15 min (colony PCR) 
 
Denaturation 94°C 30 s  
Annealing of primers X°C* 30 s 25-35 x 
Elongation 72°C 1 min/kbp  
Final elongation 72°C 10 min  
*The annealing temperature was 5°C below the lowest annealing temperature of one of both primers. 
 
II.2.1.4.1 Splice by overlap extension-PCR (SOE-PCR) 
“Splice by overlap extension-PCR” (SOE-PCR) [93] was performed to generate scFvs from 
V-region sequences. V-region sequences were first amplified in a standard PCR (II.2.1.4) by 
using the High Fidelity Taq polymerase system (Table 1, II.1.3). The “outer” primers 
introduce appropriate restriction enzyme sites (SfiI, NotI) for later cloning while the inner 
primers encode for a glycine-serine linker peptide whose DNA sequences are overlapping. In 
a second step, the SOE-PCR was performed by adding the two amplified V regions, 
respectively, and only the outer primers to the PCR reaction. 
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II.2.1.5 Cloning of DNA fragments by restriction digest and ligation 
Cloning of PCR-amplified DNA fragments (II.2.1.4) by restriction enzyme-facilitated DNA 
digest and subsequent ligation is a commonly used method to generate expression plasmids 
[82]. For this purpose a whole purified PCR product (II.2.1.4) or 2 µg of the target plasmid 
(II.1.2) were digested using 5 U of the required restriction enzymes (Table 1, II.1.3) and 
purified after agarose gelelectrophoreses (II.2.1.1). Afterwards, the ligation of target plasmid 
and insert was performed using 100 ng of digested and purified plasmid and a 5-fold molar 
excess of the cloning insert using T4 Quick DNA Ligase (Table 1, II.1.3) in a total volume of 
15 – 30 µl. 
All cloning steps were planned in silico using CLC Main Workbench 6 (II.1.9). Final 
expression vectors were generated as listed below (Table 9). Detailed plasmid maps are listed 
in the appendix (VII.5). 
 
Table 9 Cloning strategies of final expression plasmids 
Final vector Insert* Restriction enzymes 
pTRAkt/pTT5_HC-IgG1 Vh region of the needed antibody (2.44, 4G2)  AgeI, SalI 
pTRAt_HC-IgA2m(2) Vh region of the needed antibody (4G2) AgeI, NheI 
pTRAkt/pTT5_LC Vh region of the needed antibody (2.44, 4G2) AgeI, BsiWI 
   
pTT5HC-IgG1hCU 
1. SP-Vh-Chγ of pTRAkt_HC-IgG1 
2. Chγ (with human codon usage) of pAPT [87] 
EcoRI, XbaI 
SalI, XbaI 
pTT5_LChCU 
1. SP-Vl-Ck of pTRAkt_LC 
2. Cκ (with human codon usage) 
EcoRI, XbaI 
SalI, XbaI 
pTT5_HC-IgA2m(2) SP-Vh-Chα of pTRAt_HC-IgA2m(2) EcoRI, XbaI 
   
pTT5SH8Q2_EGbR201K-scFv scFv of the needed antibody (2.44, H22**, Ki4**) SfiI, NotI 
* The insert was previously amplified by PCR (II.2.1.4) using the appropriate primers (VII.2, Table 20). SP: 
signal peptide sequence; Chγ/Chα/Ck: constant domain of human antibody constant domain of IgG, IgA or Igκ. 
** H22(scFv) [94] is specific for human CD64 and was obtained from pMS-L-H22-Ang GGRRmut, (Christian 
Cremer, Institute for Applied Medical Engineering AME, Aachen); Ki4(scFv) [95] is specific for human CD30 
and was obtained from pMS-L-EGbR201K-Ki4 (Dr. Sonja Schiffer, Institute for Applied Medical Engineering 
AME, Aachen). 
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II.2.1.6 Sequencing of DNA 
Sequencing of DNA was performed at the Department of “Functional and Applied Genomics” 
of Fraunhofer IME, Aachen (Dr. Jost Muth) according to the chain-termination method 
described by Sanger et al. [96] using an ABI Prism 3730 Capillar Sequencer (II.1.9). 500 ng 
of purified plasmid DNA (II.2.2.4) or ~10 ng/100 bp of a purified PCR product (II.2.1.1) were 
sequenced using 1 pmol/µl of the respective primer (VII.4). Sequences were analyzed using 
CLC Main Workbench (II.1.9). 
 
II.2.2 Cultivation of E. coli DH5α 
II.2.2.1 Preparation of chemocompetent E. coli DH5α 
E. coli DH5α were grown in 200 ml LB medium (II.1.5) containing 20 mM MgSO4 and 
10 mM KCl at 37°C until an optical density at 600 nm (OD600 nm) of 0.8 was reached. Cells 
were pelleted (2,000 g, 10 min, 4°C). The pellet was resuspended in 15 ml of ice-cold Comp 
buffer A. Cells were again pelleted as before, followed by resuspension in 2 ml of ice-cold 
Comp buffer B, immediately frozen using liquid N2 in 50-µl aliquots and stored at -80°C. 
 
II.2.2.2 Heat shock transformation of chemocompetent E. coli DH5α 
One aliquot of E. coli DH5α (II.1.6) was thawed for 15 min on ice and mixed with either 
10 ng of a plasmid (re-transformation) (VII.5) or a whole ligation reaction (II.2.1.5) and 
further incubated for 30 min on ice. Cells were transformed at 42°C for 45 s, cooled down on 
ice for 2 min and allowed to regenerate in 500 µl SOC medium (II.1.5) for 30-60 min at 37°C 
on a suspension mixer. Bacteria were incubated on LBAmp agar plates (II.1.5) for 16 h at 37°C. 
The transformation was analyzed by colony PCR (II.2.1.4) and a positively tested clone was 
used for the isolation of the corresponding plasmid (II.2.2.4) for sequencing (II.2.1.6). 
 
II.2.2.3 Cryopreservation of E. coli DH5α for long-term storage 
400 µl of a well grown transformed E. coli DH5α (II.2.2.2) culture in LBAmp medium (II.1.5) 
of a clone containing the verified plasmid after sequencing (II.2.1.6) were mixed with 260 µl 
of a sterile 70% (v/v) glycerol solution and immediately stored at -80°C. 
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II.2.2.4 Plasmid isolation 
Plasmids were isolated from transformed E. coli DH5α (II.2.2.2) using the NucleoSpin® 
Plasmid kit (Table 1, II.1.3) prior to sequencing (II.2.1.6) or for the transformation of A. 
tumefaciens (II.2.3) from a well-grown 5 ml LBAmp culture (II.1.5). 
A larger amount of DNA was required for the transfection of HEK293-6E cells. Thus, 
plasmids were isolated using the NucleoBond® Xtra Midi Plus kit (Table 1, II.1.3) from a 
200 ml 2xTYGAmp culture (II.1.5) following the isopropanol-precipitation protocol. 
 
II.2.3 Cultivation of A. tumefaciens  
II.2.3.1 Preparation of electrocompetent A. tumefaciens  
A. tumefaciens were cultivated in YEB+KR medium (II.1.5) until an OD600 nm of 5 was reached. 
Cells were pelleted (2,000 g, 10 min) and each pellet was resuspended in 50 ml sterile H2O. 
This step was repeated thrice, but with resuspension in first 25 ml H2O followed by pooling of 
both pellets, second in 10 ml 10% (v/v) glycerol and finally in 3 ml 10% (v/v) glycerol. All 
steps were performed at 4°C. Cells were stored in aliquots of 50 µl at -80°C. 
 
II.2.3.2 Electrotransformation of A. tumefaciens 
1 µl of purified plasmid (II.2.2.4) was added to one aliquot of electrocompetent A. 
tumefaciens (II.2.3.1), transferred into a 2-mm electroporation cuvette (Eppendorf) and 
transformed for 5 ms at 2,500 V using a Multiporator® (II.1.9). Bacteria were allowed to 
regenerate for 2 h at 28°C in 950 µl SOC medium (II.1.5). Bacteria were plated on YEB+KCR 
agar plates (II.1.5) and incubated for 3-4 days at 28°C until the success of the transformation 
was verified by colony PCR (II.2.1.4). 
 
II.2.3.3 Cryopreservation of A. tumefaciens for long-term storage 
A recombinant A. tumefaciens clone (II.2.3.2) was grown in 5 ml YEB+KCR (II.1.5) for 3 days 
at 28°C on a suspension mixer. The OD600 nm was determined and the culture was pelleted 
(2,000 g, 20 min). The pellet was resuspended in an appropriate volume of A. tumefaciens 
freezing medium (II.1.5) to obtain a final OD600 nm of 20 and immediately stored at -80°C. 
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II.2.4 Expression and purification of recombinant proteins 
II.2.4.1 Transient expression of antibodies in N. benthamiana and purification 
Antibodies were produced by infiltrating N. benthamiana plants with A. tumefaciens strains 
containing the respective pTRA(k)t_HC, pTRAkt_LC (Figure 44) or pTRAc_p19si (II.1.6) 
vectors. Bacteria were separately grown in YEB+KC medium (II.1.5). Cultures were diluted to 
an OD600 nm of 1 using H2O and 2 x infiltration medium (II.1.5), mixed in a ratio of 2:2:1 for 
bacterial strains containing pTRA(k)t_HC, pTRAkt_LC and pTRAc_p19si, respectively, and 
incubated for 2 h at room temperature before infiltration. N. benthamiana plants were 
incubated as described [84]. 
Leaves were harvested after 5 days and disintegrated in 3x (v/w) ice-cold extraction 
buffer (II.1.5). The resulting extract was pre-filtered through Miracloth (EMD Millipore). A 
substantial fraction of contaminating plant proteins was precipitated using 500 mM NaCl at 
pH 8.0 and incubated for 30 min at 4°C before centrifugation (38,000 g, 20 min, 4°C). The 
supernatant was filtered through a glass fiber pre-filter and a 0.45-µm cellulose acetate filter 
(Sartorius). Antibodies were purified by Protein A or MabSelectTM (IgG1) or CaptureSelect 
IgA chromatography (IgA2m(2)) (Table 3, II.1.3). Elution fractions containing the antibody 
as determined by SDS-PAGE (II.2.5.1) were pooled, concentrated using Vivaspin centrifugal 
concentrators (II.1.9) and re-buffered to RPMI1640 supplemented with 25 mM HEPES 
(PAA). The protein was sterilized by 0.22-µm filtration and stored at -20°C. The protein 
concentration was determined by ELISA (IgG1, II.2.5.4.3) or Bradford assay [97] 
(IgAm2(2)). 
 
II.2.4.2 Transient protein expression in HEK293-6E cells and purification 
HEK293-6E cells (II.1.8) were cultivated in complete Freestyle F17 medium (II.1.5) [98] 
until the final volume with a viable cell density of ~2 x 106 cells/ml was reached. Immediately 
before transfection, ¾ of the medium were exchanged. The cells were transfected using 
1 µg DNA/ml cell culture and 2 µg polyethyleneimine (PEIproTM, Polyplus)/µg DNA [77]. 
In the case of 4G2IgG1, the DNA-mixture contained 47.5% (w/w) pTT5_4G2HC-
IgG1hCU, 47.5% (w/w) pTT5_4G2LChCU and 5% (w/w) pTT-o-GFPq (vector for intracellular 
expression of the green-fluorescent protein (GFP)) (VII.5). The latter plasmid was added to 
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monitor transfection efficiency by counting GFP-positive cells via flow cytometry using a BD 
FACSVerseTM (II.1.9). 1 day post transfection (dpt), 4 mM valproic acid, 0.5% (v/v) TN1 and 
1% (v/v) ultra-low IgG FBS were added to the cells. 3 dpt, the volume was doubled and the 
cells were split into two shaking flasks, if necessary, and 0.3% (w/v) glucose were added. The 
supernatant was harvested 6 dpt by centrifugation (4,000 g, 15 min, 4°C), clarified by 
0.45-µm filtration and antibodies were purified by Protein A chromatography (Table 3, 
II.1.3). Samples were analyzed and stored as explained (II.2.4.1). 
In the case of an EGb-scFv fusion protein, the DNA-mixture comprised 95% (w/w) 
pTT5SH8Q2_EGbR201K-scFv and 5% (w/w) pTT-o-GFPq (VII.5). 1 dpt, 4 mM valproic acid, 
0.5% (v/v) TN1 and 1% (v/v) ultra-low IgG FBS were added to the cells. 2 dpt, 1/4 (v/v) fresh 
medium and 0.3% (w/v) glucose were added. The supernatant was harvested 3 dpt. Because 
Gb needs a free N-terminus for enzymatic activity, Gb-scFv fusion proteins were expressed 
with an N-terminal protective peptide fused to an ECS to suppress enzymatic activity 
(resulting in the induction of apoptosis) in the expressing cells (=EGb-scFv), and a C-terminal 
His8-tag (Figure 47, VII.5) enabling purification by immobilized metal affinity 
chromatography using nickel-ions loaded on a nitrilotriacetic acid-agarose matrix (Ni-NTA 
agarose IMAC, Table 3, II.1.3) [99]. Samples were analyzed by SDS-PAGE and immunoblot 
(II.2.5.1, II.2.5.2), elution fractions containing the fusion protein were concentrated using 
Vivaspin centrifugal concentrators (II.1.9), re-buffered to EGb storage buffer (II.1.5), 
sterilized by 0.22-µm filtration and stored at -80°C. The concentration was determined by 
densitometry in Coomassie-stained SDS-PAA gels (II.2.5.1) using BSA as protein standard 
with the Aida Image Analyzer 4.27.039 (II.1.9). 
In some cases, cells were transfected by Carmen Franken or Nicole Kündgen-Redding, 
(both Fraunhofer IME, Aachen). 
 
  
Material and Methods
 
 
 
 
 
27 
 
II.2.5 Protein analytical methods 
II.2.5.1 SDS-PAGE and Coomassie staining 
Purifications, protein purity and protein integrity were analyzed by SDS-PAGE [100]. Protein 
solutions were mixed with an appropriate volume of 5x protein loading buffer (II.1.5) and 
separated using 1x TGS (II.1.5) as the running buffer for 60 min at 160 V. Gels were 
afterwards stained for 20 min in Coomassie staining solution followed by destaining in 
Coomassie destaining solution (II.1.5). 
 
II.2.5.2 Immunoblot analysis 
SDS-PAGE-separated proteins (II.2.5.1) were transferred onto a nitrocellulose or methanol-
activated polyvinylidene difluoride (PVDF) membrane in blotting buffer (II.1.5) for 60 min at 
360 mA [101]. Membranes were blocked for 1 h at room temperature with PBS/BSA or 
PBS/M (II.1.5) and proteins were specifically probed using the appropriate detection 
antibodies and corresponding substrates (II.1.4). 
 
II.2.5.3 Surface plasmon resonance (SPR) spectroscopy 
SPR spectroscopic analyses were performed by Holger Spiegel (Fraunhofer IME, Aachen), 
essentially as described previously [3], using a Biacore T200 (II.1.9) and CM5-S-Series 
sensor chips (BiacoreTM). These were either functionalized with recombinant Protein A 
(Sigma-Aldrich) or with the appropriate reagent from the Mouse Antibody Capture Kit 
(RαM-Fc, BiacoreTM) by EDC/NHS coupling as published [3]. All measurements were 
performed at 25°C using HBS-EP (II.1.5) as the running buffer. Binding curves were 
evaluated using BiacoreTM T200 Evaluation Software (II.1.9). Between measurements, the 
surface was regenerated by pulsing for 1 min with 30 mM HCl. Fc-1 or Fc-3 respectively 
were used as references for blank subtraction and buffer injections were used for double 
referencing. 
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II.2.5.3.1 Determination of antibody affinity 
The affinity of murine or chimeric IgG antibodies was investigated by capturing 
130-160 response units (RU) (4G2) or 320-350 RU (2.44) of the corresponding antibody onto 
immobilized Protein A (chimeric IgG) or RαM-Fc (murine IgG). The corresponding antigens 
(AMA1 (3D7) for 4G2, mE-ERH for 2.44 (II.1.7)) were injected in different concentrations at 
a flow rate of 30 µl/min for 180 s. Dissociation was followed for 420-450 s.  
 
II.2.5.3.2 Determination of antibody binding towards human CD32(a) 
The binding of recombinant or human IgG antibodies to human CD32(a) (R&D Systems) was 
investigated by capturing ~1,600 RU of the corresponding antibody (II.1.7, II.2.4, [73]) onto 
immobilized Protein A. Human CD32(a) was injected at a flow rate of 30 µl/min for 180 s. 
Dissociation was followed for at least 200 s.  
 
II.2.5.4 Enzyme-linked immunosorbent assay (ELISA) 
ELISA allows the specific detection of proteins [102] and was used for isotyping of murine 
IgGs (Table 2, II.1.3), analysing antigen binding by antibodies and derivatives (II.2.5.4.1), 
quantifying chimeric IgG (II.2.5.4.3), or assessing parasite growth in drug susceptibility 
assays (DSAs) (II.2.5.4.4). 
 
II.2.5.4.1 Antigen ELISA 
The binding of antibodies or derivatives (II.2.4) to their target antigen (II.1.7) was assessed by 
antigen ELISA. Steps were performed at room temperature in a total volume of 50 µl per well 
for 1 h unless stated otherwise and wells were washed thrice with PBST (II.1.5) between 
steps. Wells were coated with 50-100 ng of the respective target antigen over night at 4°C 
followed by blocking with 100 µl PBS/BSA (II.1.5). The antibodies or derivatives were 
applied in 1:2-fold serial dilutions in PBS (II.1.5), probed with the respective detection 
antibodies (Table 5, II.1.4) and the corresponding substrates (Table 4, II.1.4) as summarized 
in Table 10. 
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Table 10 Setup of antigen ELISA to assess the binding of an antibody or a EGb-scFv fusion protein 
Applied Protein 1
st detection 
antibody 
2nd detection 
antibody Substrate* 
    
recombinant chimeric IgG1 GαH-IgGFc
PO 
GαH-IgκLCAP 
- TMB pNPP 
    
recombinant chimeric IgA2m(2) GαH-IgκLCAP - pNPP 
    
EGb-scFv fusion protein MαGb GαM-IgGFcPO TMB 
*According to Table 4 (II.1.4), TMB was detected after stop with 1 M HCl at A450 nm and pNPP at A405 nm. 
 
II.2.5.4.2 Competition ELISA 
Competition for antigen binding between 2.44IgG1 and three PfMSP4EGF-specific murine 
antibodies was analyzed by ELISA as described above (II.2.5.4.1). In this case 500 ng/ml 
2.44IgG1 was concurrently incubated on mE-ERH-coated (II.1.7) and PBS/BSA-blocked 
(II.1.5) wells with increasing amounts of the murine IgGs in duplicate and detected with 
GαH-IgGFcPO (Table 5, II.1.4), as described (II.2.5.4.1) [3]. Cross reactivity between this 
detection antibody and the murine IgGs was excluded in a control experiment. 
 
II.2.5.4.3 IgG-quantification ELISA 
Recombinantly produced chimeric IgG1 was quantified by IgG-quantification ELISA [103] 
(Table 11). 
 
Table 11 Setup of the IgG-quantification ELISA 
Step* Agent  Dilution or 
concentration 
Diluent tinc  Tinc 
Coating GαH-Ig 2 µg/ml Coating buffer Over night 4°C 
Blocking PBS/BSA  PBS/BSA 1 h room temperature
Sample 
application 
- Standard:       
nnhuIgG 
 
- Sample 
2 µg/ml 
(12x serial 1:2) 
 
12x serial 1:2 
PBS/BSA 1 h room temperature
Detection GαH-IgGFCPO 1:9000 PBS/BSA 1 h 
room 
temperature
Visualization TMB**   5-15 min room temperature
*All steps were performed in a final volume of 50 µl per well except for the blocking step which was performed 
with 100 µl per well. In between steps, the wells were washed thrice with PBST. 
**According to Table 4 (II.1.4), TMB was detected after stop with 1 M HCl at A450 nm 
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II.2.5.4.4 Histidine-rich protein 2 (PfHRP2) sandwich ELISA 
The sandwich ELISA quantifying PfHRP2 ([104], Table 12) was used to determine parasite 
growth in the presence of Gb (II.1.7) or Gb-scFv (II.2.4.2) in DSAs (II.2.7.5).  
 
Table 12 Setup of the PfHRP2 sandwich ELISA to assess parasite growth in a DSA 
Step* Agent  Dilution or concentration Diluent tinc  Tinc 
Coating MPFM-55A  1 µg/ml PBS Over night 4°C 
Blocking PBS/BSA  PBS/BSA 1 h room temperature 
Sample 
application 
Lysed parasite 
culture 1:50 PBS 1 h 
room 
temperature 
Detection MPFG-55P 0.05 µg/ml 
PBS/BSA + 
0.1% (v/v)  
Tween-20 
1 h room temperature 
Visualization TMB   5-15 min room temperature 
*All steps were performed in a final volume of 100 µl per well except for the blocking step which was 
performed with 200 µl per well. In between steps, the wells were washed thrice with PBST (II.1.5). 
 
II.2.5.5 IgG-Fc N-glycan analysis 
IgG-Fc N-glycan profiles were analyzed by quadrupole time-of-flight mass spectrometry 
(QTof; Waters, Hertfordshire, UK) at the University of Natural Resources and Life Sciences 
(Prof. Dr. F. Altmann; Vienna, Austria). 4 µg of purified antibody (II.1.7, II.2.4, [73]) were 
separated under reducing conditions using 4-12% (w/v PAA) protein gels (Life 
Technologies®), the bands for the heavy chains were excised and analyzed as described [6].  
 
II.2.6 Cultivation of P. falciparum 
P. falciparum strains 3D7A (MRA-151), D10 ACP(transit)-GFP (MRA-569, D10 with 
cytosolic expression of the GFP) [105] and K1 (MRA-159) were obtained from the Malaria 
Research and Reference Reagent Resource Center (MR4, ATCC) and cultivated in MCM at 
37°C in a gassed incubator (II.1.9) at 5% (v/v) O2, 5% (v/v) CO2 and 90% (v/v) N2 [106]. 
Parasites were maintained at 5% (v/v) hematocrit in 0+ erythrocyte pools from 15-20 blood 
donors from the regional blood bank (Dr. med. G. Hutschenreuter, RWTH Aachen University 
Clinic). Pelleted erythrocytes (500 g, 15 min) were washed thrice and stored at 66% (v/v) 
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hematocrit, both in SAG-mannitol (II.1.5). Parasites were synchronized using 5% (w/v) 
sorbitol in H2O in three consecutive cycles prior to growth inhibition assays (GIAs) (II.2.7.1) 
or DSAs (II.2.7.5) [107]. Cryopreservation and thawing of parasites was performed as 
described [108]. The strains were identified by isolation of DNA using the QIAamp DNA 
Blood Mini Kit (Table 2, II.1.3), sequencing of the AMA1 gene (II.2.1.6, VII.4) and 
alignment of the obtained sequences to GenBank® database sequences (Accession numbers: 
3D7A: AAN35928.1; D10: ACB87778.1; K1: AAC47109.1) [109]. 
 
II.2.6.1 Preparation of free merozoites and merozoite extract 
Schizonts were collected from sorbitol-synchronized P. falciparum cultures (II.2.6) by 70% 
(v/v) Percoll-gradient centrifugation (II.1.5) [110] and incubated in MCM (II.1.5) 
+ 10 µM E64 until they were fully mature [111]. These were pelleted (1,900 g, 10 min), 
resuspended in 5 ml MCM (II.1.5) and ruptured by passage through a 1.2-µm Acrodisc 
syringe filter (VWR) [111]. Merozoites were adjusted to 5 x 107 /ml in RPMI + 20 mM 
HEPES and either used immediately for phagocytosis assays (II.2.7.4), or stored at -80°C for 
mADRB assays (II.2.7.2). Merozoite extract was prepared by thawing of merozoites, 
centrifugation (16,000 g, 6 min) and resuspension in 1/50 vol PBS containing an appropriate 
amount of 5x denaturing non-reducing protein loading buffer (II.1.5). 
 
II.2.6.2 Immunofluorescence assay (IFA) 
Binding of antibodies to their native antigens was assessed by IFA. E64-treated schizonts 
(II.2.6.1) were transferred in FCS onto Superfrost microscopy slides, fixed for 20 min in 
100% (v/v) methanol at -20°C, wrapped in tissue paper and stored at room temperature. IFAs 
were carried out essentially as described [5]. Fields were separated using a hydrophobic 
marker pen (Calbiochem). Antibodies were used at 50 µg/ml, unless stated otherwise, and 
probed with the appropriate detection antibodies (Table 5, II.1.4). All incubation steps were 
performed at room temperature in a moist box (Thermo Fisher Scientific) for 1 h and slides 
were washed thrice with PBS (II.1.5) between steps. Parasite nuclei were stained with 
10 µg/ml Hoechst 33342. Slides were mounted with ProLong® Antifade Gold (Invitrogen), 
coated with a cover slip and analyzed using a TCS SP8 Confocal Microscope (II.1.9). 
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II.2.7 Functional assays 
II.2.7.1 GIA 
GIAs were performed as described [6, 86]. Briefly, 0.3% synchronized schizonts (II.2.5.5) 
were incubated at 2% hematocrit for 48 h in the presence of the relevant antibodies in 96-well 
half-area microtiter cell culture plates in a final volume of 50 µl. Parasites were lysed by 
freeze-thawing and growth was analyzed by quantifying the parasite’s lactate dehydrogenase 
(pLDH) activity by adding 100 µl of 37°C-prewarmed pLDH buffer (II.1.5) to each well. 
A655 nm was determined using the Epoch spectrophotometer (II.1.9) after incubation for 30 min 
on a multiplate shaker at room temperature in the dark. The percentage of growth inhibition 
was calculated as described [86]. 
 
II.2.7.2 ADRB assays 
Antibody-mediated stimulation of PMNs was determined using ADRB assays. To enable easy 
distinction of the applied ADRB assay by its name, the three different assays were assigned 
the following names in this PhD thesis [1]: sADRB assay: ADRB assay using solid-phase 
coated antigens; mADRB: ADRB assay using opsonized merozoites; or cADRB assay: 
ADRB assay using directly coated antibodies (Figure 5).  
 
Figure 5 Experimental strategies of the antibody-dependent respiratory burst (ADRB) assays. 
The antibody-mediated stimulation of PMNs was determined in three distinct assays which were distinguished 
by their nomenclature: 
The sADRB assay (top) measures the reactivity of PMNs against antibodies bound to solid-phase immobilized 
antigen on polystyrene plates. 
The mADRB assay (middle) measures the response of PMNs towards antibody-opsonized merozoites. 
The cADRB assay (bottom) uses directly coated antibodies. 
Generated ROS were visualized by measuring luminol-enhanced chemiluminescence.  
Merozoite: www.qiagen.com. Illustration modified from [1]. 
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ADRB assays were carried out in opaque 96-well high-binding plates in a final volume of 
75 µl. PMNs were isolated from heparinized venous blood of healthy malaria-naïve donors 
prior to each assay by dextran sedimentation, gradient centrifugation and hypotonic lysis of 
residual erythrocytes, as described previously [1]. Briefly, antibodies were either applied to a 
coated and blocked well (sADRB assay), directly coated (cADRB assay) or used to opsonize 
purified merozoites (II.2.6.1) (mADRB assay): 1.25 x 106 merozoites were opsonized with 
25 µl decomplemented plasma or purified antibody (II.1.7, II.2.4, [73]) for 2 h at room 
temperature, pelleted (1,500 g, 20 min) and resuspended in 25 µl HBSS without Ca2+ and 
Mg2+ (PAA). Plasma samples were always decomplemented at 56°C for 30 min before usage 
in any assay, and this specific HBSS was used to enhance assay sensitivity, because HBSS 
supplemented with Ca2+ and Mg2+ was shown to generate too high background noise in 
control experiments. 1.5 x 105 purified PMNs were added immediately before readings were 
initiated using a GENios Pro multiplate reader (II.1.9) in the presence of 83.3 µM luminol 
(Table 13).  
 
Table 13 Setup of the sADRB, mADRB and cADRB assay 
Step sADRB assay 
mADRB 
assay 
cADRB 
assay tinc Tinc 
Coating* 75 µl target antigen - 
75 µl purified 
antibody 
Over 
night 4°C 
Blocking 350 µl PBS/BSA 2 h room temperature
Sample 
application* 
Antibody or 
plasma diluted in 
PBS 
25 µl 
opsonized 
merozoites 
- 1 h room temperature
Visualization 83.3 µM luminol 1.5 x 105 purified PMNs 
60 min in 
~2-min 
intervalls 
37°C 
*Specific modifications (the amount of coated antigen or antibody, the concentration of applied or opsonizing 
antibody) are stated in the respective figure legends. If plasma was used, this was used 1:5-fold diluted in the 
sADRB assay, or undiluted in the mADRB assay. 
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II.2.7.2.1 FcγR treatment of PMNs and localization of ROS 
The neutrophilic ADRB responses were characterized using two decomplemented plasma 
samples as examples: plasma from the semi-immune Ghanaian donor 5 (SIP 5) and a plasma 
sample pool containing four medium reactive samples to rule out individual differences (SIP-
pool) from based on their previously determined ADRB reactivity [1, 73]. The contribution of 
either present FcγR to the neutrophilic ADRB was determined by removing CD16(b) with Pi-
PLC (Table 1, II.1.3) or blocking CD32(a) with MαH-CD32 (Table 5, II.1.4) from freshly-
purified PMNs. The availability of FcγR was monitored by flow cytometry on a BD 
FACSVerseTM (II.1.9) using fluorophore-conjugated antibodies (MαH-CD16FITC, MαH-
CD32647 and MαH-CD64FITC (Table 5, II.1.4)), as described previously [1]. Resulting ADRB 
responses were detected (II.2.7.2) and compared between untreated and treated PMNs.  
Resulting ROS after stimulation were localized for intra- or extracellular appearance by 
scavenging extracellular ROS with 2,000 U/ml CAT and 50 U/ml SOD before addition of 
PMNs [1, 112-114], and resulting responses were compared to standard ADRB measurements 
(II.2.7.2) without scavengers. Control experiments were performed using the less membrane-
permeable luminescence amplifier isoluminol instead of luminol.  
 
II.2.7.3 Flow-cytometric mADRB 
The flow-cytometric mADRB [1] was performed using dihydrorhodamine-123 (DHR-123). 
Opsonized merozoites were prepared as explained before (II.2.7.2). Freshly-isolated PMNs 
(II.2.7.2) were pre-incubated for 30 min with 100 µM DHR-123 at 4°C in the dark. 3 x 105 of 
these PMNs were then exposed to the opsonized merozoites for 30 min at 37°C and 
immediately analyzed by flow cytometry on a BD FACSVerse™ (II.1.9), counting 5,000 
PMNs per sample. 
 
II.2.7.4 Phagocytosis assay 
The induction of phagocytosis by opsonized merozoites was assessed using GFP-expressing 
merozoites of the strain P. falciparum D10 (ACP)transit-GFP (II.2.6) which were previously 
opsonized with either SIP or NIP using flow cytometry (BD FACSVerse™ (II.1.9)) and laser-
scanning fluorescence microscopy (TCS SP8 Confocal Microscope (II.1.9)) as described [1]. 
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II.2.7.5 Drug susceptibility assay (DSA) 
II.2.7.5.1 Activation of EGb(-scFv fusion) proteins by rEK digest 
The N-terminal protective peptide with rEK cleavage site was removed from EGb (II.1.7) or 
EGb-scFv (II.2.4.2) by adding 0.02 U rEK/µg protein for 16 h at 23°C in EGb storage buffer 
(II.1.5) supplemented with 2 mM CaCl2 prior to each DSA (II.2.7.5.2). Proteins were 
quantified by densitometry in Coomassie-stained SDS-PAA gels (II.2.4.2). The restored 
enzymatic activity of Gb was verified using a colorimetric assay [88]: Cleavage of 200 µM of 
the artificial substrate Ac-IETD-pNA (Calbiochem) to pNA by 250 ng of Gb or 500 ng 
Gb-scFv was determined in a 60-min kinetic window at 37°C at 405 nm using a GENios Pro 
multiplate reader (II.1.9). A Gb-standard (Table 1, II.1.3) was used as reference. Enzymatic 
activities were calculated by linear regression of this increase during the first 10 min [88]. 
 
II.2.7.5.2 DSA 
DSAs were performed based on a published method [115] in 96-well half-area microtiter cell 
culture plates in a final volume of 50 µl. Sorbitol-synchronized parasites (II.2.5.5) were 
incubated at 1.5% hematocrit in the presence of the relevant proteins (II.1.7, II.2.4) for 
30-72 h as indicated below (Table 14) and explained before [2]. Plates were frozen at -20°C 
to lyse erythrocytes. Parasite growth was assessed by PfHRP2 sandwich ELISA (II.2.5.4.4). 
The percentage of inhibition was calculated based on the formula of a GIA (II.2.7.1). 
 
Table 14 Parameters of performed DSAs to assess the antimalarial activity of Gb-scFv fusion proteins 
DSA type 
(replication cycles) 
Starting 
parasitemia [%]* 
Covered parasite 
stages 
Specific reason for the DSA 
type 
72-h DSA (1.5) 0.05 Ring-schizont-ring-schizont Standardized DSA [115]  
48-h DSA (1) 0.05 Schizont-ring-schizont 
Specific evaluation of co-
importing step 
30-h DSA (0.5) 0.2 Ring-schizont Lack of co-importing step 
*The starting parasitemias for each assay were chosen based on the steady growth factor x4 per schizont rupture, 
so that the final parasitemias were equal at the end of each assay. 
 
۷ܖܐܑ܊ܑܜܑܗܖ	ሾ%ሿ = 100	% − Aସହ଴	୬୫	(sample) 	−	Aସହ଴	୬୫	(background)Aସହ଴	୬୫	(parasite	control) 	−	Aସହ଴	୬୫	(background) × 100	% 
 
A450 nm (sample): Absorbance at 450 nm of the (E)Gb(-scFv fusion) protein-containing sample 
A450 nm (background): Absorbance at 450 nm of uninfected erythrocytes (30-h, 72-h DSA) or in the presence of 
4 mM EDTA (48-h DSA). 
A450 nm (parasite control): Absorbance at 450 nm of parasites without added proteins. 
Results
 
 
 
 
 
36 
 
III. Results 
III.1 Functional dissection of the neutrophilic ADRB 
The experimental procedures of the ADRB assays have been established before during my 
master thesis [73]. The results of this chapter (III.1) have already been published [1]. 
Most importantly, different kinetic profiles for the neutrophilic ADRB responses in the 
sADRB and mADRB assay were identified during the establishment of these assays [73]. 
While the stimulation of PMNs in the sADRB assay led to a peak-shaped response profile 
with its maximum after ~5-10 min, opsonized merozoites induced a plateau- or bell-shaped 
response profile, depending on the PMN donor (exemplary profiles: Figure 7A, B). These 
observations led to the conclusion that the different types of stimulating immune complexes 
may lead to distinct activation mechanisms. This conclusion served as the starting point for 
the in-depth characterizations performed within this PhD thesis to achieve the first aim, the 
functional dissection of the neutrophilic ADRB (I.3). 
At first, the contribution of each present FcγR to the respiratory burst was analyzed in 
both, the sADRB and the mADRB assays. Following this, the cellular location of the 
corresponding ADRB response was determined in these assays. Finally, the neutrophilic anti-
merozoite response was assessed by phagocytosis assays (III.1.1 – III.1.3). The comparative 
measurements were performed with two representative malaria-reactive semi-immune 
Ghanaian plasma samples, SIP 5 and the SIP-pool (II.2.7.2.1). 
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III.1.1 The dependence on FcγR 
The dependence of the neutrophilic sADRB and mADRB on FcγR was characterized by 
selective enzymatic removal of CD16(b) using Pi-PLC from freshly-isolated PMNs or 
antibody-mediated blocking of CD32(a) on freshly-isolated PMNs (II.2.7.2), followed by 
comparative ADRB assays using untreated PMNs as well (II.2.7.2). The high-affinity FcγRI 
(CD64) was not present on the isolated PMNs as confirmed by flow cytometry (Figure 6A). 
Each treatment showed an efficiency of 75-80% without markedly affecting the respective 
other present FcγR (Figure 6B). 
 
 
Figure 6 FcγR profile of isolated PMNs and residual availabilities after treatments. 
A: Isolated PMNs were analyzed by flow cytometry for the presence of either FcγR using FcγR-specific 
fluorophore-conjugated detection antibodies (Table 5, II.1.4, II.2.7.2.1). The median fluorescence intensity 
(MFI) ± SD of two to three experiments in technical duplicates each is shown. 
B: After either enzymatic removal of CD16(b) or blocking of CD32(a) (II.2.7.2.1), the residual availability of 
either present FcγR was monitored by flow cytometry using FcγR-specific, fluorophore-conjugated detection 
antibodies (Table 5, II.1.4), whereby the MFI of untreated PMNs was set to 100%. 
MFI: median fluorescence intensity; PMN: polymorphonuclear neutrophil granulocyte; FcγR: receptor for IgG. 
Illustration modified from [1]. 
 
After enzymatic removal of CD16(b), the intensity of the neutrophilic response in both, 
the sADRB assay (Figure 7A, C) and the mADRB assay (Figure 7B, D) was reduced to a 
residual intensity of 50-60%, indicating no predominant contribution of CD16(b) on either 
ADRB. 
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Figure 7 Dependence of the neutrophilic ADRB on CD16(b).  
The role of CD16(b) in the neutrophilic ADRB was assessed in a 60-min kinetic window (II.2.7.2) using 
A: untreated PMNs in the sADRB assay using 75 ng immobilized AMA1 (filled symbols), 
B: untreated PMNs in the mADRB assay (filled symbols), 
C: PMNs with removed CD16(b) by Pi-PLC treatment (II.2.7.2.1) in the sADRB assay using 75 ng immobilized 
AMA1 (open symbols), or 
D: PMNs with removed CD16(b) Pi-PLC treatment (II.2.7.2.1) in the mADRB assay (open symbols). 
The reactivities of PMNs were measured against SIP 5 (circles), the SIP-pool (squares) and one NIP (triangles), 
as representative examples. The data represent the mean ± SD of two experiments using PMNs from two 
different donors, each in technical duplicates. In A and B, luminescence intensities were normalized to the 
reactivity of SIP 5 in each assay and therefore are presented in arbitrary units. In C and D, the residual 
percentages compared to the respective kinetics without Pi-PLC treatment are depicted. 
PMN: polymorphonuclear neutrophil granulocyte; Pi-PLC: phosphatidylinositol-specific phospholipase C; 
SIP: semi-immune plasma; NIP: non-immune plasma; a. u.: arbitrary units. 
Illustration taken from [1]. 
 
The contribution of CD32(a) to the neutrophilic ADRB was investigated next. Blocking 
of CD32(a) (II.2.7.2.1) reduced the sADRB response to even <20% compared to the 
corresponding response using untreated PMNs. In particular, the overall response profile was 
completely altered (Figure 8A, C). The first distinct peak was entirely abolished and, in 
general, only a basal level of ROS was generated. In the mADRB assay, blocking of CD32(a) 
led to a residual response intensity of 50-60% (Figure 8B, D), as also observed for PMNs with 
removed CD16(b) (Figure 7B, D). 
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Figure 8 Dependence of the neutrophilic ADRB on CD32(a). 
The importance of CD32(a) for the neutrophilic ADRB was assessed in a 60-min kinetic window (II.2.7.2) using 
A: untreated PMNs in the sADRB assay using 75 ng immobilized AMA1 (filled symbols), 
B: untreated PMNs in the mADRB assay (filled symbols), 
C: PMNs with blocked CD32(a) (MαH-CD32; II.2.7.2.1) in the sADRB assay using 75 ng immobilized AMA1 
(open symbols), or 
D: PMNs with blocked CD32(a) (MαH-CD32; II.2.7.2.1) in the mADRB assay (open symbols). 
The reactivities of PMNs were measured against SIP 5 (circles), the SIP-pool (squares) and one NIP (triangles), 
as representative examples. The data represent the mean ± SD of two experiments using PMNs from two 
different donors, each in technical duplicates. In A and B, luminescence intensities were normalized to the 
reactivity of SIP 5 in each assay and therefore are presented in arbitrary units. In C and D, the residual 
percentages compared to the respective kinetics without blocking of CD32(a) are depicted. 
PMN: polymorphonuclear neutrophil granulocyte; SIP: semi-immune plasma; NIP: non-immune plasma; 
a. u.: arbitrary units. 
Illustration taken from [1]. 
 
Regarding these experiments analyzing the contribution of either FcγR, CD32(a) was 
determined to be the major contributing FcγR for the induction of the neutrophilic sADRB. 
However, no clear conclusion could be made for the neutrophilic mADRB because both 
treatments, the removal of CD16(b) (Figure 7B, D) and the blocking of CD32(a) (Figure 
8B, D), led to similar residual activities of the PMNs. Therefore, a blood donor with 
CD16(b)-deficient PMNs was recruited. The absence of CD16(b) was confirmed by flow 
cytometry (Figure 9A). A similar behavior of these CD16(b)-deficient PMNs to non-deficient 
PMNs was ensured by verifying the same kinetic response profile when PMNs were left 
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untreated (Figure 10A, B). These CD16(b)-deficient PMNs were then exposed to the same 
FcγR treatments, i. e. the enzymatic treatment with Pi-PLC to analyze the influence of this 
procedure on the activity of the PMNs, and the antibody-mediated blocking of CD32(a). The 
treatment with Pi-PLC resulted in a similar residual availability of the receptor as prior to 
treatment, and blocking of CD32(a) showed an efficiency of ~80% (Figure 9B), as also 
observed for the non-deficient PMNs (Figure 9B). 
 
 
Figure 9 FcγR profile of CD16(b)-deficient PMNs and residual FcγR availabilities after treatments. 
A: Isolated CD16(b)-deficient PMNs were analyzed by flow cytometry for the presence of either FcγR using 
FcγR-specific fluorophore-conjugated detection antibodies (Table 5, II.1.4, II.2.7.2.1) and results are presented 
as MFI ± range of one experiment. 
B: After either treatment of CD16(b)-deficient PMNs with Pi-PLC, or blocking of CD32(a) on their surface 
(II.2.7.2.1), the residual availability of CD32(a) was monitored by flow cytometry using the MαH-CD32647 
antibody (Table 5, II.1.4), whereby the MFI of untreated PMNs was set to 100%. 
MFI: median fluorescence intensity; PMN: polymorphonuclear neutrophil granulocyte; Pi-PLC: 
phosphatidylinositol-specific phospholipase C. Illustration modified from [1]. 
 
The resulting sADRB and mADRB responses after treatments were investigated (Figure 
10). The results were clear for the neutrophilic sADRB. After treatment with Pi-PLC, PMNs 
responded to a lesser extent (Figure 10A, C), similar to the reduction using non-deficient 
PMNs (Figure 7A, C). When CD32(a) was blocked, no residual response was recorded any 
more (Figure 10A, E), suggesting a predominant role for CD32(a) in triggering the 
neutrophilic sADRB response. In the mADRB assay, treatment of CD16(b)-deficient PMNs 
with Pi-PLC led to a remaining signal intensity of 60-80% (Figure 10B, D). By specific 
blocking of CD32(a), the response was even more reduced to ~40-60% (Figure 10B, F). 
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Figure 10 Dependence of the neutrophilic ADRB on FcγR using CD16(b)-deficient PMNs. 
The predominant contribution of CD32(a) was confirmed by measuring the sADRB (left panel) and mADRB 
(right panel) in a 60-min kinetic window (II.2.7.2) using CD16(b)-deficient PMNs. These were either used 
A: untreated in the sADRB assay using 75 ng immobilized AMA1 (filled symbols), 
B: untreated in the mADRB assay (filled symbols), 
C: treated with Pi-PLC in the sADRB assay using 75 ng immobilized AMA1 (open symbols), 
D: treated with Pi-PLC in the mADRB assay (open symbols), 
E: with blocked CD32(a) (MαH-CD32; II.2.7.2.1) in the sADRB assay using 75 ng immobilized AMA1 (half-
filled symbols), or 
F: with blocked CD32(a) (MαH-CD32; II.2.7.2.1) in the mADRB assay (half-filled symbols). 
The reactivities of PMNs were measured against SIP 5 (circles), the SIP-pool (squares) and one NIP (triangles), 
as representative examples. The data represent the mean ± range of one experiment using CD16-deficient PMNs 
from one donor in technical duplicates. In A and B, luminescence intensities were normalized to the reactivity of 
SIP 5 in each assay and therefore are presented in arbitrary units. In C-F, the residual percentages compared to 
the respective kinetics using untreated CD16(b)-deficient PMNs are shown. 
PMN: polymorphonuclear neutrophil granulocyte; SIP: semi-immune plasma; NIP: non-immune plasma; 
Pi-PLC: phosphatidylinositol-specific phospholipase C; a. u.: arbitrary units. Illustration taken from [1]. 
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III.1.2 The cellular site of the generation of ROS  
After assessment of the contribution of each FcγR to the neutrophilic sADRB and mADRB, 
the generated ROS were localized for intra- or extracellular appearance (Figure 11). For this 
purpose, extracellular ROS were scavenged using the enzymes CAT and SOD (II.2.7.2.1). 
 
  
Figure 11 The cellular sites of the generated ROS during the sADRB and mADRB. 
The cellular sites of generated ROS during the neutrophilic ADRB were determined in a 60-min kinetic window 
(II.2.7.2, II.2.7.2.1) by measuring 
A: the total chemiluminescence in the sADRB assay using 75 ng immobilized AMA1 (filled symbols), 
B: the total chemiluminescence in the mADRB assay (filled symbols), 
C: the intracellular chemiluminescence sADRB assay using 75 ng immobilized AMA1 (open symbols), or 
D: the intracellular chemiluminescence mADRB assay (open symbols). 
Intracellular ROS were quantified by depleting the extracellular ROS with SOD and CAT (C, D, open symbols). 
The reactivities of PMNs were measured against SIP 5 (circles), the SIP-pool (squares) and one NIP (triangles), 
as representative examples. The data represent the mean ± SD of two experiments using PMNs from two 
different donors, each in technical duplicates. In A and B, luminescence intensities were normalized to the 
reactivity of SIP 5 in each assay and therefore are presented in arbitrary units. In C and D, the residual 
percentages compared to the respective kinetics using luminol without extracellular ROS scavengers are shown. 
PMN: polymorphonuclear neutrophil granulocyte; SIP: semi-immune plasma; NIP: non-immune plasma; 
a. u.: arbitrary units. Illustration modified from [1]. 
 
The already observed different contribution of either FcγR was accompanied by distinct 
occurrences of the generated ROS. The neutrophilic sADRB was characterized by an almost 
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exclusive extracellular appearance of ROS (Figure 11A, C). In contrast, the neutrophilic 
mADRB response appeared to be almost restricted at intracellular level, because no reduced 
signal intensity was observed when extracellular ROS scavengers were present (Figure 
11B, D). In fact, the response was slightly delayed and even higher than without scavengers 
being present.  
These observations were verified by measuring the sADRB and mADRB responses 
using the less membrane-permeable luminescence amplifier isoluminol (II.2.7.2.1, Figure 12).  
 
 
Figure 12 Confirmation of the cellular sites of ROS generation during the ADRB using isoluminol. 
The cellular sites of generated ROS during the sADRB (left panel) and mADRB (right panel) responses were 
confirmed by quantification of predominantly extracellular ROS using the less membrane-permeable 
chemiluminescence amplifier isoluminol (II.2.7.2.1). The respective ADRB kinetics were determined using 
A: isoluminol in the sADRB assay using 75 ng immobilized AMA1 (filled symbols), 
B: isoluminol in the mADRB assay (filled symbols), 
C: isoluminol with extracellular ROS scavengers SOD and CAT in the sADRB assay using 75 ng immobilized 
AMA1 (open symbols), or 
D: isoluminol with extracellular ROS scavengers SOD and CAT in the mADRB assay (open symbols). 
SIP 5 (circles), the SIP-pool (squares) and one NIP (triangles) were used as examples. The data represent the 
mean ± SD of two experiments using PMNs from two different donors, each in technical duplicates. In A to D, 
the residual percentages compared to the respective kinetics using luminol without extracellular ROS scavengers 
are shown (Figure 11A, B). 
PMN: polymorphonuclear neutrophil granulocyte; SIP: semi-immune plasma; NIP: non-immune plasma. 
Illustration modified from [1]. 
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Using this control-setup for the determination of the cellular sites of ADRB responses, also a 
peak-shaped response profile was determined for the neutrophilic sADRB, but in the mADRB 
assay only basal levels of luminescence were recorded. No neutrophilic sADRB responses 
were observed when extracellular ROS were enzymatically scavenged (Figure 12A, C). 
Similar basal levels of extracellular ROS were recorded in either experimental setup for the 
mADRB assay (Figure 12C, D), whereby the mADRB response in the presence of the 
scavengers was again slightly delayed compared to the response without present scavengers 
(Figure 12B, D). These findings were coherent with the previous results that ROS were 
generated at extracellular level in the sADRB assay whereas the mADRB was characterized 
by an intracellular ROS response (Figure 11, Figure 12). 
 
III.1.2.1 Confirmation of intracellular ROS generation via flow cytometry 
To more specificly confirm the intracellular activation of the neutrophilic NADPH oxidase-
dependent oxidative metabolism, a fluorescent flow-cytometric mADRB was performed 
(II.2.7.3). This assay confirmed that ROS are generated intracellularly by approx 80% of 
PMNs if these were exposed to SIP-opsonized merozoites in comparison to NIP-opsonized 
merozoites or buffer alone (Figure 13).  
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Figure 13 Confirmation of NADPH-oxidase activation in a flow-cytometric mADRB.  
In order to control the specificity of the luminol-based readout, a similar experiment was performed using 
DHR-123. DHR-123-loaded PMNs were incubated for 30 min at 37°C with opsonized merozoites (II.2.7.2) or 
buffer alone (PBS) and analyzed for DHR-123 fluorescence (DHR-123+) by flow cytometry (II.2.7.3). Data 
represent the mean ± range of two single experiments with PMNs from two different donors. 
DHR-123+ PMNs: polymorphonuclear neutrophil granulocytes showing a positive dihydrorhodamine-123 
fluorescence; SIP: semi-immune plasma; NIP: non-immune plasma. Illustration modified from [1]. 
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III.1.3 Phagocytosis as mechanism in the mADRB assay 
After having determined the intracellular localization of ROS in the standard (III.1.2) and 
flow-cytometric (III.1.2.1) mADRB, it remained to be verified that these observations 
represented phagocytosis events. This hypothesis was confirmed using phagocytosis assays 
(II.2.7.4). When GFP-expressing merozoites were opsonized with SIPs, a portion of exposed 
PMNs showed a positive GFP-signal compared to those exposed to NIP-opsonized 
merozoites (Figure 14A). This portion was significantly higher for 31 SIPs compared to 
6 NIPs using the Mann-Whitney test (p = 0.0001) (Figure 14B). Finally, the intracellular 
localization of merozoites was confirmed by confocal laser-scanning fluorescence microscopy 
(Figure 14C). The GFP fluorescence of the merozoites was observed in the same focal plane 
as the nuclei of the PMNs, thus extracellular adherence of merozoites was excluded. 
 
 
Figure 14 Confirmation of phagocytosis by flow cytometry and confocal laser-scanning microscopy. 
A: PMNs were isolated and exposed to opsonized GFP-expressing merozoites for 10 min at 37°C and 
immediately analyzed by flow cytometry (II.2.7.4). GFP-positive PMNs (phagocytosis signal) were gated and 
are highlighted in green, as exemplarily shown for SIP 5, the SIP-pool and one NIP. 
B: The significance of the different rates of phagocytosis when SIP- or NIP-opsonized merozoites were used 
were estimated using the Mann–Whitney test. Data are presented as Box-Whisker-plot of 31 SIPs or 6 NIPs. The 
dashed line at the bottom shows the background phagocytosis of merozoites incubated in buffer only. 
C: The intracellular location of the merozoites was verified by confocal laser-scanning fluorescence microscopy 
(II.2.7.4). (i) The nuclei of PMNs and (ii) GFP-expressing merozoites were stained with Hoechst 33342. (iii) 
Red arrows in the overlay image, which includes the bright field image, indicate co-localization of the GFP and 
Hoechst 33342 fluorescence signals of merozoites. Scale bar = 10 µm. 
GFP: green-fluorescent protein; FSC: forward scatter; PMNs: polymorphonuclear neutrophil granulocytes; 
SIP: semi-immune plasma; NIP: non-immune plasma. Illustration modified from [1].  
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III.2 Generation and functional characterization of recombinant 
antimalarial antibodies 
The second objective of this PhD thesis was the functional characterization of monoclonal 
antimalarial antibodies with major focus on direct growth inhibitory properties and especially 
the stimulation of PMNs (I.3), by use of the exemplary AMA1-specific 4G2 antibody [78]. 
This antibody was at first cloned into the respective expression vectors for HEK293-6E cells 
and N. benthamiana, both as IgG1 and IgA2m(2) antibody, and transiently expressed (III.2.1). 
Finally, antigen recognition, direct growth inhibition and especially their suitability to induce 
a neutrophilic ADRB response were intensively investigated (III.2.2). 
 
III.2.1 Generation of 4G2-based antibodies 
III.2.1.1 Cloning of pTRA(k)t expression vectors 
The Vh regions of the 4G2 antibody were amplified by PCR (II.2.1.4) from the ordered 
pMK-RQ vector containing the appropriate sequences (GeneArt®, VII.6). The Vh region was 
amplified using the primers 4G2Vh_fwd_AgeI and 4G2Vh_rev_SalI for cloning into 
pTRAkt_HC-IgG1 (allotype m17.1 [41]) or 4G2Vh_rev_NheI for cloning into 
pTRAt_HC-IgA2m(2). The 4G2Vl region was amplified using the primers 4G2Vl_fwd_AgeI 
and 4G2Vl_rev_BsiWI (VII.2, Figure 15A) for cloning into pTRAkt_LC. The final vectors 
(VII.5) were confirmed by sequencing (II.2.1.6). 
The pTRAt_HC-IgA2m(2) was generated by insertion of a project unrelated antibody 
sequence which was ordered as part of a pMK-RQ vector (GeneArt®, VII.6, comprising 
“SP – V region – IgA2m(2) C region”). This sequence was flanked by the restriction enzyme 
sites NcoI and XbaI, which were used for directed cloning into the pTRAt vector backbone. 
pTRAt was used instead of pTRAkt, because the kanamycin resistance gene in the pTRAkt 
vector, which is only needed for the generation of stably transfected plants, contains an 
internal NheI restriction site. The sequence enables easy replacement of V regions by AgeI 
and NheI (Figure 15B). The pTRAt_HC-IgA2m(2) vector was generated by Anja Roden 
during her bachelor thesis under my technical supervision [116]. The IgA2m(2)-allotype was 
chosen because of its enhanced stability: IgA2 has a shorter hinge-region compared to IgA1, 
and the m(2) allotype bears disulfide bonds which lack in the m(1) allotype [50]. 
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Figure 15 Amplification of 4G2V regions by PCR and final expression cassettes. 
A: 4G2V regions were amplified by PCR (II.2.1.4) and the whole reaction mixture was separated by agarose 
gelelectrophoreses (II.2.1.1), as indicated above the lanes. The bands correspond to the expected sizes of 395 bp 
for 4G2Vh (HC-IgG1), 355 bp for 4G2Vl or 393 bp for 4G2Vh (HC-IgA2m(2)), respectively. 
DNA marker: 2.5 µl of 2-log ladder (NEB #N3200). 
B: The final expression cassettes of the pTRA(k)t vectors consist of the 35S promoter of the Cauliflower mosaic 
virus (p35SS), a 5’ untranslated region of the Tobacco Etch virus (5’ UTR); a sequence encoding for a murine 
immunoglobulin signal peptide targeting to the plant apoplast (SP), the V regions of the 4G2 antibody, which 
were inserted using the indicated restriction enzyme sites (II.2.1.5), the corresponding human Ig constant regions 
(Cγ: IgG1; Cα: IgA2m(2), Cκ: Igκ) and a polyadenlytion signal of the Cauliflower mosaic virus (pA35S). The 
codons for the constant regions were optimized for expression in N. benthamiana. 
 
III.2.1.2 Cloning of pTT5 expression vectors 
The pTT5_4G2HC-IgG1hCU and pTT5_4G2LChCU expression vectors (hCU: human codon 
usage; VII.5) were generated in several steps from the pTRA(k)t expression vectors, to 
generate similar expression vectors for HEK293-6E cells which facilitate easy cut-and-paste 
cloning of V regions of different antibodies (Figure 16). In principle, the expression cassettes 
encoding for the “SP – V region – C region” were amplified using the primers 
pTT5IgG/LC_EcoRI and PS3’ for the HC-IgG1 or the LC, respectively, while the forward 
primer for the amplification of 4G2HC-IgA2m(2) was pTT5IgA_EcoRI due to a different SP 
(VII.2). After amplification by PCR (II.2.1.4), these cassettes were subcloned using EcoRI 
and XbaI into pTT5 (II.2.1.5, Figure 16). To enhance the yield of 4G2IgG1, the constant 
regions (bearing a plant-optimized CU) were exchanged to sequences bearing a hCU, to 
finally yield pTT5_4G2HC-IgG1hCU and pTT5_4G2LChCU (VII.5). An internal AgeI 
restriction site in the IgG1hCU sequence was finally mutated using the QuikChange Lightning 
kit (Table 2, II.1.3) enabling a direct replacement of the Vh regions via AgeI and SalI.  
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Figure 16 Construction of the pTT5_4G2HC-IgG1hCU or pTT5_4G2LChCU vectors. 
The encoding sequences for the “SP - V domain - C domain” of a project-unrelated antibody were amplified by 
PCR (II.2.1.4) using the primers pTT5IgG/LC_EcoRI and PS3’ (VII.4) using the corresponding pTRAkt vectors 
(VII.5) as template, and inserted using EcoRI and XbaI (II.2.1.5) into the multiple cloning site of the pTT5 
vector. The 4G2V regions were then amplified (III.2.1.1, II.2.1.4) and inserted (II.2.1.5) into this vector using 
AgeI and SalI for the Vh region, or AgeI and BsiWI for the Vl region. To change the optimized CU for N. 
benthamiana (CU: Nb) to a human one (CU: human; hCU), the corresponding Cγ domain was amplified 
(II.2.1.4) from the pAPT:H10 vector [87] using the primers pHC-IgG1_fwd_SalI and pHC-IgG1_rev (VII.4). 
The Cκ domain was amplified from human cDNA (provided by Gudrun Breuer; Fraunhofer IME, Aachen) using 
the primers pCk-hCU_fwd_BsiWI and pCk-hCU_rev_XbaI (VII.4). Both were inserted into pTT5_4G2HC-IgG1 
or pTT5_4G2LC, respectively, using the appropriate restriction enzyme sites (II.2.1.5) to yield the final 
expression vectors pTT5_4G2HC-IgG1hCU or pTT5_4G2LChCU (VII.5). 
p35SS: 35S promoter of the Cauliflower mosaic virus; pCMV: promoter of the human Cytmegalovirus; 
5’ UTR: 5’ untranslated region; SP: sequence encoding for a murine immunoglobulin signal peptide targeting to 
the plant apoplast or cell culture supernatant; Cγ/α/κ: human Ig constant regions of IgG1/IgA2m(2)/Igκ; 
pA: polyadenlytion signal.  
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Finally, the pTT5-based expression vectors for chimeric or human IgG1 or IgA2m(2) were 
generated (Figure 17). 
 
  
Figure 17 Final expression cassettes of the pTT5 expression vectors and relevant restriction sites. 
The final expression cassettes of the pTT5-based vectors consist of the promoter of the human Cytmegalovirus 
(pCMV), an enhancer region, the SP of the pTRA(k)t vectors, the V regions of the 4G2 antibody, which were 
inserted using the indicated restriction enzyme sites (II.2.1.5), the corresponding human Ig constant regions (Cγ: 
IgG1hCU; Cα: IgA2m(2), Cκ: IgκhCU) and a polyadenylation signal (pA). 
 
III.2.1.3 Expression and purification of 4G2-based antibodies 
4G2-based antibodies were expressed as IgG1 and IgA2m(2) in N. benthamiana and 
HEK293-6E cells, respectively (II.2.4). All antibody variants except for 4G2IgA2m(2) 
produced in HEK293-6E cells (4G2IgA2m(2)HEK) were expressed in sufficient amounts 
(Table 15) for detailed further functional characterizations (III.2.2). 
 
Table 15 4G2-based antibody nomenclature and yields after transient expression and purification 
Antibody Expression host Nomenclature Yield* 
4G2IgG1  N. benthamiana 4G2IgG1Nb 64 mg/kg fresh leaf weight HEK293-6E 4G2IgG1HEK 5-10 mg/l cell culture supernatant 
4G2IgA2m(2) N. benthamiana 4G2IgA2m(2)Nb 17.5 mg/kg fresh leaf weight HEK293-6E 4G2IgA2m(2)HEK ~0.1 mg/l cell culture supernatant 
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After the corresponding purifications (II.2.4), antibodies were analyzed by SDS-PAGE 
(II.2.5.1) for purity and complete assembly (Figure 18). All antibodies were highly pure. The 
light chains as well as the γ-heavy chains ran at their predicted molecular size of 23.3 kDa and 
49.5 kDa, respectively. Although the α-heavy chain has a lower predicted molecular size of 
47.9 kDa it appears at a higher size on the SDS-PAA gel (Figure 18A), which may be due to 
more predicted N-glycosylation sites (NetNGlyc 1.0 Server (II.1.9)). There are four predicted 
N-glycosylation sites for the α-heavy chain in comparison to one for the γ-heavy chain [50, 
117]. Additionally, the three high-yielding antibodies 4G2IgG1HEK, 4G2IgG1Nb and 
4G2IgA2m(2)Nb showed a correct antibody assembly (Figure 18A). Both isotypes expressed 
in N. benthamiana showed a slightly visible band for dissociated light chain after purification 
and a marginal portion of un- or partly assembled heavy-chains at ~50 kDa and 100 kDa. 
4G2IgG1HEK had no significant portions of free antibody chains. For 4G2IgA2m(2)HEK, the 
assembly-analysis was omitted due to its very low expression yield (Table 15, Figure 18B).  
 
Figure 18 Analysis of purified recombinant 4G2-based antibodies by SDS-PAGE. 
A: 2 µg of purified (II.2.4) 4G2-based antibody (II.1.2) were separated on a 12%-SDS-PAA gel (II.2.5.1) under 
reducing and non-reducing conditions, as indicated above slots. 
B: 8 µl of the elution fraction of 4G2IgA2m(2)HEK after Protein A chromatography (II.2.4.2) were separated by 
SDS-PAGE (II.2.5.1) under reducing conditions. The faint bands for the heavy and light chain are indicated with 
arrows. 
Protein marker: 7 µl prestained protein marker, NEB #P7708. 
 
4G2IgG1Nb, 4G2IgG1HEK and 4G2IgA2m(2)Nb were used for an extensive further 
functional characterization, whereas 4G2IgA2m(2)HEK was only analyzed for the most 
important properties, i. e. antigen binding and PMN stimulation (III.2.2) 
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III.2.2 Functional characterization of 4G2-based antibodies 
III.2.2.1 Antigen binding 
Initially, affinities were determined for the 4G2IgG1 isotype from both expression hosts 
towards AMA1 (P. falciparum strain 3D7, II.1.7) by SPR spectroscopy (II.2.5.3.1), resulting 
in similar affinity constants (KD values) of 0.6 nM (± 0.002 nM) for 4G2IgG1Nb or 0.7 nM 
(± 0.003 nM) for 4G2IgG1HEK, respectively. Because the determination of the affinity of 
4G2IgA2m(2) was not possible by SPR spectroscopy, the antigen binding characteristics were 
analyzed by ELISA (II.2.5.4.1), as alternative. The 4G2IgA2m(2)-antibodies showed equal 
binding characteristics, which were as well independent from the expression host. But 
compared to the 4G2IgG1 isotype, the binding activity was ~2-fold lower as seen by the 
lower plateau of the binding curve (Figure 19A). When normalizing the obtained values for 
A405 nm to the highest value in each data series, all binding curves were similar to each other, 
indicating equal affinities for all four antibodies (Figure 19B). 
 
 
Figure 19 Analysis of antigen binding by the recombinant 4G2-based antibody variants by ELISA. 
A: Binding of 4G2IgG1 (circles, black line) and 4G2IgA2m(2) (squares, grey line) expressed in N. benthamiana 
(II.2.4.1, filled symbols) or HEK293-6E (II.2.4.2, open symbols) to 50 ng immobilized AMA1/well was assessed 
by antigen ELISA (II.2.5.4.1). Antibodies were detected with GαH-IgGκLCAP and visualized using pNPP for 
30 min (II.1.4). 
B: The same ELISA is shown, but determined absorbances were normalized to the highest obtained value for 
each data set and A405 nm is therefore shown in %. 
Data represent the mean ± range of one experiment each in technical duplicates. 
 
All antibodies except for 4G2IgA2m(2)HEK were analyzed by IFA (II.2.6.2) for their 
ability to recognize native AMA1 on the surface of P. falciparum 3D7A (Figure 20).  
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Figure 20 Detection of native AMA1 by the recombinant 4G2-based antibody variants by IFA. 
Recognition of native AMA1 on the surface of methanol-fixed P. falciparum 3D7A schizonts was assessed by 
IFA (II.2.6.2). Merozoites were co-stained with 20 µg/ml of the MSP1-specific murine 5.2 antibody which was 
detected with GαM-IgG488 secondary antibody (green). 4G2-based antibodies (III.2.1) or controls (II.1.7) were 
used at 50 µg/ml: 
A: 4G2IgG1Nb 
B, C: 4G2IgG1HEK 
D: H10IgG1CHO (negative control, II.1.7) 
E: 4G2IgA2m(2)Nb 
F: no antibody (negative control) 
IgG1 was detected with GαH-IgGCy3, IgA with GαH-IgA647 as secondary antibody, respectively (red). Parasite 
nuclei were stained with Hoechst 33342 (blue) and the overlay image (right panel) includes the bright field 
image. Detection antibodies are listed in Table 5, II.1.4. Scale bar = 2.5 µm. 
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All of the 4G2-based antibodies show the characteristic apical staining of the single 
merozoites in early E64-treated schizonts (Figure 20A, B, E). In mature schizonts and free 
merozoites, AMA1 relocalises over the whole schizont surface [111, 118], resulting in a 
circular staining pattern comparable to the “bunch of grapes”-like staining pattern reported for 
the MSPs [69], as exemplarily shown for 4G2IgG1HEK (Figure 20C). 
 
III.2.2.2 In vitro growth inhibition 
Three of the four produced antibody variants were analyzed for their growth inhibitory 
potential using P. falciparum 3D7A using a GIA (II.2.7.1, Figure 21). 4G2IgA2m(2)HEK was 
excluded from this analysis because of its low expression yield (Table 15). 
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Figure 21 Analysis of direct growth inhibitory properties of 4G2-based antibodies by GIA. 
The ability of 4G2-based antibodies to inhibit growth of P. falciparum 3D7A was assessed using a GIA 
(II.2.7.1). 0.3% synchronized schizonts (II.2.6) at 2% hematocrit were incubated in the presence of 4G2IgG1Nb 
(filled circles, black line), 4G2IgG1HEK (open circles, black line) or 4G2IgA2m(2)Nb (filled squares, grey line) 
(III.2.1) for 48 h. Data represent the mean ± SD of three to four experiments at least in duplicates each. 
 
Both 4G2IgG1 variants inhibited P. falciparum 3D7A similarly with half-maximal 
inhibitory concentrations (IC50 values) of 200-250 µg/ml, whereas 4G2IgA2m(2)Nb has an 
approx. 4-fold reduced inhibitory activity with an IC50 value of ~900 µg/ml (Table 16).  
 
Table 16 IC50 values of 4G2-based antibody variants in the GIAs 
Antibody IC50 value (95% CI) [µg/ml] 
4G2IgG1Nb 243 (236–250) 
4G2IgG1HEK 197 (184–211) 
4G2IgA2m(2)Nb 894 (820–974) 
IC50 values were calculated from the data presented in Figure 21, rounded to the nearest integer. 
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III.2.2.3 Induction of the neutrophilic ADRB by recombinant antibodies 
After assessment of binding to AMA1 and inhibition of P. falciparum growth, 4G2-based 
antibodies were analyzed for their PMN-stimulatory capacity in a series of sADRB, cADRB 
or mADRB assays (II.2.7.2). cADRB assays were sometimes chosen to ensure a comparable 
antigen-independent PMN stimulation by antibodies of different specificities. 
 
III.2.2.3.1 Characterization of the 4G2IgG1-induced neutrophilic sADRB 
The general capacity of the recombinant monoclonal IgGs to induce a neutrophilic ADRB 
was verified by the example of the mammalian-produced 4G2IgG1HEK (Figure 22). The 
stimulation resulted in the same kinetic profile with a steep peak-activation after 5-10 min as 
previously characterized for native human polyclonal IgGs (III.1). However, the intensity of 
the 4G2IgG1HEK-induced sADRB was 60-fold lower than that of the human IgG (represented 
by the decomplemented SIP-pool), although 4G2IgG1HEK was used in ~100-fold excess 
amounts, and 4G2IgG1Nb completely failed to induce any neutrophilic ADRB response (data 
not shown here, refer to Figure 24). This conspicuous finding turned out to be the main 
challenge during the analysis of the recombinant IgG-induced sADRB. 
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Figure 22 Induction of the neutrophilic sADRB by recombinant 4G2IgG1HEK. 
The neutrophilic sADRB (II.2.7.2) was monitored using 1125 ng coated AMA1 and 3 mg/ml 4G2IgG1HEK 
(black), 1:5-fold diluted decomplemented SIP-pool (green, containing ~30 µg/ml AMA1-specific IgG [73]) or 
PBS (II.1.5, grey). Response kinetics are from one typical experiment ± range of technical duplicates.  
 
Results
 
 
 
 
 
55 
 
III.2.2.3.2 The influence of the IgG-Fc N-glycan profile on the stimulation of PMNs 
The influence of the expected differences in the IgG-Fc N-glycan profiles (Figure 3) on the 
stimulation of PMNs was investigated to resolve the reduced activity of recombinant 
antibodies in comparison to native human ones, because the IgG-Fc N-glycan essentially 
contributes to FcγR binding [49]. The actual IgG-Fc N-glycan profiles were determined for 
the two recombinant antibody variants 4G2IgG1HEK and 4G2IgG1Nb, as well as for a 
deglycosylated variant of 4G2IgG1HEK (4G2IgG1HEK-Glyc) as control. The latter was generated 
by enzymatic deglycosylation of 4G2IgG1HEK using Remove-iTTM Endo S (Table 1, II.1.3). 
Purified native human IgG of the Ghanaian plasma donor 5 (purified by myself previously 
[73]) was used as a human reference sample. Furthermore, a CHO-DG44 derived antibody, 
H10IgG1CHO (II.1.7), was used to assess a potential difference between HEK293-6E and 
CHO-DG44 as mammalian expression host. The expected N-glycan profile of CHO-derived 
proteins is closest to the native human N-glycan profile (Figure 3). The glycan profile of 
H10IgG1CHO has been determined before [87].  
 
 
Figure 23 SDS-PAGE-separated antibodies for the analysis of IgG-Fc N-glycans. 
~4-6 µg per purified antibody preparation (human IgG 5 [73], 4G2IgG1Nb, 4G2IgG1HEK and 4G2IgG1HEK-Glyc 
(II.2.4, Table 1, II.1.3)) were separated on a pre-cast 4-12%-SDS-PAA gel under reducing conditions (II.2.5.5). 
Protein marker: 7 µl prestained protein marker, NEB #P7708. 
 
Prior to the IgG-Fc N-glycan analysis, heavy and light chains of the antibodies were 
separated by SDS-PAGE (Figure 23). 4G2IgG1 contains one N-glycosylation site at Asn300 
as predicted by NetNGlyc 1.0 Server (II.1.9). The heavy chain of the deglycosylated 
4G2IgG1HEK-Glyc runs at a slightly reduced size (~2 kDa) on the SDS-PAA-gel, giving 
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evidence of a successful removal of the IgG-Fc N-glycan. The bands for the heavy chains 
were excised from the gel and their IgG-Fc N-glycan profiles were determined by QTof 
(II.2.5.5, Table 17).  
 
Table 17 IgG-Fc N-glycan profiles of the analyzed antibody samples 
N-Glycan 
abbreviation 
Cartoon 
Human 5 
[%] 
HEK 
[%] 
CHO 
[%] 
HEK-Glyc 
[%] 
Nb 
[%] 
No N-glycan   0.7  2.3 32.3 
core Gn / GnF  /    20.5 / 77.2  
Man5  2.14    
MA 2.6     
GnGn 1.3 3.2 1.1  2.6 
GnA 3.9     
AA 6.4     
ANa 4.5     
UGnF  2.5 5.4    
MGnF 7.0 10    
MAF 4.7 2.14    
GnGnF 16.2 56.8 54.7   
GnAF 25.1 19.64 39.8   
AAF 17.6  4.4   
ANaF 8.2     
… continued on next page  
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Table 17 - continued 
N-Glycan 
abbreviation 
Cartoon 
Human 5 
[%] 
HEK 
[%] 
CHO 
[%] 
HEK-Glyc 
[%] 
Nb 
[%] 
GnGnX     6.6 
MGnXF*     9.6 
GnGnXF*     48.8 
*: The plant-specific core-fucose is attached in a α1-3 linkage instead of the mammalian-specific α1-6 linkage. 
Human 5: purified polyclonal IgG from donor 5; HEK: 4G2IgG1HEK; CHO: H10IgG1CHO; HEK-Glyc; 
4G2IgG1HEK-Glyc; Nb: 4G2IgG1Nb; 
A (yellow circle): galactose; F (red triangle): fucose; Gn (blue square): N-acetylglucosamine; M (green circle): 
mannose; X (brown star): xylose; Na (hot pink diamond): N-acetylneuraminic acid; U: unsubstituted 
 
The human IgG 5 bore the most diverse IgG-Fc N-glycan profile when compared to all 
recombinant antibodies. ~60% of antibodies contained N-acetylglucosamine (Gn) and/or 
galactose (A) on at least one terminus. With 12.7% of antibodies being sialylated (Na-
isoforms), this sample was also the only one having any sialylations. The Fc-glycan of 
4G2IgG1HEK was less diverse than the human sample, with 76.44% N-glycan structures 
terminating with Gn(Gn/A)F. The most homogenous preparation was the H10IgG1CHO, which 
originated from a stably-transfected cell line (II.1.7). This sample comprised in sum 100% N-
glycan profiles with Gn or A at their termini. This antibody preparation also did not contain 
any terminal sialic acid but more galactosylations than 4G2IgG1HEK. The complete 
deglycosylation was confirmed for 4G2IgG1HEK-Glyc as it only showed peaks for the single 
core Gn or fucose (F) attached to this core Gn (core GnF). Remove-iTTM Endo S does not 
remove the whole N-glycan structure from IgG, but cleaves in between the two Gn-residues 
of the chitobiose core [119, 120]. The main difference of 4G2IgG1Nb to the former antibodies 
is an additional xylose (X) present in 65% of this antibody preparation. Additionally, this 
sample is the only one containing 1/3 unglycosylated antibodies which probably results from 
the transient expression and the harvesting procedure (II.2.4.1, IV.2.2.1.2).  
After the actual IgG-Fc N-glycan profiles had been determined (Table 17), the influence 
of these differences on the induction of neutrophilic ADRB response was characterized 
(Figure 24) in depth. At first, IgG-Fc N-glycan-dependent binding towards human CD32(a) 
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was investigated by SPR spectroscopy (II.2.5.3.2), because this receptor had previously been 
shown to be the main contributing receptor for the IgG-induced neutrophilic ADRB (III.1). 
4G2IgG1HEK and H10IgG1CHO showed similar binding towards human CD32(a). However, 
the binding activity of the human IgG sample 5 was ~15% higher. In contrast,  
4G2IgG1HEK-Glyc and 4G2IgG1Nb showed an approx. 7-fold reduced binding, which was 
barely detectable using this experimental setup (Figure 24A). 
 
Figure 24 The influence of the IgG-Fc N-glycan on CD32(a)-binding and ADRB-induction. 
A: The binding of ~1,600 RU Protein A-captured purified human antibodies of Ghanaian donor 5 (red-pink) or 
recombinant antibodies (4G2IgG1HEK (black-grey), H10IgG1CHO (blue-light blue), deglycosylated 
4G2IgG1HEK-Glyc (green-light green) and 4G2IgG1Nb (magenta-light magenta)) towards 666 nM or 166 nM 
human CD32(a), injected at 0 s, was assessed by SPR spectroscopy (II.2.5.3.2). The data represent a single 
measurement per sample. 
B: The neutrophilic cADRB was determined towards four 1:2-fold serial dilutions starting at 50 µg/ml of coated 
4G2IgG1HEK, 4G2IgG1Nb, 4G2IgG1HEK-Glyc, H10IgG1CHO, purified total IgG of Ghanaian donor 5 or PBS (II.1.5) 
during a 60-min kinetic window (II.2.7.2). The data represent the maximum peak height per sample ± range of 
technical duplicates of one representative measurement. 
C: The neutrophilic sADRB was determined using 1125 ng coated AMA1 and five 1:3-fold serial dilutions 
starting at 1000 µg/ml of 4G2IgG1HEK and purified IgG from Ghanaian donor 5 during a 60-min kinetic window 
(II.2.7.2). The concentrations mean total IgG and not AMA1-specific IgG. Purified IgG from Ghanaian donor 5 
contain ~1/20 AMA1-specific IgG. The data represent the maximum peak height per sample ± range of technical 
duplicates of one representative measurement. 
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The impact of the glycosylation-dependent binding activities towards CD32(a) on the 
induction of the neutrophilic ADRB was assessed using the antigen-independent cADRB 
assay (II.2.7.2). 4G2IgG1HEK-Glyc and 4G2IgG1Nb, both showing a strongly reduced binding 
activity towards CD32(a) (Figure 24A), were not able to induce a cADRB response (Figure 
24B). On the other hand, the similar binding of 4G2IgG1HEK and H10IgG1CHO towards 
CD32(a) was reflected in similar stimulation of PMNs in the cADRB assay. Surprisingly, the 
slightly enhanced binding of the purified human IgG sample 5 to human CD32(a) did not 
promote a better stimulation of PMNs, but in fact showed a 3-fold lower cADRB activity. 
Finally, the antigen-dependent stimulation of PMNs was assessed using the sADRB 
assay (II.2.7.2). Here, the purified human IgG sample stimulated the PMNs to a higher extent 
than the 4G2IgG1HEK (Figure 24C). The human IgG sample 5 contains approx. 1/20 AMA1 
specific IgG [73], so that the 3-fold enhanced activity at 1000 µg/ml total IgG multiplies to a 
~60-fold enhanced sADRB-inducing activity of the human IgG. 4G2IgG1HEK-Glyc and 
4G2IgG1Nb were excluded from this investigation because these variants were not even able 
to induce a cADRB response. H10IgG1CHO was not used in this sADRB assays because it 
recognizes another target antigen (II.1.7) and already showed similar stimulation in the 
previous cADRB assay (Figure 24B). 
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III.2.2.3.3 The effect of FcγR crosslinking for the stimulation of PMNs 
The former results suggest that the slightly altered N-glycan profile is not the major reason for 
the reduced ability of the recombinant antibodies to induce a neutrophilic ADRB (III.2.2.3.2). 
Therefore, the influence of efficient FcγR crosslinking was investigated. For this purpose, 
different amounts of antigen were immobilized in an ELISA (II.2.5.4.1) and in an sADRB 
assay (II.2.7.2), and differences in the reactivities between the 4G2IgG1HEK and the human 
IgG sample 5 were analyzed (Figure 25). 
 
 
Figure 25 The effect of antigen density on binding activity and PMN stimulation. 
A: The binding activity of 4G2IgG1HEK (circles) and human IgG 5 (squares) was assessed by antigen ELISA 
(II.2.5.4.1) using 1125 ng AMA1 (filled symbols) or 75 ng AMA1 (open symbols). Antibodies were applied in 
eleven 1:3-fold serial dilutions starting at 50 µg/ml total IgG, but the AMA1-specific IgG concentration is 
plotted on the X-axis. Antibodies were detected with GαH-IgGFcPO and visualized using TMB (II.1.4). 
B: The influence of the antigen density on efficient PMN stimulation was investigated by measuring the 
neutrophilic sADRB (II.2.7.2) towards four 1:3-fold serial dilutions of 4G2IgG1HEK or human IgG 5 starting 
with 1000 µg/ml total IgG towards 75 ng or 1125 ng immobilized AMA1 per well. The line at the bottom shows 
the background signal obtained with PBS (II.1.5) instead of antibody-containing sample. 
Data represent the mean ± range of one representative experiment. 
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By using an excess amount of immobilized AMA1, the binding activity of 4G2IgG1HEK was 
enhanced by a factor of 1.5 (Figure 25A). In contrast, the activity of the human IgG sample 5 
was only slightly enhanced 1.1-times when using a 20-fold increased amount of immobilized 
AMA1. The binding curves towards 1125 ng immobilized AMA1 match almost perfectly for 
4G2IgG1HEK and the human IgG 5, showing a similar detection limit in this experimental 
ELISA setup. In the corresponding sADRB assay, the increased binding activity of 
4G2IgG1HEK on increased amounts of immobilized antigen was also reflected in an enhanced 
capacity to induce a neutrophilic sADRB (Figure 25B). Using 75 ng AMA1, no signal above 
background (PBS) was detectable, whereas increasing the AMA1 density by 15-fold to 
1125 ng AMA1 led to a significant PMN stimulation. Although 4G2IgG1HEK and human 
IgG 5 showed the same binding activity towards 1125 ng immobilized AMA1 in the ELISA 
(Figure 25A), the human sample was much more efficient in the induction of the neutrophilic 
sADRB (Figure 25B). Furthermore, the increased AMA1 density also only led to a slightly 
increased stimulation of PMNs by a factor of 1.6, suggesting that for this sample the lower 
amount of immobilized AMA1 is almost already in a saturating range needed for an efficient 
FcγR crosslinking. A further increase in the amount of immobilized AMA1 to 3000 ng per 
well did not promote a better PMN stimulation for neither 4G2IgG1HEK nor human IgG 5 
(data not shown). 
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III.2.2.3.4 Characterization of the 4G2IgA2m(2)-induced sADRB 
After the characterization of the 4G2IgG1-induced neutrophilic sADRB, similar experiments 
were performed with 4G2IgA2m(2). At first, the influence of the expression host on the 
4G2IgA2m(2)-induced neutrophilic sADRB was assessed, revealing an equal, expression-host 
independent functionality of 4G2IgA2m(2)HEK and 4G2IgA2m(2)Nb (Figure 26). 
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Figure 26 Expression host-dependent induction of the neutrophilic sADRB by 4G2IgA2m(2). 
The neutrophilic sADRB was determined using 75 ng coated AMA1 per well and two concentrations of each, 
4G2IgA2m(2)Nb (black)) and 4G2IgA2m(2)HEK (grey) or PBS (II.1.5, light grey) in a 60-min kinetic window 
(II.2.7.2). The data represent the mean ± range of one representative experiment in technical duplicates. 
 
Further characterizations were performed exclusively with 4G2IgA2m(2)Nb because of 
the low expression yield of 4G2IgA2m(2)HEK (Table 15). Furthermore, their expression host-
independent PMN-stimulatory functionality had been verified (Figure 26). For this reason 
also no further intensive characterizations of the IgA-Fc N-glycan were necessary, like it had 
been the case for the IgG-Fc N-glycan (III.2.2.3.2). Therefore, the focus of the following 
analyses was only set on the efficiency of FcαR engagement and crosslinking. 
The intensity of the 4G2IgA2m(2)Nb-induced sADRB was assessed in reference to its 
IgG-counterpart, 4G2IgG1HEK, as well as one human reference sample, the SIP-pool (Figure 
27). The 4G2IgA2m(2)Nb-induced neutrophilic sADRB did not reach the intensity which was 
achieved with the polyclonal human SIP-pool, despite the generally more efficient stimulation 
of PMNs stimulation in comparison to 4G2IgG1HEK.  
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Figure 27 The neutrophilic sADRB induced by 4G2IgA2m(2) in comparison to IgG. 
The intensity of PMN stimulation induced by IgG or IgA was comparatively analyzed by measuring the 
neutrophilic sADRB towards 4G2IgA2m(2)Nb applied at four 1:2-fold serial dilutions starting with 100 µg/ml 
bound to 1125 ng immobilized AMA1 during a 60-min kinetic window (II.2.7.2). As references, 4G2IgG1HEK 
was used also in four 1:2-fold serial dilutions starting with 3000 µg/ml, as well as the decomplemented SIP-pool 
in a single measurement representing ~30 µg/ml AMA1-specific IgG.  
The data represent the mean ± range of one representative experiment in technical duplicates. 
 
In a next instance, it was investigated whether an increased antigen density, and 
therewith antibody-density, also enhances the efficiency of the 4G2IgA2m(2)Nb-induced 
neutrophilic sADRB (Figure 28).  
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Figure 28 Characterization of the neutrophilic sADRB induced by 4G2IgA2m(2)Nb. 
The influence of the amount of coated antigen was investigated by measuring the neutrophilic sADRB during a 
60-min kinetic window towards 4G2IgA2m(2)Nb, applied at four 1:2-fold serial dilutions (black - grey) starting 
with 12.5 µg/ml, bound to 75 ng or 375 ng immobilized AMA1 (II.2.7.2). PBS (II.1.5, light grey) was used as 
negative control representing the background luminescence. The data represent the mean ± range of one 
representative experiment in technical duplicates. 
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Using 75 ng AMA1 per well, the recorded response was only 5 times higher than the 
background noise (PBS). The readout was increased by ~55-fold when using 375 ng 
immobilized AMA1 per well. Using these experimental conditions, no titration was observed 
between 12.5 µg/ml and 6.25 µg/ml, and concentrations even as low as 1.5625 µg/ml of 
4G2IgA2m(2)Nb were easily detectable. This also shows that an increased FcαR-engaging 
4G2IgA2m(2)-density enhances the intensity of the neutrophilic sADRB response, as it had 
been the case for 4G2IgG1 previously (III.2.2.3.3). 
 
III.2.2.3.5 Induction of the neutrophilic mADRB by recombinant antibodies 
The mADRB assay is the method which is closest to the situation in vivo (III.1) and therefore 
should be applied to analyze the functionality of anti-merozoite antibodies. Consequently, the 
capacity of AMA1-specific 4G2-based antibodies to induce a neutrophilic mADRB response 
was assessed next (Figure 29).  
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Figure 29 Induction of the neutrophilic mADRB by 4G2-based antibodies. 
The neutrophilic mADRB (II.2.7.2) was determined towards purified merozoites (II.2.6.1) opsonized with 
100 µg 4G2IgG1HEK (black) or 4G2IgA2m(2)Nb (grey) in comparison to the SIP-pool (green). The SIP-pool 
contained ~120 µg total IgG (corresponding to ~4 µg AMA1-specific IgG). PBS (II.1.5, light grey) was used as 
negative control. The data represent the mean ± range of one representative experiment in technical duplicates. 
 
This analysis was only performed with the two most promising variants as determined 
in cADRB and sADRB assays, 4G2IgG1HEK and 4G2IgA2m(2)Nb. Neither isotype was 
capable of inducing any neutrophilic mADRB response. The positive control, the 
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decomplemented SIP-pool, stimulated PMNs in similar applied concentrations of total IgG, 
which corresponds to ~3% AMA1-specific IgG. Surely, this polyclonal preparation comprises 
naturally-acquired antibodies directed against a much wider variety of epitopes of multiple 
antigens. The usage of different batches of 4G2-based antibodies or merozoites, freshly 
prepared merozoites, increased amounts of opsonizing antibody or the addition of different 
percentages of BSA as stabilizer during the opsonization step did not improve the readout. In 
accordance with these findings, neither of the recombinant antibodies was able to induce 
phagocytosis (II.2.7.4) of P. falciparum D10 ACP(transit)-GFP merozoites (data not shown), 
although the antibodies were able to recognize AMA1 on the surface of merozoites as verified 
by IFA (III.2.2.1). Besides, antibodies were able to effectively inhibit P. falciparum growth in 
vitro (III.2.2.2), further strengthening the ability of the recombinant 4G2-based antibodies to 
bind to native AMA1. 
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III.3 Enhanced antimalarial activity of Gb by scFv-mediated 
targeting to P. falciparum 
This chapter summarizes the key results obtained to achieve the third objective of this PhD 
thesis (I.3), namely the verification of the proposed antimalarial activity of the serine protease 
Gb in a first instance (III.3.1). Afterwards, the strategy of using antibody-based fusion 
proteins for the targeted delivery of Gb was investigated (III.3.2.3). This goal was achieved 
within two steps. At first, a PfMSP4EGF-specific antibody sequence was isolated, expressed as 
chimeric IgG1 in N. benthamiana (following the strategy explained in III.2.1), and 
demonstration of its retained binding specificity (III.3.2.1). Second, the confirmed V-region 
sequences were used for the generation of a fusion protein comprising Gb and the 
corresponding scFv, which was expressed in HEK293-6E cells and analyzed for an enhanced 
antimalarial activity in comparison to Gb alone or P. falciparum-unrelated Gb-scFv fusion 
proteins (III.3.2.3). 
The results of this chapter have already been published [2, 3]. 
 
III.3.1 The antimalarial activity of Gb 
Recombinant EGb was obtained as purified protein from Dr. Sonja Schiffer (Institute for 
Applied Medical Engineering AME, Aachen; II.1.7). This protein was used to verify the 
proposed general antimalarial activity of Gb. 
As explained before, Gb was expressed as a fusion protein with an N-terminal 
protective peptide containing an rEK cleavage site (= EGb) to suppress enzymatic activity in 
the expressing cells (II.2.4.2). Therefore, its enzymatic activity was restored after purification 
by rEK digest (II.2.7.5.1). The influence of active Gb and inactive EGb on the growth of P. 
falciparum 3D7A was assessed in vitro using a 72-h DSA (II.2.7.5.2). Digested Gb showed a 
similar enzymatic activity compared to the commercial Gb-standard (Table 1, II.1.3) whereas 
undigested EGb showed no substrate conversion (Figure 30A). In the following 72-h DSA 
(Figure 30B), the inactive EGb did not influence the growth of P. falciparum 3D7A in vitro, 
whereas active Gb inhibited the growth of the parasites with an IC50 value of 1590 nM 
(95% CI: 1197-2112 nM).  
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Figure 30 The susceptibility of P. falciparum 3D7A towards rEK digest-activated Gb. 
A: Before applying Gb in a DSA, the N-terminal protective peptide, which suppresses enzymatic activity during 
the expression, needed to be removed by rEK digest from EGb (II.1.7) to restore enzymatic activity. This 
restored activity of Gb was assessed in a colorimetric assay (II.2.7.5.1). Cleavage of 200 µM of the artificial 
substrate Ac-IETD-pNA to pNA by 250 ng of active Gb (light grey), inactive EGb (dashed light grey) and a 
commercial Gb-standard (green; Table 1, II.1.3) was determined in a 60-min kinetic window at 37°C at 405 nm. 
Data are representative from one experiment. 
B: The susceptibility of P. falciparum 3D7A towards Gb was assessed in a 72-h DSA (II.2.7.5.2). Synchronous 
ring-stage parasites (II.2.6) at 0.05% parasitemia and 1.5% hematocrit were incubated in the presence of active 
Gb (crossed open circles) and inactive EGb (crosses) for 72 h. Data represent the mean ± SD of two experiments 
using technical duplicates. 
EGb: Granzyme B with retained N-terminal protective peptide fused to an enterokinase cleavage site; 
Gb: Active Gb in which the N-terminal protective peptide had been cleaved off by enterokinase digest 
(II.2.7.5.1); Gb-standard: commercial Granzyme B standard (Table 1, II.1.3). 
Illustration modified from [2]. 
 
Inhibitions ≤20% can be neglected. Tiny deviations from the growth of the parasites 
also occur in the absence of any protein, and these deviations in parasite growth add up to 
±20%. This means that these 20% reflect the background of the assay readout, which 
quantifies PfHRP2 by ELISA (II.2.5.4.4). 
With these experiments the antimalarial activity of Gb was verified, opening the path 
for the evaluation of Gb-scFv fusion proteins as potential therapeutic agent against P. 
falciparum (III.3.2). 
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III.3.2 Increasing the antimalarial activity of Gb by direct targeting to P. 
falciparum 
After having confirmed the direct antimalarial activity of Gb, the specificity and therewith the 
antimalarial activity should be increased. This goal was pursued by isolation of a PfMSP4EGF-
specific antibody sequence and its verification (III.3.2.1), followed by the generation and 
evaluation of Gb-scFv fusion proteins (III.3.2.3). 
 
III.3.2.1 Isolation and verification of a PfMSP4EGF-specific antibody 
The isolation, expression and characterization of the PfMSP4EGF-specific 2.44IgG1, as well as 
the generation and initial expression of the EGb-2.44scFv was performed in part by Melanie 
de Almeida during her bachelor thesis under my technical supervision [121]. 
 
III.3.2.2 V-region rescue 
V regions were rescued from eight murine hybridoma cell lines (II.1.7) by RNA-isolation, 
cDNA-synthesis and amplification of V regions by PCR (II.2.1.3). The antibody was expected 
to be an IgG1:κ antibody (Figure 31) as determined by isotyping (Table 2, II.1.3) of the 
murine 2.44 antibody as example. 
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Figure 31 Isotype analysis of the murine 2.44 antibody. 
Culture supernatant of the hybridoma cell line 2.44 was applied for the isotype analysis using the Mouse 
Immunoglobulin Isotyping ELISA Kit (Table 2, II.1.3), showing only reactivity for IgG1 and Igκ. NC: negative 
control (ISF-1 medium). PC: positive controls (provided by the reaction kit). The isotype analysis was performed 
by Kai Fuhrmann (Fraunhofer IME, Aachen). 
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Using oligodT-primed cDNA as template (II.2.1.3), four PCR products for the Vh region and 
two for the Vκl region were obtained using the published primer set [89]. These were purified 
by gel-extraction (II.2.1.1) and sequenced (II.2.1.6) using the corresponding forward and 
reverse primers. The four rescued Vh-region sequences were identical for all 4 primer pairs 
per hybridoma cell line and additionally for all eight hybridoma cell lines. For the Vkl region, 
at least two PCR products were obtained with the different primer pairs for each cell line. 
After sequencing, only two unique sequences were found, again being identical for all eight 
hybridoma cell lines. Out of these two unique sequences, one was identified as pseudogene of 
the myeloma fusion partner Sp2/0-Ag14 [122]. The second Vkl-region sequence was analyzed 
using the IMGT/V-quest tool, the same applied for the obtained Vh-region sequence. The 
sequences were identified as belonging to the Vh3- and Vκl4-gene families (Figure 32). The 
sequences showed high homology to the closest germ-line sequences with 96.06% for the 
Vh-gene sequence, and 97.87% for the Vκl-gene sequence. Most mutations occurred in the 
CDR regions, as expected. In general, the high homologies indicate only a minor affinity 
maturation. 
 
 
Figure 32 2.44 V(D)J-gene sequences and alignment to the closest V-gene germ-line sequence. 
The rescued 2.44V-region sequences were aligned to the most probable V-gene germ-line sequence using the 
IMGT/V-quest tool on nucleotide-sequence basis (II.2.1.3). The alignment directly shows the resulting amino 
acid sequence with mutations to the most probable germ-line sequence as well as the – according to the Kabat 
rules [123] – predicted complementary determining regions (CDR) 1-3 of the Vh and Vl genes, respectively. 
A: The rescued 2.44Vh-gene sequence was identified as Vh3-gene sequence. Homology: 96.06%. 
B: The rescued 2.44Vl-gene sequence was identified as Vkl4-gene sequence. Homology: 97.87%. 
Illustration taken from [3]. 
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III.3.2.2.1 Generation and characterization of the full-size recombinant 2.44IgG1  
The identified V regions were amplified (II.2.1.4) from the generated cDNA (II.2.1.3) using 
the primers 2.44Vh_fwd_AgeI and 2.44Vh_rev_SalI for the Vh region, or 2.44Vl_fwd_AgeI 
and 2.44Vl_rev_BsiWI for the Vl region (VII.2). These facilitated direct insertion of the V 
regions into the corresponding binary plant expression vectors pTRAkt_HC-IgG1 via AgeI 
and SalI or pTRAkt_LC via AgeI and BsiWI, respectively, as explained (III.2.1.1) [3]. 
After transient expression by infiltration of N. benthamiana plants using transformed A. 
tumefaciens (II.2.4.1), 45 mg/kg fresh leaf weight of pure recombinant 2.44IgG1 were 
purified by Protein A chromatography (II.2.4.1, Figure 33). Under reducing conditions, the 
heavy and light chain ran separately at their predicted molecular sizes of 49.5 kDa for the 
heavy chain and 23.4 kDa for the light chain, respectively. Under non-reducing conditions, a 
correctly assembled antibody without free heavy or light chains was detectable. 
 
 
Figure 33 Analysis of purified recombinant 2.44IgG1 by SDS-PAGE. 
2 µg of 2.44IgG1 purified by Protein A chromatography (II.2.4.1) were separated on a 12%-SDS-PAA gel under 
reducing and non-reducing conditions (II.2.5.1). Protein marker: 7 µl prestained protein marker, NEB #P7708. 
Illustration modified from [3]. 
 
The retained binding activity of the recombinant 2.44IgG1 was demonstrated by antigen 
ELISA (II.2.5.4.1, Figure 34A). Using the presented setup wit 100 ng immobilized mE-ERH 
(II.1.7), a saturation of antigen binding was observed in concentrations above 500 ng/ml. 
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Figure 34 Analysis of antigen binding by the recombinant 2.44IgG1 by ELISA. 
Binding characteristics of the recombinant 2.44IgG1 to its target antigen was assessed by ELISA (II.2.5.4).  
A: Binding to PfMSP4EGF by the recombinant 2.44IgG1 was assessed by antigen ELISA (II.2.5.4.1) towards 
100 ng of immobilized mE-ERH (II.1.7). Bound recombinant 2.44IgG1 was probed with GαH-IgGFCPO and 
visualized using TMB (II.1.4). 
B: Competition for antigen binding of 500 ng/µl of the recombinant 2.44IgG1 to 100 ng of immobilized 
mE-ERH (II.1.7) by the three maternal murine antibodies 2.44, 2.48 and 2.7 (II.1.8) was analyzed by 
competition ELISA (II.2.5.4.2). The recombinant antibody was detected with GαH-IgGFCPO and TMB (II.1.4). 
Data represent the mean ± range of one experiment each in technical duplicates. 
Illustration modified from [121] and [3]. 
 
To ensure the correctness of the rescued V-region sequences, comparative analyses of 
the purified recombinant 2.44IgG1 and the murine antibodies were performed by competition 
ELISA (II.2.5.4.2) and SPR spectroscopy (II.2.5.3.1). Murine antibodies were purified from 
three exemplary hybridoma cell lines (2.44, 2.48 and 2.7) by Protein A chromatography 
(Table 3, II.1.3). Afterwards, a competition ELISA (II.2.5.4.2) was performed to verify that 
the three murine antibodies compete antigen binding by the recombinant 2.44IgG1 in a 
similar way, indicating the equality of the binding epitope and thereby certifying their identity 
(Figure 34B). Additionally, affinities were determined by SPR spectroscopy (II.2.5.3.1), 
revealing similar KD values of 8 nM (± 0.15 nM) and 10 nM (± 0.01 nM) for the murine and 
recombinant antibody, respectively, which altogether underlines the correctness of the V-
region rescue. 
Finally, the ability to recognize native PfMSP4 on the parasite surface was determined 
by IFA (II.2.6.2) and by immunoblot analysis using SDS-PAGE separated merozoite extract 
(II.2.5.1, II.2.6.1) (Figure 35).  
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Figure 35 Detection of native MSP4 by recombinant 2.44IgG1. 
A: Specific binding of the murine 2.44IgG1 to methanol-fixed P. falciparum 3D7A schizonts was assessed by 
IFA (II.2.6.2). The murine 2.44IgG1 was visualized with GαM-IgG488 secondary antibody (green) and AMA1 on 
the parasite surface was stained with Rα-AMA193, 3rd which was visualized with GαR-IgG594 secondary antibody 
(red), showing the circular localization of AMA1 in mature E64-treated schizonts (II.2.6.1). Nuclei were stained 
with Hoechst 33342 (blue). The overlay image includes the bright field image. The small overlay shows the lack 
of green staining obtained with an irrelevant murine IgG. Scale bar = 2.5 µm.  
B: AMA1 on the parasite surface was stained with Rα-AMA193, 3rd and visualized with a GαR-IgG488 secondary 
antibody (green), showing a circular localization of AMA1 indicating fully mature schizonts. The recombinant 
2.44IgG1 was visualized with a GαH-IgGCy3 secondary antibody (red). Nuclei were stained with Hoechst 33342 
(blue). The overlay image includes the bright field image. The small overlay shows the lack of red staining 
obtained with an irrelevant chimeric IgG. Scale bar = 2.5 µm. 
C: Detection of native PfMSP4 by recombinant 2.44IgG1 was additionally verified by immunoblot analysis 
(II.2.5.2). Merozoite extract (II.2.6.1) was separated by SDS-PAGE under non-reducing conditions (II.2.5.1), 
transferred on a methanol-activated PVDF membrane (II.2.5.2) and probed with 4 µg of the recombinant 
2.44IgG1 as primary antibody and with GαH-IgGH+LAP as secondary antibody, which was visualized with 
NBT/BCIP, revealing one specific band at ~40 kDa. 
Detection antibodies are listed in Table 5, II.1.4. 
Illustration taken from [3]. 
 
The murine and the recombinant 2.44IgG1 show the same circular, “bunch of grapes”-
like staining pattern in the IFA, which is characteristic for MSPs (Figure 35A, B) [69]. 
Specific detection of PfMSP4 was verified and cross-reactivity to any other of the parasite 
proteins excluded by immunoblot analysis of merozoite extract (Figure 35C). One single 
specific band was visible at 40 kDa, corresponding to the anticipated molecular size of 
PfMSP4 [69]. 
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III.3.2.3 MSP4-targeted enhanced antimalarial activity of Gb 
III.3.2.3.1 Generation and characterization of EGb-scFv fusion proteins 
2.44scFv in Vh-Vl orientation was generated by SOE-PCR (II.2.1.4.1) using the V-region 
sequences from the corresponding pTRAkt vectors as templates (III.3.2.2.1) and specifically 
designed primers (VII.2). These introduced both, a glycine-serine-rich linker in between the 
V-region domains and the appropriate restriction sites (SfiI, NotI) flanking the scFv (Figure 
36A). The scFv was then inserted into pTT5SH8Q2_EGbR201K-scFv (Figure 36B). 
 
 
Figure 36 Generation of 2.44scFv and structure of the EGb-scFv expression cassette of pTT5SH8Q2. 
A: The V regions of the 2.44 antibody were amplified from the pTRAkt expression vectors (VII.5) using the 
primers 2.44Vh_fwd_SfiI and 2.44Vh_rev_linker for the Vh region, or 2.44Vl_fwd_linker and 2.44Vl_rev_NotI 
for the Vl region (II.2.1.4). The scFv was the generated by SOE-PCR (II.2.1.4.1) by adding the amplified V 
regions and the outer primers (2.44Vh_fwd_SfiI, 2.44Vl_rev_NotI) in a second step. 
DNA marker: 2.5 µl of 2-log ladder (NEB #N3200). 
B: The 2.44scFv was inserted into the pTT5SH8Q2_EGbR201K-scFv vector using SfiI and NotI (II.2.1.5) to yield 
pTT5SH8Q2_EGbR201K-2.44 (VII.5). 
pCMV: promoter of the Cytomegalie virus; SP: sequence encoding for a signal peptide targeting to the 
extracellular space; ECS: N-terminal protective peptide fused to an enterokinase cleavage site. 
Illustration modified from [121]. 
 
For later analysis of enhanced activity of the Gb-2.44 fusion protein, two P. falciparum-
unrelated scFvs, H22(scFv) [94] and Ki4(scFv) [124] were also subcloned (II.2.1.5) from two 
pMS-based vectors into the pTT5SH8Q2_EGbR201K-scFv expression vector (VII.5) by SfiI 
and NotI as listed in the methods section (Table 9).  
EGb-scFv fusion proteins were expressed in HEK293-6E cells and purified by Ni-NTA 
IMAC (II.2.4.2), yielding up to 10 mg EGb-scFv/l cell culture supernatant (Figure 37).  
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Figure 37 Analysis of purified EGb-scFv fusion proteins by SDS-PAGE and immunoblot. 
A: 1 µg of EGb-scFv purified by Ni-NTA IMAC (II.2.4.2) was separated on a 12%-SDS-PAA gel under 
reducing conditions (II.2.5.1). 
B: 200 ng of EGb-scFv purified by Ni-NTA IMAC (II.2.4.2) were analyzed by immunoblotting (II.2.5.2). SDS-
PAGE-separated proteins were transferred onto a nitrocellulose membrane (II.2.5.2), probed with MαGb and 
GαM-IgGH+LAP and bands were visualized using NBT-BCIP (II.1.4). 
Protein marker: 7 µl prestained protein marker, NEB #P7708. 
 
All proteins were highly pure and expressed in sufficient amounts for the following in 
vitro activity studies of Gb in DSAs (III.3.2.3). Only for EGb-Ki4 a minor band of free scFv 
at approx. 30 kDa was observed. The purified EGb-2.44 fusion protein retained its binding 
ability to PfMSP4EGF as assessed by ELISA (Figure 38), although high concentrations were 
needed for a significant binding activity. While the 2.44IgG1 full size antibody already 
reached saturating absorbances at 1 µg/ml towards 100 ng of immobilized mE-ERH, 
100 µg/ml of EGb-2.44scFv were not sufficient to reach saturation in similar experimental 
conditions. 
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Figure 38 Retained binding of EGb-2.44 to PfMSP4EGF by antigen ELISA. 
Retained binding activity of EGb-2.44 to PfMSP4EGF was assessed by antigen ELISA (II.2.5.4.1) using 100 ng of 
coated mE-ERH (II.1.7). Bound EGb-2.44 was probed with Mα-Gb and GαH-IgGFCPO and visualized for 12 min 
using TMB (II.1.4). Data represent the mean ± range of one typical experiment in technical duplicates. 
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III.3.2.3.2 Cross-strain, enhanced antimalarial activity of Gb-2.44 
Prior to the analysis of an enhanced antimalarial activity of Gb-2.44 in comparison to Gb or 
P. falciparum-unrelated Gb-scFv fusion proteins, their enzymatic activity was restored by 
rEK digest (II.2.7.5.1) (Figure 39). This enzyme cleaves the N-terminal protective peptide 
present in the final protein to suppress enzymatic activity in the expressing cells (II.2.4.2, 
III.3.1). 
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Figure 39 Enzymatic activity of rEK digest-activated Gb(-scFv fusion proteins). 
Before applying Gb or Gb-scFv in a DSA, the N-terminal protective peptide, which suppresses enzymatic 
activity during the expression, needed to be removed by rEK digest to restore enzymatic activity. This restored 
activity of was assessed in a colorimetric assay using 200 µM of the artificial substrate Ac-IETD-pNA, and was 
calculated as the slope of the resulting activity curve at A405 nm during the first 10 min (II.2.7.5.1). Data are 
representative from one experiment ± range of technical duplicates.  
Gb: active Granzyme B; Gb-2.44: active Gb fused to the PfMSP4EGF-specific scFv “2.44”; Gb-H22: active Gb 
fused the human CD64-specific scFv “H22”; Gb-Ki4: active Gb fused the human CD30-specific scFv “Ki4”.  
Figure generated from data published in [2]. 
 
Activated proteins showed similar enzymatic activities. These active proteins were 
afterwards applied in 48-h DSAs (II.2.7.5.2) using P. falciparum 3D7A (Figure 40A) and the 
multidrug-resistant strain P. falciparum K1 (Figure 40B). Enhanced inhibition of parasite 
growth by Gb-2.44 was determined in comparison to all unrelated controls on both strains. 
Additionally, the recombinant 2.44IgG1 antibody was used in these assays, resulting in no 
inhibition in relevant concentrations. This clarifies that the resulting inhibition of Gb-2.44 is 
not the outcome of growth inhibitory properties of the antibody itself but rather of the activity 
of Gb. Undigested EGb-scFv fusion proteins did not affect parasite growth as well (data not 
shown). 
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Figure 40 The 48-h DSA using P. falciparum strains 3D7A and K1. 
The enhanced antimalarial activity of Gb by PfMSP4EGF-specific targeting was determined in a 48-h DSA 
(II.2.7.5.2). 0.05% synchronized schizonts (II.2.6) at 1.5% hematocrit were incubated in the presence of Gb-2.44 
(filled circles), the unrelated fusion proteins Gb-H22 (open squares) and Gb-Ki4 (open diamonds), non-fused Gb 
(crossed open circles) and the recombinant 2.44IgG1 (stars) for 48 h. 
A: 48-h DSA using the standard laboratory strain P. falciparum 3D7A. Data represent the mean ± SD of three 
(Gb-2.44, Gb-H22), two (Gb-Ki4, Gb) or one (2.44IgG1) experiment(s) in technical triplicates. 
B: 48-h DSA using the multidrug-resistant strain P. falciparum K1. Data represent the mean ± SD of two 
(2.44IgG1, Gb-2.44) or one (Gb-H22, Gb-Ki4) experiment(s) in technical triplicates. 
Gb: active Granzyme B; Gb-2.44: active Gb fused to the PfMSP4EGF-specific scFv “2.44”; Gb-H22: active Gb 
fused the human CD64-specific scFv “H22”; Gb-Ki4: active Gb fused the human CD30-specific scFv “Ki4”; 
2.44IgG1: PfMSP4EGF-specific recombinant chimeric antibody.  
Illustration modified from [2]. 
 
All IC50 values resulting from the data presented in Figure 40 were corrected by their 
relative enzymatic activity (Figure 39) and are shown in Table 18.  
 
Table 18 IC50 values of all tested samples in the 48-h DSAs 
 strain IC50 value (95% CI)[nM] 
Relative enzymatic 
activity [AU] 
Activity-corrected IC50 
value (95% CI) [nM] 
2.44IgG1 
3D7A 
> 25000* NA NA 
Gb-2.44 176 (154–202) 1 176 (154–202) 
Gb-H22 1103 (949–1283) 0.95 1048 (902–1219) 
Gb-Ki4 1500 (1180–1905) 0.85 1275 (1003–1619) 
Gb 970 (852–1104) 1.09 1057 (929–1203) 
Gb-2.44 
K1 
386 (306–488) 1 386 (306–488) 
Gb-H22 3497 (2368–5166) 0.95 3322 (2250–4908) 
Gb-Ki4 > 2000* 0.85 NA 
IC50 values and relative enzymatic activities were calculated from the data presented in Figure 39 and Figure 40, 
rounded to the nearest integer. NA: not applicable 
*: The highest applied concentration is given if this concentration resulted in no significant inhibition. 
Gb: active Granzyme B; Gb-2.44: active Gb fused to the PfMSP4EGF-specific scFv “2.44”; Gb-H22: active Gb 
fused the human CD64-specific scFv “H22”; Gb-Ki4: active Gb fused the human CD30-specific scFv “Ki4”.  
Table modified from [2]. 
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III.3.2.3.3 The necessity of the invasion step for enhanced activity of Gb-2.44 
30-h DSAs were performed (II.2.7.5.2) to further prove that the enhanced antimalarial activity 
of Gb-2.44 in comparison to the P. falciparum-unrelated controls depends on the merozoite-
invasion step. This assay only lasted from ring stage to schizont stage and thus omitted the 
co-import of the P. falciparum-specific Gb-2.44 fusion protein. 
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Figure 41 The 30-h DSA using strain P. falciparum 3D7A. 
The dependence of the enhanced antimalarial activity of Gb-2.44 on the merozoite invasion step and thus a co-
import of the fusion protein was verified in a 30-h DSA (II.2.7.5.2). 0.2% synchronized rings at 1.5% hematocrit 
were incubated in the presence of Gb-2.44 (filled circles), the unrelated fusion protein Gb-H22 (open squares) 
and non-fused Gb (crossed open circles) for 30 h. The assay was performed with strain P. falciparum 3D7A. 
Data represent the mean ± SD of two experiments in technical triplicates. 
Gb: active Granzyme B; Gb-2.44: active Gb fused to the PfMSP4EGF-specific scFv “2.44”; Gb-H22: active Gb 
fused the human CD64-specific scFv “H22”.  
Illustration modified from [2]. 
 
In the 30-h DSA (Figure 41), parasites are similarly inhibited by all three applied Gb-
scFv fusion proteins (Table 19). This underlies the necessity of a co-import step for an 
enhanced antimalarial activity of the PfMSP4EGF-specific Gb-2.44. 
 
Table 19 IC50 values of all tested samples in the 30-h DSAs 
 strain IC50 value 
(95% CI)[nM] 
Relative enzymatic 
activity [AU] 
Activity-corrected IC50 
value (95% CI) [nM] 
Gb-2.44 
3D7A 
1773 (1496–2102) 1 1773 (1496–2102) 
Gb-H22 3668 (2804–4798) 0.95 3485 (2664–4558) 
Gb 2143 (1426–3220) 1.09 2336 (1554–3510) 
IC50 values and relative enzymatic activities were calculated from the data presented in Figure 39 and Figure 41, 
rounded to the nearest integer. 
Gb: active Granzyme B; Gb-2.44: active Gb fused to the PfMSP4EGF-specific scFv “2.44”; Gb-H22: active Gb 
fused the human CD64-specific scFv “H22”. 
Table modified from [2]. 
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IV. Discussion 
IV.1 Functional dissection of the neutrophilic ADRB 
P. falciparum-reactive IgGs originate either from premune individuals or vaccine-trial 
volunteers, or are recombinantly produced. Several assays have been developed to 
characterize the antimalarial activity of these antibodies. These assays include the GIA to 
determine the invasion inhibitory capacity of IgGs [86], the ADCI assay, which determines 
the cooperative effect of IgGs and blood monocytes [28], and the ADRB assay, which 
measures antibody-mediated activation of PMNs [29, 125]. Recently, the urgent demand for 
precise assays evaluating protective immune responses in malaria has been raised. Assays 
involving PMNs as key immune cell were proposed as such potential promising ones [126]. 
The stimulation of PMNs mediated by malaria-specific antibodies was characterized in depth 
in two assay setups, the sADRB and mADRB assay (Figure 5) to address these current 
demands. Their reaction kinetics were determined, their individual dependence on FcγR 
defined, the generated ROS localized and the neutrophilic anti-merozoite mode of action 
identified (III.1). 
 
IV.1.1 CD32(a) is the predominant contributing receptor of the 
neutrophilic ADRB 
CD32(a) bears a cytoplasmic domain containing immunoreceptor tyrosine-based activation 
motifs (ITAMs) whereas CD16(b) is a GPI-anchored FcγR and lacks a cytoplasmic tail. 
Therefore, CD32(a) has direct ability of initiating intracellular phosphorylation cascades [49].  
CD32(a) was clearly identified as the main responsible FcγR for the induction of the 
neutrophilic sADRB response. CD16(b)-deficient PMNs with blocked CD32(a) showed no 
respiratory burst activity (III.1.1). Non-deficient PMNs with blocked CD32(a) showed only a 
basal level of ROS production, maybe relying on antibody binding by CD16(b), followed by 
displacement of the CD32(a)-blocking antibody and induction of a weaker and altered 
respiratory burst via CD32(a) [127]. Results were less clear in the mADRB assay. Blocking of 
CD32(a) resulted in a lower, but still comparably high signal intensity, even on CD16(b)-
deficient PMNs, and also the removal of CD16(b) did not abolish respiratory burst activity. 
This indicates that both receptors contribute to the neutrophilic mADRB. A possible 
Discussion
 
 
 
 
 
79 
 
explanation for this observation may be that the remaining 25% of CD32(a) are sufficient for 
initial immune complex binding, induction of phagocytosis and the production of low 
amounts of ROS in the mADRB assay setup. Exposure to (exogenous) ROS has been shown 
to enhance the transport of CD32(a) to the plasma membrane [128], thus the minimal 
activation represented by the 25% of residual CD32(a) could facilitate the induction of the 
mADRB. CD32(a) is also described as a very efficient receptor for phagocytosis, so the low 
amounts of CD32(a) can still be sufficient for its partial performance [129]. 
It is under debate which of the FcγRs plays the predominant role in PMN activation, 
especially for phagocytosis [34, 127, 129-133]. Four possible models for CD16(b) and 
CD32(a) cooperation and signaling have been discussed by Edberg et al. [134]: (1): Both 
receptors bind their ligands and induce a separate signaling cascade; (2): CD16(b) serves as 
initial ligand-binding and -presenting receptor due to its higher expression, but signaling 
occurs only through CD32(a). (3): Initial engagement of CD16(b) by ligands enhances the 
functional response of CD32(a). (4): Both receptors act synergistic in inducing one signaling 
response. The results presented here support the model of CD16(b) as an additional (ligand-
presenting) receptor, especially in the mADRB assay. Whether or not signaling only occurs 
via CD32(a) and/or CD16(b) was not assessed in these experiments but should be part of 
further investigations (refer to chapter V). In the context of malaria, the predominant 
contribution of CD32(a) for the neutrophilic ADRB is of importance because of its allelic 
polymorphisms. The mutation of Arg131 to His131 leads to a reduced affinity towards IgG2 
and IgG3. The implication of this allelic alteration is discussed controversially. While some 
authors associated the homozygous Arg-genotype with an increased susceptibility to severe 
malaria and anemia [135, 136], others correlated this with reduced occurrence of high-density 
parasitemia [137, 138]. Consequently, the influence of this polymorphism requires further 
clarification, because it seems to be of major importance regarding the predominance of 
CD32(a) in the anti-merozoites response of PMNs. 
In summary, the discrepant dependence of the neutrophilic sADRB and mADRB on 
either FcγR demonstrate differences in activation pathways and thus response mechanisms, 
although only CD32(a) is capable of inducing signaling cascades by its own due to its 
cytoplasmic ITAMs. This observation is coherent with two former observations: 1) treatment 
of PMNs with pertussis toxin or prostaglandin E1 showed a distinct impact on their responses 
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to different types of immune complexes [131]; 2) distinct activation pathways of nuclear 
factors by CD32(a) and CD16(b) have also been presented [139].  
 
IV.1.2 ROS are generated at distinct locations depending on the ADRB 
assay 
The readout system for the respiratory burst relies on the visualization of ROS that are 
produced by a membrane-associated NADPH oxidase. This enzyme may be activated either 
in intracellular phagosomes or at the outer cell membrane [113, 140]. Coherent with the 
distinct contribution of either FcγR to the neutrophilic sADRB and mADRB, these assays 
differed in the cellular site of ROS generation. The sADRB was characterized by a 
predominant extracellular ROS response. In contrast, the mADRB occurred mainly 
intracellular, representing phagocytosis events (III.1.2). The addition of ROS scavengers to 
the mADRB assay destroyed the early extracellular ROS, resulting in a slight shift in the 
onset of the detected response. The presence of early extracellular ROS in the mADRB assay 
without scavengers may reflect secretory granule release prior to phagocytosis [141] or the 
appearance of ROS resulting from the formation of the phagocytic vesicle. Furthermore, a 
portion of extracellular ROS is also a common feature of phagocytosis in PMNs [129]. 
Surprisingly, the kinetic profiles presented in this study differ from those reported by Joos et 
al. who used isoluminol as chemiluminescence amplifier in their study [29]. Opsonized 
merozoites induce a ROS response at intracellular level but isoluminol predominantly detects 
extracellular ROS because it is less membrane-permeable. Therefore, it is crucial to use 
luminol when determining the neutrophilic mADRB response to cover the whole breadth of 
response, including especially the predominant intracellular events, and to avoid detection of 
only basal extracellular events. Additionally, our results support the proposed protective role 
of PMNs in the immune response against malaria [142]. In this clinical study, Greve et al. 
show that fast parasite clearance time is significantly associated with high PMN-produced 
ROS levels. 
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Summarizing the key findings of the here-performed characterization of the neutrophilic 
sADRB and mADRB response, the sADRB was strongly dependent on CD32(a) and resulted 
in extracellular generation of ROS. In contrast, PMNs generated ROS at intracellular level in 
the mADRB assay. This stimulation is dependent on both, CD32(a) and CD16(b) (Figure 42).  
 
 
Figure 42 Functional dissection of the neutrophilic sADRB and mADRB. 
A: PMN stimulation in the sADRB assay results in CD32(a)-dependent and extracellular generation of ROS 
which are experimentally visualized using luminol. 
B: PMN stimulation in the mADRB assay results in CD32(a)-dependent and predominantly intracellular 
generation of ROS. CD16(b) thereby serves as ligand-presenting receptor. For clarity of the figure the additional 
ROS (H2O2, HO•, HOCl) are not shown in the schematic representation of the mADRB assay, as it is shown for 
the sADRB assay. 
 
  
Discussion
 
 
 
 
 
82 
 
IV.1.3 The role of PMNs in the antimalarial immune response needs 
evaluation in precise assays 
The observations made in this PhD thesis provide evidence that phagocytosis rather than ROS 
secretion is the main neutrophilic anti-merozoite mode of action of PMNs. This was verified 
by the specific phagocytosis of SIP-opsonized GFP-expressing merozoites. This means that 
PMNs do not kill merozoites by a strong extracellular ROS response, but ingest them rapidly, 
followed by subsequent digestion in the intracellular phagosome. From this stage, the 
digestion does not need to take place quickly as it would be crucial in the case of extracellular 
ROS-mediated killing. This finding is of key importance because only small amounts of ROS 
are targeted to the extracellular space, thus minimizing damage to surrounding cells. This is 
advantageous, if not even urgently needed, in the case of an anti-merozoite response in vivo 
since this extracellular stage of the parasite is only present for a few minutes in the blood 
stream [111]. The neutrophilic intracellular ROS response appears concomitant with 
phagocytosis and may therefore substitute the elaborative determination of phagocytosis when 
studying PMN stimulation by antibodies. These results propose additionally to apply the 
mADRB assay to investigate antibody-mediated stimulation of PMNs instead of the more 
commonly used sADRB assay in malaria research. The mADRB assay best represents the 
natural situation in the circulation . The sADRB assay may be useful to initially study antigen 
binding and PMN stimulation, or if other final applications are of interest, such as the 
neutrophilic response towards solid tumors, which cannot be easily ingested.  
However, until now, there is no proof for the relevance of PMNs for protection in vivo, 
apart from the correlation between clinical protection from malaria and ADRB-inducing 
potential of naturally-acquired antibodies in two Senegalese populations [29]. It has recently 
been reported that the PMN-activating potential of certain IgG-subclasses specific for 
MSP-119 was not correlated with increased protection from malaria in mice [40]. Furthermore, 
although showing increased sADRB-based PMN stimulation, IgA1 was also not found to act 
protectively in human FcαR-transgenic mice [38]. Although FcγRs have been shown to 
control murine P. berghei and P. chabaudi infections [143, 144], no correlation between the 
ex vivo activity of neutrophils from wild-type or FcγR-knockout mice and in vivo protection 
could be determined in another recent study [145]. Despite a ~2.5-fold increased mADRB-
like activity of isolated PMNs, the corresponding mice were not protected neither after 
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vaccination with MSP142, nor after a vaccination with a sub-lethal dose of P. yoelii. The 
authors draw two main conclusions: 1) the choice of the antigen for a vaccine is of crucial 
importance, as the response of the PMNs is not only dependent on the antibody concentration, 
but also on the accessibility of the opsonizing antibody for the PMN. This is completely in 
line with the observation that antibodies against MSP3 perform poorly in GIA, but mediate 
very good inhibition in ADCI assays using monocytes as effector cells [27]; 2) this model 
might not be completely transferrable to the human malaria infection, as murine PMNs only 
express (the inhibitory) CD32(b), but not (the activating) CD32(a). Therefore, comparable 
studies should be performed using human PMNs (refer to chapter V). Recently, Dasari et al. 
have shown that digestive vacuoles, which are released at schizont rupture along with 
merozoites and hemozoin, were preferentially taken up by the PMNs instead of the released 
merozoites even in the presence of reactive antibodies [146]. These results, conclusively, 
suggest that PMNs may act only in a first line of defense at low parasitemia levels, 
accompanied by a low load of digestive vacuoles, before more potent immune mechanisms 
become active [147]. 
The neutrophilic anti-merozoite mode of action was confirmed to be dependent on 
phagocytosis rather than on extracellular ROS-dependent mechanisms. This is coherent to 
literature where even PMNs defective in oxygen metabolism were shown to inhibit parasite 
growth in vitro [148]. This was emphasized by the intracellular localization of ROS during 
the mADRB assay which was in connection to phagocytosis on a single cell-level. Two 
related assays to study ADRB reactivity of PMNs have been characterized, providing insight 
into the activation mechanisms and resulting responses. The mADRB assay might serve as 
valuable tool for the evaluation of possible in vivo efficacy of vaccines in inducing protective 
antibody responses. In particular, recombinant antibodies could be more efficiently analyzed 
for their possible application as passive vaccine or therapeutic agent.  
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IV.2 Generation and functional characterization of recombinant 
antimalarial antibodies 
During this second project, the two main aims were achieved: First, functional recombinant 
chimeric antibodies from the previously-published AMA1-specific rat antibody 4G2 [78] 
were successfully cloned, expressed, and purified (III.2.1). Subsequently, these were 
functionally characterized and especially the prerequisites for the efficient induction of the 
neutrophilic ADRB were assessed (III.2.2). Second, these results were finally used to 
establish a screening system for new isolated monoclonal antimalarial antibodies with focus 
on direct growth inhibition and especially PMN stimulation. 
 
IV.2.1 Expression of functional antibodies and characterization of 
antigen binding 
Both expression systems, N. benthamiana and HEK293-6E, were suitable for the expression 
of 4G2IgG1 (III.2.1.3). The yield of 64 mg/kg for the transient expression of 4G2IgG1Nb were 
in the lower range as expected for transient agro-infiltration based expression of antibodies, 
because up to 1 g/kg fresh leaf weight have been reported [149]. Due to the wide variety of 
vector systems with different promoter sequences or silencing inhibitors, including 
noncompeting viral vector systems [150], yields are only difficult to compare. The range of 
64 mg/kg, however, lies within the range of transient expression yields in-house. Also the 
yield for 4G2IgG1HEK lies below values published, which raise up to 1 g/l cell culture 
supernatant [151], but most of these high yields were only achieved in controlled fermenters 
and not in shaking flasks as it was the case in this thesis. Nevertheless, it was possible to 
produce sufficient amounts of 4G2IgG1 in both expression systems for extensive 
characterizations, with advantages and disadvantages for both systems. Especially the short 
period of time, meaning 6-7 days, is advantageous for both expression systems. The easy 
processing of the HEK293-6E cell culture supernatant, which contains only vey low amounts 
of contaminating proteins, is a major advantage of this system. On the other hand, N. 
benthamiana is more robust, and some low-expressing antibodies in the mammalian system 
expressed well in the plant system, e. g. the 4G2IgA2m(2) antibody. 
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The 4G2IgG1 antibodies from both expression systems showed similar affinities and ELISA-
based activities, indicating that both expression systems are equally suitable for the 
production of high-quality antibodies (III.2.2.1). This was also reflected in similar growth 
inhibitory activities with IC50 values of ~200-250 µg/ml (III.2.2.2). The determined inhibitory 
activity lies within the expected range, because 4G2Fab-fragments show IC50 values of 
~140 µg/ml [152]. Surprisingly, in this publication the full size original rat antibody showed 
no significant inhibition, opposing the first citation of this antibody, where ~60-70% of 
growth inhibition were achieved, although no concentration is given [78]. 
4G2IgA2m(2)HEK and 4G2IgA2m(2)Nb were equally suitable to bind the target antigen 
AMA1 (Figure 19) and stimulate PMNs (Figure 26). Only the latter antibody was used for all 
subsequent functional characterizations because of the low expression yield of 
4G2IgA2m(2)HEK (Table 15). The affinity could not be determined by SPR spectroscopy, but 
the performed ELISA experiments suggested equal affinities compared to the 4G2IgG1 
antibody, but a lower activity (III.2.2.1). This may be due to the fact that the IgA2m(2) 
antibody has a shorter hinge region compared to IgG1, comprising eight amino acids instead 
of 15, including a 5-fold proline stretch. Following this, IgA2 antibodies form a T-shaped 
instead of a Y-shaped structure, which altogether contribute to a reduced flexibility [33, 153-
155]. This lower activity, which has also been observed by Pleass et al. for an MSP1-specific 
IgA1 [39], probably leads to the observed lower inhibitory activity in the GIA.  
To conclude this initial screening, the IgG1 isotype is superior to the IgA2m(2) isotype 
concerning 1) high-yield expression in both expression systems, HEK293-6E and N. 
benthamiana, 2) antigen binding activity, although the affinity of all four tested antibody 
variants was similar and 3) ability to inhibit P. falciparum growth in vitro. 
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IV.2.2 The ability to induce a neutrophilic ADRB 
One of the most critical steps during the induction of the neutrophilic ADRB is the efficient 
FcγR engagement. It was shown that both recombinant isotypes, IgG1 and IgA2m(2), are able 
to induce a neutrophilic ADRB, but are inferior to the used human IgG-containing SIP-pool 
(Figure 22, Figure 27). The aim of the following characterizations then was the dissection of 
the underlying reasons for this phenomenon. At first, it was investigated whether the 
antibody-Fc N-glycan structure plays the predominant role in the induction of the neutrophilic 
ADRB (IV.2.2.1). Finally the influence of FcR crosslinking was characterized (IV.2.2.2).  
 
IV.2.2.1 The role of the antibody-Fc N-glycan profile 
IV.2.2.1.1 The IgG-Fc N-glycan profile: Mammalian expression systems 
The 4G2IgG1HEK variant carried indeed a distinct N-glycan profile compared to the purified 
human IgG sample, as determined by QTof mass spectrometry (Table 17). The most striking 
difference was the lack of Na at the N-glycan termini for the 4G2IgG1HEK. Although it was 
expected from literature searches that a recombinant protein expressed in HEK cells would 
carry N-acetylgalactosamine (Ga) instead of A after the branched M (Figure 3) [45, 46], they 
did in fact all carry A (if any residue was present after the branched M and Gn). In the former 
cited studies, soluble human CD16(a) or interleukin-17A were characterized after expression 
in HEK293 cells without further specification or HEK293-F cells. It has been reported that 
two proteins expressed in the same expression host can receive different N-glycan profiles 
[156]. Furthermore, the IgG-Fc N-glycan faces inwards the two heavy polypeptide chains, 
whereas the N-glycans of the proteins used for the mentioned HEK-glycosylation studies are 
probably directed more to the “protein surface”. Ga is bigger than A (220 Da va. 180 Da), 
which may be the reason that the addition of A is energetically preferred in case of an IgG 
molecule.  
Because CHO cells may show an increased portion of N-glycan structures terminating 
with Na [46], H10IgG1CHO was included in these investigations. However, in case of this 
antibody also no Na was present (Table 17). Thus, the inwards-facing IgG-Fc N-glycan 
structure may furthermore explain the low or even absent sialylation. Although CHO cells 
express the α2,3-sialyltransferase, its activity is influenced by several factors such as cell 
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density, growth conditions or culture medium [157, 158]. Overexpression of the 
corresponding enzyme, or a sialyltransferase catalyzing the α2,6-linkage which is more 
common in humans, has been shown to enhance the total portion of sialylated IgG to 
~60-90% [158-160]. In vivo, asialylated proteins are more rapidly cleared from the blood 
stream by the asialoglycoproteinreceptor [161]. This may additionally contribute to the 
enhancement of the total portion of completely sialylated IgGs in vivo. In general, simply 
enhanced sialylation can also adversely affect effector functions of an antibody [162, 163]. 
Beside this, both (not sialylated) recombinant antibodies, 4G2IgG1HEK and H10IgG1CHO, 
were as efficient as human IgG in binding to CD32(a) and the induction of the (antigen-
independent) neutrophilic cADRB (Figure 24), so that the lack of sialylation or an altered 
overall N-glycan profile was not the reason for the decreased induction of the (antigen-
dependent) neutrophilic sADRB. Although the human sample showed a ~15%-enhanced 
binding activity to human CD32(a) in the SPR spectroscopic analysis, its capacity to induce a 
neutrophilic cADRB response was ~3-fold lower (Figure 24). A similar phenomenon was 
observed by Forthal et al., who determined that certain IgG-Fc N-glycan profiles show 
enhanced binding activity to CD16(a), but not always enhanced virus inhibition by NK cells 
through the same receptor [48]. 
 
IV.2.2.1.2 The IgG-Fc N-glycan profile: N. benthamiana as expression system 
The 4G2IgG1Nb variant contained another IgG-Fc N-glycan profile than its HEK-expressed 
counterpart (Table 17). 1/3 of the antibodies carried no glycosylation at all, and the residual 
molecules carried N-glycan structures containing an additional β1,2-X at the branching M. 
The comparably large portion of unglycosylated antibody resulted from the 5-day transient 
expression itself and the harvesting procedure. Whole leaves were harvested and shred 
(II.2.4.1), and not just the apoplastic fluid which corresponds to the mammalian cell culture 
supernatant. Thus, also premature antibodies are recovered, which are not completely 
assembled and/or glycosylated. This is also reflected in a slightly higher portion of un- or only 
partly assembled antibodies expressed in N. benthamiana, albeit this portion is negligibly low 
in the present preparations (Figure 18). Unglycosylated IgG1 was not bound by CD32(a) in 
the SPR spectroscopic analysis, and thus failed to induce a neutrophilic ADRB as verified by 
use of an enzymatically deglycosylated 4G2IgG1HEK-Glyc (Figure 24). It has previously been 
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shown that aglycosylated IgG1 is only able to productively engage FcγR under avid 
conditions [164], or when proteinchemically engineered [165]. Also the residual 67.7% of 
glycosylated 4G2IgG1Nb preparation failed to strongly bind to CD32(a), and thus also to 
induce any neutrophilic ADRB. By a stepwise truncation of the IgG-Fc N-glycan a loss of 
thermal stability of an IgG was demonstrated by differential scanning calorimetry, which 
resulted in a lower affinity towards CD32(b) in SPR spectroscopic analyses [166]. This 
reduced affinity was later shown to rely on a conformational change by resolution of the 
corresponding crystal structures [167]. Therefore, it seems as if the additional plant-specific X 
probably also alters the overall IgG-Fc conformation and therewith inhibits the binding of 
CD32(a) to 4G2IgG1Nb [168]. This is in agreement with previous findings [48], in which the 
knocking down of X and F by RNA interference increased the binding of a plant-produced 
antibody to a TZM-bl cell line transfected with CD32(a) [48].  
 
IV.2.2.1.3 The IgG-Fc N-glycan profile: FcγR and corresponding effector cells 
The work of Forthal et al. also emphazises that binding studies using CD16(a) cannot be 
transferred to CD32(a) [48]. Different binding ratios of an antibody to FcγR-transfected 
TZM-bl cells was shown to be dependent on its IgG-Fc N-glycan profile and the respective 
studied FcγR. In fact, even CD32(a) and CD32(b) show different binding characteristics 
towards the antibodies with alternate glycosylation structures, so that even no direct 
comparison between two FcγR isotypes is possible. Using NK cells as effector cells, the 
different linkage of the plant-specific F (α1-3 instead of α1-6) has no influence on binding to 
CD16(a) and thus the induction of effector functions [169], although the complete lack of F 
increases these functions [163]. These findings remain to be investigated using PMNs as 
effector cells, because of slightly distinct IgG-Fc−FcγR interaction sites for each FcγR, 
although they all are in close proximity. Therefore, IgG-Fc−FcγR interactions may not be 
equally affected by alterations in the IgG-Fc N-glycan structure for each FcγR [49, 170]. 
Many studies investigating the functionality of (glyco-) engineered antibodies have been 
performed using NK cells (CD16(a)) or mononuclear cells (CD64) in the context of viral 
diseases (AIDS, Ebola) [48, 171-173], cancer or inflammation [168]. Until now, only few 
functional analyses of IgG-Fc glycosylation variants using PMNs have been published with 
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none concerning malaria. Although glycoengineering has been presented as efficient tool to 
increase some effector functions of PMNs [174, 175], it is questionable if these optimizations 
result in a comparably high stimulation of PMNs as it was demonstrated for the human-
derived samples in this work. This aspect is addressed in a following chapter (IV.2.2.2). 
 
IV.2.2.1.4 The IgA-Fc N-glycan profile 
In case of the 4G2IgA2m(2)-induced neutrophilic ADRB, the expression host did not impact 
the PMN-stimulatory capacity of the antibody at all (Figure 26) indicating a N-glycosylation-
independent PMN stimulation. The received N-glycan profile may differ from the one 
determined for the recombinant 4G2IgG1 variants, as shown by Westerhof et al. before [156]. 
But a detailed N-glycan profiling was considered not to be essential because there was no 
functional difference between the two antibodies from the assessed expression systems. This 
observation is also in agreement with the current understanding that the recognition of IgA by 
CD89 is independent from the N-glycan profile [50], although most studies have been 
performed with IgA1 and not IgA2 [176, 177]. In the IgA2 isotype, one predicted IgA-Fc N-
glycosylation site is close to the CD89-docking site at the CH2/CH3 boundary [178], which 
does not seem to have an influence on the recognition of CD89, because CD89 binds both 
IgA-subtypes equally well [179]. 
 
IV.2.2.2 The importance of efficient FcR crosslinking  
Although the IgG-Fc N-glycan profile significantly contributes to the stimulation of PMNs, it 
does not explain the superiority of the human reference samples to the recombinant 4G2-
based antibodies (IV.2.2.1). An enhanced neutrophilic sADRB response for both 4G2-based 
isotypes was observed by increasing the antigen density (Figure 25, Figure 27). Neither 
isotype was able to induce a neutrophilic mADRB response (III.2.2.3.5). Therefore, results 
obtained for the neutrophilic sADRB and cADRB can only be used to extrapolate their 
implications on the mADRB assay and phagocytosis. These results suggest that efficient 
FcR crosslinking is the most crucial parameter for an efficient induction of the neutrophilic 
ADRB. All here-studied FcR, CD16(b), CD32(a) and CD89, show a low affinity towards 
monomeric antibodies but require efficient FcR crosslinking [31, 180, 181]. 
Discussion
 
 
 
 
 
90 
 
This efficient FcR crosslinking can be achieved in two ways: 1) by using different antibodies 
to enhance the clonality of the preparation; 2) by targeting highly abundant antigens with 
well-accessible epitopes. In the sADRB assay, the antigen density can easily be varied, but 
the density as well as its accessibility on the surface of the merozoite is fixed. The here-used 
target antigen AMA1 is a protein which circumferentially redistributes from the apical end to 
the whole merozoite surface at the time of or closely after schizont rupture (Figure 20) [118], 
a process which is not inhibited by bound 4G2 [152]. AMA1 is a membrane-anchored protein 
and therefore remains in close proximity of the merozoite surface membrane [182, 183]. 
Therefore, the usage of more-exposed target antigens may facilitate improved concurrent 
binding of an antibody to both, its antigen and the FcγR of the effector cell. In this context, 
proteins which are supposed to associate as surface-exposed protein complex would be 
promising alternative candidates, like the most abundant surface protein MSP1, but also 
MSP2, 3, 6 and 7 [184, 185]. Three of these would be of special interest: 
1) MSP119, because this fragment of MSP1 stays on the merozoite surface after 
processing by the subtilisin-like protease 1 (PfSUB1) [186]. Therefore, an antibody blocking 
this process may be an important component of an antibody cocktail. The suitability of MSP1 
may be argued though: Merozoite-phagocytosis by PMNs was demonstrated with 
MSP119-specific monoclonal antibodies [39]. However, Pleass et al. targeted CD64 [39], the 
FcγRI with high affinity also for monomeric IgGs. In this PhD thesis, the response of 
unstimulated PMNs (without CD64) was studied. There is no proof of CD64-upregulation in 
malaria. In contrast, CD64 was even shown to be downregulated on dendritic cells in 
P. vivax-infected individuals [187], and no upregulation of CD64 was determined in human 
FcγR-transgenic mice [188]. In conclusion, the presence of CD64 on PMNs during malaria 
infection may be argued, especially in a first line of defense when PMNs are not cytokine-
activated. Furthermore, naturally-acquired MSP142-specific antibodies were not able to 
control a P. yoelii infection in a mouse model [145], as discussed (IV.1.3). Besides, MSP1 is 
located in proximity to the merozoite surface and may be shielded by the natural 20-nm thick 
filamentous surface coat surrounding the merozoite under native conditions. This coat is 
sensitive even to treatment with PBS [189]. Therefore, phagocytosis may be observed with 
this target antigen experimentally in vitro, but may not be possible in vivo. 
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2) MSP2, because it likely has a structural role in the surface coat [185] and may therefore be 
more exposed and better accessible. 
3) MSP3, because monocyte-mediated ADCI activity is closely correlated to 
MSP3-reactivity of antibodies [27].  
As previously mentioned, the antigen- and therewith antibody-density is the most 
important parameter for an efficient induction of the ADRB. Taking all the previous 
discussions concerning antigen density and chosen antigen itself into consideration, the 
abundance or the exposed position of a target antigen may alone not be sufficient. Probably 
the concurrent targeting of several epitopes of one antigen or even of multiple antigens with a 
polyclonal antibody-cocktail is required for an efficient induction of the mADRB.  
In contrast, NK cell-mediated virus neutralization has been shown to be efficient with a 
monoclonal antibody [48]. However, this effector function is triggered through CD16(a) 
whose affinity for monomeric antibodies is slightly higher than that of the other three FcR 
[31]. Furthermore, the specific antibody, 2G12, recognizes the glycoprotein gp120 on the 
surface of the human immunodeficiency virus (HIV) [190], the only surface protein apart 
from the membrane-spanning gp41. Although it may have a low density on the viral surface 
with minimally ~71-111 molecules per virion, the virus only spans 80-120 nm in diameter, 
which is 1/10 the diameter of a merozoite (1 µm x 1.5 µm) [21, 191]. An IgG1 antibody can 
span at maximum ~15 nm [192]. Taken together, these facts seem to be sufficient for the 
induction of a NK cell-mediated anti-HIV immune response by FcγR crosslinking.  
To conclude these very extensive characterizations concerning the induction of a 
significant neutrophilic ADRB response, the IgA2m(2) isotype is superior to the IgG1 
isotype. This is probably due to the higher CD89-density on the PMN’s cell surface compared 
to CD32(a) (I.2.1). Its functionality can very easily be detected in the sADRB assay with 
lower amounts of immobilized antigen. 75 ng AMA1 were sufficient for an 4G2IgA2m(2)-
induced ADRB (Figure 26), whereas at least 1125 ng were required for a significant 
neutrophilic reaction towards bound 4G2IgG1HEK (Figure 25). If suitable antibodies for the 
in-depth characterization of the neutrophilic mADRB in response to recombinant antibodies 
would be isolated, it can be expected that their functionality can be screened using the IgA 
isotype much more comfortably also in the mADRB assay, since less amount is needed for 
the induction of a response compared to the IgG isotype even in the sADRB assay. 
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IV.2.3 Optimal screening strategy for new antimalarial antibodies 
The second aim of this second working package was the establishment of a screening strategy 
for new isolated antimalarial antibodies based on the presented results (IV.2.1, IV.2.2). Prior 
to the start of the developed screening route (Figure 43), an isolated sequence was cloned into 
the general vector systems (III.2.1), and the antigen-specificity was previously determined by 
a small-scale expression in a few N. benthamiana leaves or ~30 ml of HEK293-6E culture 
and evaluation of antigen recognition by ELISA (II.2.5.4) or SPR spectroscopy (II.2.5.3), or 
in general merozoite-specificity by IFA (II.2.6.2). 
 
Figure 43 Screening strategy for new isolated antibodies. 
After the V-region sequences of a malaria-specific antibody have been verified by testing of a 
small-scale-expressed IgG1, the corresponding recombinant IgG1 and IgA2m(2) antibodies can be produced in 
N. benthamiana in a larger scale (II.2.4.1) and analyzed for growth inhibitory properties in the GIA (II.2.7.1) 
using the IgG1 isotype, or for the induction of the neutrophilic ADRB (II.2.7.2) using the IgA2m(2) isotype, 
preferably in the mADRB assay. After one of these functionalities has been verified, the antibody should be 
expressed as IgG1 in a mammalian expression system to circumvent the reduced serum stability of the IgA2m(2) 
isotype, and the regulatory issues of plant-derived biopharmaceuticals. If neither of these functionalities is 
verified, other potential applications can be considered. 
 
Direct growth inhibitory properties are preferably screened using the IgG1 isotype due 
to its higher antigen-binding activity (III.2.2.1) and thus inhibitory capacity (III.2.2.2). 
Although there was no difference between HEK293-6E- and N. benthamiana-derived 
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antibodies in these aspects, and additionally only the 4G2IgG1HEK antibody was capable of 
stimulating PMNs (III.2.2.3.1), N. benthamiana should be chosen as an expression system for 
this approach. This system is in general more robust, meaning it is able to express even 
hardly-expressing antibodies in suitable amounts. If the IgG1 should be expressed in a 
mammalian system to facilitate concurrent screening for growth inhibition and PMN 
stimulation, HEK293-6E cells should be chosen. The transient yields obtained from HEK 
cells is usually higher than from CHO cells [193], and ~0.5-1 l of transfected HEK293-6E cell 
suspension usually yields sufficient amounts for these screenings.  
If the antibody does not inhibit merozoite invasion, PMN stimulation has to be assessed 
next, preferably using the IgA2m(2) isotype as less antibody is needed for the induction of a 
response compared to the IgG isotype. This isotype should also be expressed in N. 
benthamiana, because of the reasons already listed above. An additional benefit for this 
application is the expression system-independent stimulation of PMNs via CD89 (Figure 26).  
This complete screening can be performed within 6-8 weeks if both tracks are followed 
in parallel. In either case, the antibody should be expressed as IgG1 in a mammalian system 
for its preclinical evaluation as potential therapeutic. For therapeutic applications as passive 
vaccine or acute treatment option, a long serum-stability is favourable, and this is 3-fold 
higher for IgG compared to IgA [50]. CHO cells, the gold-standard for the production of 
biopharmaceuticals [42], would be the cell line of choice in this aspect. However, it has to be 
considered that the expression of biopharmaceuticals in mammalian expression systems is a 
cost-intensive process, especially when needed for poverty-related diseases such as malaria. 
The production of such a therapeutic antibody in plants may therefore be advantageous 
because of its general lower costs. Furthermore, the first plant-derived protein received 
approval for human use in 2012, which could open new licensing paths of plant-derived 
biopharmaceuticals [75]. Much progress has been made in the glycoengineering of plants as 
an expression system to yield “humanized” IgG-Fc N-glycan profiles. Sometimes the effector 
functions could be enhanced to a level even above the effector functions of the same antibody 
produced in CHO cells [48, 149, 194, 195]. 
If neither of these functionalities applies to the isolated antibody, it could be analyzed 
for applications as a diagnostic tool or as a fusion partner for antimalarial molecules. This will 
be discussed in the next chapter (IV.3). 
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IV.3 Enhanced antimalarial activity of Gb by scFv-mediated 
targeting to P. falciparum 
The most important prerequisite for this third strategy aiming to generate and characterize 
antibody-based antimalarial molecules was the direct verification of Gb as a molecule bearing 
antimalarial activity. This aim was successfully demonstrated as a starting point for this 
project. Following this, a suitable antibody for the targeted guidance of Gb to the parasite was 
successfully isolated and characterized, its scFv generated and genetically fused to Gb. This 
fusion protein was finally used to demonstrate its enhanced antimalarial activity in 
comparison to Gb alone or malaria-unrelated Gb-scFv fusion proteins. 
 
IV.3.1 Efficient rescue of antibody V regions 
The PfMSP4EGF-specific antibody 2.44 was successfully isolated (III.3.2.2) and characterized 
for retained binding properties in comparison to the parental murine antibody (III.3.2.2.1). 
The V-region sequences were rapidly and accurately rescued by use of a published primer set 
which achieves ~60% rescue efficiency on single cell level [89]. One unique sequence was 
isolated from eight monoclonal hybridoma cell lines. This phenomenon called “clonal identity 
of several hybridoma cell lines” results from the limiting dilution procedure during the 
generation of monoclonal hybridoma cell lines. Also Broering et al. only identified three 
unique sequences out of 18 monoclonal hybridoma cell lines [196]. Therefore, the 
determination of the exact immunoglobulin sequences of murine monoclonal hybridoma cell 
lines is crucial, even if no further recombinant antibodies or derivatives are wanted. With this 
strategy, a highly-increased workload due to the characterization of multiple identical clones 
can be circumvented. 
One major alteration in the subsequently applied procedure was introduced compared to 
the strategy pursued by Tiller et al. [89], namely the design of the Vh-region forward primer. 
The obtained sequence information was aligned to the most probable germ-line framework 
region 1 (FWR1) sequence of the Vh region (Figure 32) using the open-accessible online 
database IMGT [90] instead of again using consensus primers for the identified Vh-gene 
family. This step was brought in because the initial Vh-region forward rescue primer binds in 
the FWR1 and thus generally may introduce nucleotide changes which may also result in 
mutations in the amino acid sequence. Those mutations have to be avoided, because one 
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single substitution even within antibody FWRs may reduce or even completely abolish 
antigen binding [197]. In their work, de Haard et al. identified residue six in the Vh-FWR1 as 
one of the most crucial residues for correct antibody folding and thus antigen recognition. 
Even though mutations may occur in heavily affinity matured antibodies even at the highly 
conserved amino acid position six of FWR1, this was probably not the case for the rescued 
antibody 2.44, because it showed a strong homology with the reference sequence of ~96%, 
meaning that it underwent only a minor affinity maturation. 
Next, N. benthamiana has been chosen as rapid and efficient expression system based 
on the strategy presented in the previous chapter (IV.2.3). In this case only a functional 
characterization concerning antigen binding was of interest and no stimulation of effector 
cells, because it should be ensured that the corresponding scFv would be generated from a 
verified sequence and encoded specificity. The expression of a functional and highly pure 
recombinant 2.44IgG1 again nicely confirmed the suitability of N. benthamiana as 
competitive expression host. The murine and recombinant counterparts of the 2.44 antibody 
had similar affinities, and binding of the recombinant 2.44IgG1 was successfully competed by 
the murine 2.44IgG1 so that the specificity was proven to have been conserved. Of major 
importance was also that the generated antibody recognizes native antigen and not only 
soluble recombinant protein (immobilized onto a polystyrene plate), which was verified using 
the IFA and WB analyses (III.3.2.2.1). 
Although the ultimately wanted antibody format was the scFv, a preceding confirmation 
of the V-region rescue in the full-size antibody format was of importance. Uncorrected 
primer-derived mutations may lead to loss of epitope-specificity and affinity as well as 
problems with expression yields and solubility, especially in the scFv-format [198]. These 
drawbacks were circumvented by the direct comparison of the antigen-binding properties of 
the rescued antibody and its original murine counterpart. The 2.44scFv showed a ~100-fold 
decreased binding activity towards PfMSP4EGF (Figure 38), which may be a result reduced 
avidity of the scFv only bearing one antigen binding site. Furthermore, the composition of the 
linker peptide between the V regions may influence binding activity [199], as maybe does the 
overall protein conformation due to the fused Gb. The binding activities of the 2.44IgG1 and 
Gb-2.44scFv were determined using different detection antibodies. Altogether, these issues 
may contribute to the comparably low binding activity of the 2.44scFv. 
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IV.3.2 The antimalarial activity of Gb 
By demonstration of the direct antimalarial activity of Gb (III.3.1), the most important 
prerequisite for this subproject was achieved. Another important prerequisite was the lack of 
growth inhibition mediated by the 2.44IgG1. If its scFv was used for the delivery of Gb into 
the developing parasite, the antibody must not inhibit parasite growth itself. The lack of 
inhibition in concentrations below 2 µM (~300 µg/ml) is in accordance with literature. Here 
murine antibodies were raised against PfMSP4EGF, and these were not able to significantly 
inhibit parasite growth [200]. Gb fused to the 2.44scFv showed an enhanced growth 
inhibitory effect on P. falciparum 3D7A when compared to the inhibitions mediated by the 
unrelated controls. Moreover, the fusion protein was able to act also against the multidrug-
resistant P. falciparum strain K1, albeit with a 2-fold higher IC50 value (III.3.2.3.2). 2.44IgG1 
also showed a lower inhibition on this strain. Therefore, the 2.44IgG1/scFv may have a lower 
binding activity towards P. falciparum K1 MSP4. P. falciparum K1 MSP4EGF shares 97% 
sequence homology with P. falciparum 3D7A MSP4EGF (GenBank accession numbers 
AF295306.1 and AAN07096.1). The Gly213 is replaced by Asp213 in P. falciparum K1, thus 
giving the protein another charge in this region, possibly contributing to a slightly decreased 
antibody binding. Considering also the higher IC50 values of the unrelated controls, another 
possibility for the reduced antimalarial activity of Gb or Gb-scFv fusion proteins on this strain 
may be its inherited drug resistance. Since the mechanism of Gb’s antimalarial activity has 
not been resolved until now, it may be speculated that Gb is slightly inhibited by one of the 
resistance mechanisms against chloroquine, pyrimethamine or sulfadoxine. To further verify 
this speculative hypothesis, a set of resistant strains would have to be screened for reduced 
susceptibility towards Gb, provided that the 2.44scFv is able to bind to these strains’ MSP4. 
Boyle et al. were not able to show the co-import of different MSP4-specific monoclonal 
antibodies, directed against various epitopes of PfMSP4, although MSP4 was shown to be 
imported into the erythrocyte at the invasion step. A possible explanation may be that the 
PfMSP4EGF-specific Gb-2.44 fusion protein is 40% the size of a full-size antibody (~58 kDa 
vs. ~150 kDa), so that a possible steric hindrance mediated by full-size antibodies was 
circumvented. Another possibility may be the target epitope. Although one of the investigated 
MSP4-specific full-size antibodies was also directed against the PfMSP4EGF, there is still the 
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chance of a slightly different binding epitope, so that the here-used specific antibody-
fragment was co-imported.  
The concept of recombinant ITs or CFPs has been intensively investigated in the field 
of targeted tumor therapy with various bacterial and human effector domains including Gb 
(I.2.2). After binding to a disease-specific cell surface antigen, these fusion proteins are 
internalized by receptor-mediated endocytosis, released from endosomal compartments into 
the cytoplasm, and very efficiently kill the malignant cell. In case of Gb, DNA-fragmentation 
and thus apoptosis is induced by starting a caspase-cleavage cascade, being initiated by Gb 
[56]. Comparably, P. falciparum bears one designated metacaspase PfMCA-1 [201], which 
may be the target of Gb. Another hypothesis is the induction of eryptosis in infected 
erythrocytes [61]. Apart from the cleavage of caspases, Gb induces the disruption of 
mitochondria by activation of Bid, so also leading to cell death in mammalian cells [58]. 
Although granzymes have a conserved substrate specificity, and Gb being the only serine 
protease that prefers substrates with acidic amino acids [58], multiple proteins have been 
shown to serve as substrate for Gb. Apoptosis-initiating proteins are cleaved by Gb, as well as 
proteins involved in DNA-repair, transcription or protein folding, as well as structural 
proteins, cytoskeleton proteins or diverse receptors located at the cell surface [202]. In recent 
first studies, eryptosis (by visualization of surface exposed phosphatidylserine using annexin 
V [61]) or fragmentation of DNA (by terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) [203]) in response to treatment with Gb or Gb-2.44 were investigated. 
However, no clear results were obtained, which may have also been the result of experimental 
complexities. 
Despite these uncertainties in the actual antimalarial mechanism of Gb, the presented 
data provide solid evidence that Gb-containing malaria-specific fusion proteins are valuable 
drug candidates, also acting against a multidrug-resistant P. falciparum strain. The IC50 value 
of this innovative immunotherapeutic lies within the range for a hit candidate, as suggested by 
the Medicines for Malaria Venture (MMV) (available at http://www.mmv.org/research-
development/essential-information-scientists; accessed November 29th 2014). Furthermore, 
the activity is specific, because the EC50 of recombinant Gb in vitro (measured using Jurkat 
cells) has been determined to ~8 µM [204], thus the estimated selectivity index of the here-
evaluated antimalarial fusion protein is > 40.  
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IV.3.3 Implications for therapeutic use of Gb-scFv fusion proteins 
against malaria 
To put the obtained IC50 values for the novel antimalarial fusion protein Gb-2.44 into a better 
perspective, they can be compared with soluble Gb levels in healthy or ill individuals. Normal 
circulating concentrations of Gb were reported to be around 10 pg/ml (~0.3 pM), which can 
raise up to 2,000-4,000 pg/ml (~60-120 pM) during malaria infections, as well as during 
infection with Epstein-Barr virus, or in rheumatoid arthritis [60, 205]. These values are 
~2,000- to 2,000,000-fold lower than the determined IC50 value of Gb-2.44, but the effective 
concentration of NK cell-released Gb upon cell-cell contact is supposed to be much higher 
than the overall concentration in the blood stream. Therefore, the first priority for the pre-
clinical evaluation of such Gb-based antimalarial fusion proteins is the reduction of the IC50 
value and therewith enhancement of their antimalarial activity, after the antimalarial mode of 
action will have been dissected. This may be achieved by the usage of other potential target 
antigens and/or high affinity antibodies or rather corresponding scFvs, as discussed in the next 
chapter (V). In targeted tumor therapy, Gb-scFv fusions or fusion proteins using natural 
ligands as binding moiety show activity in the low nM-range [206]. Nevertheless, a high 
dose-tolerance for Gb may be expected, first because of its human origin, and second, because 
it is strongly involved in the natural process of the induction of apoptosis. So the development 
of neutralizing antibodies by the human immune system is rather unlikely [207]. 
One still might argue that the application of expensive recombinant protein-based 
immunotherapeutics against the poverty-related disease malaria is far beyond any practical 
attempt. The expression of the fusion protein in HEK293-6E cells could also be replaced by 
an expression in plants. This cost-efficient and competitive strategy has been pursued in 
various studies before for the production of antigens for vaccination approaches, also in the 
context of malaria [5-7, 75, 208, 209]. The expression of fusion proteins containing especially 
human-derived effector molecules may be advantageous in such a system. Plants likely lack 
the molecular targets of the chosen effector molecule, so that the protein may be expressed 
already in its active form. Following this, the activation step could be omitted, again saving 
costs. Furthermore, plant-derived biopharmaceutical protein-preparations do not contain 
human pathogens, a fact which increases their safety profile for approval, and the first plant-
derived biopharmaceutical protein already received approval in 2012 [75].  
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V. Outlook 
In this PhD thesis, at first the neutrophilic sADRB and mADRB were successfully 
functionally dissected, leading to phagocytosis as preferred anti-merozoite mode of action of 
PMNs. This mechanism is mimicked best by using the mADRB assay (IV.1.3). Still, there are 
some open questions left to be answered in future investigations. In one aspect, additional 
effector functions of PMNs in response to especially opsonized merozoites, such as 
degranulation, actin- or Ca2+-mobilization could be studied, as well as the evaluation which 
receptor, CD32(a) or CD16(b), finally induces a molecular signaling cascade. All these 
processes take part in a complete neutrophilic anti-pathogen response [129, 174], apart from 
the generation of ROS that was studied during this PhD thesis. In another aspect, the 
establishment of a stable assay similar to the ADCI assay [210], using monocytes as effector 
cells, would be of great interest for further studies. Such an assay is useful to quantify the 
antibody-induced PMN-mediated inhibition of P. falciparum growth in vitro. It bears the 
significant advantage of taking much more factors into account which represent the complex 
situation of a malaria infection more exactly. Such factors are the short time frame in which 
merozoites are accessible after schizont rupture [111] or the co-released digestive vacuoles 
which have been supposed to inhibit phagocytosis of merozoites [146]. Last but not least, a 
good in vivo model is indispensable. Such a model must bear human instead of murine PMNs 
as effector cells, because the latter differ in the expressed FcγRs and corresponding signaling 
pathways [145]. For this approach, a controlled human malaria infection (CHMI) model 
would be suitable [211], if previously-generated in vitro data secure ethical acceptability.  
As a further step, a screening strategy for the functional characterization of new isolated 
antibodies has been successfully set up, as discussed (IV.2.3). Following investigations 
should concentrate at first on the isolation of suitable antibodies, which are able to induce a 
neutrophilic mADRB response, to be able to investigate the underlying mechanisms to a 
greater extent. As pointed out (IV.2.2.2), especially MSP3-specific antibodies would be of 
great interest, because these also show monocyte-mediated ADCI activity [27]. First 
experiments have already been performed with a monoclonal MSP3-specific antibody, which 
was expressed as IgG1HEK and IgA2m(2)Nb and applied in the mADRB assay. In these 
experiments no stimulation of PMNs was observed. This may be the result of a non-suitable 
epitope for concurrent antigen binding and stimulation of PMNs, so that a panel of MSP3-
Outlook
 
 
 
 
 
100 
 
specific antibodies may be screened to identify the most suitable candidates [212], which 
should show mADRB activity either as monoclonal or as polyclonal preparation. 
As a final aspect of this PhD thesis, the antimalarial functionality of antibodies was 
expanded to the guidance of antimalarial molecules to the invading merozoite and thus the 
intraerythrocytically-developing parasite. These data serve as proof-of-principle data and 
leave a lot of space for further interesting investigations. These include at first the resolution 
of the exact antimalarial mechanism(s). For this purpose, the Gb-scFv should be localized 
after co-import by e. g. life-cell imaging techniques. By this approach, the large number of 
possible target proteins (as summarized in IV.3.2) can be restricted. Here, also targeted 
proteome-analyses would serve as a good starting point to identify one or multiple possible 
target proteins that are involved in the process of Gb-mediated growth inhibition of P. 
falciparum parasites. Finally, once the target protein(s) of Gb in the parasite will be identified, 
this/these might as well serve as target molecules for a high-throughput screening approach 
for the identification of novel antimalarial (synthetic) compounds by use of such a 
“backwards-facing approach”. 
The specificity and antimalarial activity of this fusion protein need to be improved. This 
can be achieved by optimizing both of the two components of the antimalarial fusion protein, 
the targeting and the effector moiety. Other MSP4-specific antibodies or antibody-fragments 
could be screened for their suitability as targeting moiety to finally analyze the impact of the 
epitope or the affinity of an antibody on its functionality. Additionally, further potential target 
proteins, which have also been shown to remain on the merozoite surface after erythrocyte 
invasion, may be evaluated. One highly interesting candidate antigen is MSP2, because some 
MSP2-specific antibodies have been shown to be carried into the erythrocyte [67]. Also 
MSP119 is a promising target in this context [71]. Suitable antibodies directed against this 
target must not inhibit the PfSUB1-catalysed processing of MSP142 to MSP119, as blocking of 
this crucial event leads to the inhibition of merozoite invasion [186]. Maybe also other 
effector moieties may be useful to enhance the antimalarial activity of such an antimalarial 
fusion protein, depending on the target antigen and the cellular localization after co-import. 
Potentially suitable human effector domains would be e. g. the microtubule-stabilizing protein 
MAP(tau) [55] or the ribonuclease angiogenin [54]. 
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VII. Appendix 
VII.1 List of abbreviations 
Ac-IETD-pNA  Acetyl-Ile-Glu-Thr-Asp p-nitro aniline 
ADC   antibody-drug conjugate 
ADCI   antibody-dependent cellular inhibition 
ADRB   antibody-dependent respiratory burst 
AIDS   acquired immune deficiency syndrome 
AMA1   apical membrane antigen 1 
Asn297   asparagine residue at amino acid position #297 
APAD   3-Acetylpyridine Adenine Dinucleotide 
APC   allophycocyanin 
approx.   approximately 
APS   ammonium persulfate 
A405 nm / A450 nm / A655 nm absorbance at 405 / 450 / 655 nm 
BSA   bovine serum albumin 
CFP   cytolytic fusion protein 
CHAPS   3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CHMI   controlled human malaria infection 
CHO cells  chinese hamster ovary cells 
95% CI   95% confidence interval 
(h)CU   (human) codon usage 
cv   column volume 
DMSO   dimethyl sulfoxide 
dpt   day(s) post transfection 
DHR-123  Dihydrorhodamine-123 
DSA   drug susceptibility assay 
DTT   dithiothreitol 
EDC/NHS coupling coupling using ethyl(dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide 
EDTA Ethylenediaminetetraacetic acid 
EGF   epidermal growth factor 
ELISA   enzyme-linkend immunesorbent assay 
E64 trans-Epoxysuccinyl-L-leucylamido(4-guanidino)butane,L-trans-3-Carboxyoxiran-2-
carbonyl-L-leucylagmatine,N(trans-Epoxy-succinyl)-L-leucine-4-guanidinobutylamid 
e. g. for example 
Fc constant fragment of an antibody 
FCS   fetal calf serum  
FDA   US Food and Drug Administration 
FITC   fluorescein isothiocycanate 
FWR1   framework region 1 
g   gram 
g   gravity of earth (9.81 m/s²) 
GIA   growth inhibition assay 
GFP   green-fluorescent protein 
GM-CSF  granulocyte monocyte colony-stimulating factor 
h   hour 
HBSS   Hank’s buffered saline solution 
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HEK293 cells  Human embryonic kidney cells 
HEPES   2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HIV   human immunodeficiency virus 
HRP2   Histidine-rich protein 2 
HT   hypoxanthine/thymidine medium supplement HEPES 
H2O   deionized water 
IC50 value  half-maximal inhibitory concentration 
IgG   Immunoglobulin G 
IME   Institute for Molecular Biology and Applied Ecology 
ITAM   immunoreceptor tyrosine-based activation motifs 
IT   immunotoxin 
JIR   Jackson ImmunoResearch 
ka   association constant (1/Ms) 
kd   dissociation constant (1/s) 
KD   affinity constant = kd/ka 
l   liter 
pLDH   plasmodium lactate dehydrogenase 
LSM   lymphocyte separation medium 
PCR   Polymerase chain reaction 
PE   phycoerythrin 
PEI   polyethyleneimine 
PO   peroxidase 
M   molar 
MACS   magnetic cell separation 
MCM   Malaria cell culture medium 
mE-ERH fusion protein consisting of the EGF-domains of MSP1, MSP4 and MSP8 (1st and 2nd 
EGF-domain)  
MFI median fluorescence intensity 
min minute 
MMV Medicines for Malaria Venture 
MSP   merozoite surface protein 
MWCO   molecular weight cut-off 
M&N   Macherey-Nagel 
NADPH   nicotinamide adenine dinucleotide phosphate 
NBT   nitro blue tetrazolium chloride 
NEB   New England Biolabs 
Ni-NTA IMAC immobilized metal affinity chromatography using nickel-ions loaded on a 
nitrilotriacetic acid-agarose matrix 
NIP decomplemented non-immune plasma 
NK cells  natural killer cells 
OD600 nm   Optical density at 600 nm 
PAA   poly-acrylamide 
PAGE   poly-acrylamide gelelectrophoresis 
PBS   phosphate buffered saline 
PfMSP4EGF  EGF-domain of PfMSP4 
Pi-PLC   phosphatidylinositol-specific phospholipase D 
PMN   polymorphonuclear neutrophil 
pNPP   para-nitrophenylphosphate 
PVDF   polyvinylidene difluoride 
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QTof   Quadrupole time-of-flight mass spectrometry 
rEK   recombinant enterokinase 
RaM-Fc   Rabbit anti-mouse IgG-Fc Capture Kit 
RU   response units 
scFv   single-chain antibody variable fragment 
SD   standard deviation 
SDS   sodium dodecyl sulfate 
SE   standard error 
SIP   decomplemented semi-immune plasma 
SOE-PCR  Splice by overlap extension-PCR 
SP   sequence encoding for a signal peptide targeting to the apoplast/culture supernatant 
SPR   surface plasmon resonance 
SUB1   subtilisin-like protease 1 
T   temperature 
TEMED   N,N,N',N'-Tetramethylethylendiamin 
TUNEL   terminal deoxynucleotidyl transferase dUTP nick end labeling 
U   unit (1 U = 1 µmol/min) 
V   volt 
Vh   variable region of an antibody’s heavy chain 
V(k/l)l   variable region of an antibody’s (kappa/lambda) light chain 
vol   volumes 
WHO   World Health Organization 
°C   degrees on the Celsius-scale 
 
VII.1.1 Abbreviations in the context of IgG-Fc N-glycan analysis 
A (yellow circle)  galactose 
F (red triangle)  fucose 
Ga (yellow square) N-acetylgalactosamine 
Gn (blue square)  N-acetylglucosamine 
M (green circle)  mannose 
Na (pink diamond) N-acetylneuraminic acid 
U   unsubstituted 
X (brown star)  xylose 
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VII.4 List of oligonucleotides 
All oligonucleotides were ordered from eurofins Genomics and are listed in Table 20. 
 
Table 20 Oligonucleotides 
Name Sequence (5‘-3‘ orientation) Purpose 
AMA1testF GGTATAATTATTGAGAATTC PCR and sequencing of AMA1 gene, 
identification of P. falciparum strains AMA1testR AGGACCATTATTTTCTTGA 
PS5’ ATCCTTCGCAAGACCCTTCCTCT Colony PCR and sequencing of 
pTRA(k)t PS3’ AGAGAGAGATAGATTTGTAGAGA 
pTT5IgG/LC_EcoRI AATAATGAATTCCATGGGATGGTCATG Generation of pTT5_HC-IgG1, 
pTT5_HC-IgA2m(2) and pTT5_LC pTT5IgA_EcoRI AATAATGAATTCCATGGACTGGACCTGG PS3’ AGAGAGAGATAGATTTGTAGAGA 
pHC-IgG1_fwd_SalI AACAGCGTCGACCAAGGGCCCATCGGTCTTC
C Cloning of Ch domain with human codon usage for pTT5_HC-IgG1 pHC-IgG1_rev GGATCCAACCCTTGAGCTGGATCC 
pCk-hCU_fwd_BsiWI AACAACCGTACGGTGGCTGCACCATCTGTCT
TC Cloning of Ck domain with human 
codon usage for pTT5_HC-IgG1 pCk-hCU_rev_XbaI AACAACTCTAGACTAACACTCTCCCCTGTTG
AAGCTCTT 
pTT_seq_fwd CCACTTTGCCTTTCTCTCC Colony PCR and sequencing of 
pTT5(SH8Q2) pTT_seq_rev GAGAGACACAAAAAATTCC 
2.44Vh_fwd_AgeI AACAACACCGGTGTACATTCCGATGTGCAGC
TTCAGGAGTCGGG Cloning of pTRAkt_2.44HC-IgG1 2.44Vh_rev_SalI GTTGTTGTCGACGCTGAGGAGACGGTGACCG
TGGTCCC 
2.44Vl_fwd_AgeI AACTGCAACCGGTGTACATTCCGAAATTGTC
CTCACCCAGTCTCC Cloning of pTRAkt_2.44LC 2.44Vl_rev_BsiWI GTTGTTCGTACGTTTTATTTCCAACTTTGTCC
CC 
2.44Vh_fwd_SfiI AACAACGGCCCAGCCGGCCATGGCCGATGT
GCAGCTTCAGGAGTCGGG 
Generation of 2.44scFv by SOE-PCR 
and subsequent and cloning of 
pTT5SH8Q2_EGbR201K-2.44 
2.44Vh_rev_linker GGAGCCGCCGCCGCCAGAACCACCACCACC
AGAACCACCACCACCTGAGGAGACGGTGAC
CGTGGTCCC 
2.44Vl_fwd_linker GGCGGCGGCGGCTCCGGTGGTGGTGGATCC
GAAATTGTCCTCACCCAGTCTCC 
2.44Vl_rev_NotI ATGGTGGGCGGCCGCTTTTATTTCCAACTTT
GTCCCC 
4G2Vh_fwd_AgeI AACAACACCGGTGTACATTCCGAGGTTCAGC
TTGTTGAATCTGG Cloning of pTRAkt/pTT5_4G2HC-IgG1 4G2Vh_rev_SalI GTTGTTGTCGACGCAGAAGAAACGGTCACA
GAGGTTCCC 
4G2Vh_rev_NheI GTTGTTGCTAGCAGAAGAAACGGTCACAGA
GGTTCCC Cloning of pTRAt_4G2HC-IgA2m(2) 
4G2Vl_fwd_AgeI AACTGCAACCGGTGTACATTCATCTATTGAG
CTGACCCAGTCTCC Cloning of pTRAkt/pTT5_4G2LC 4G2Vl_rev_BsiWI GGTGGTCGTACGCTTCAGCTCCAACTTAGTA
CCACC 
pAgeI-Mut_fwd TCAAGGACTACTTCCCCGAGCCGGTGACGG Mutation of endogenous AgeI restriction 
site in the IgG1-Fc-region sequence in 
pTT5_4G2IgG1hCU to facilitate 
replacement of V-region sequences via 
AgeI and SalI 
pAgeI-Mut_rev CCGTCACCGGCTCGGGGAAGTAGTCCTTG
A 
Restriction sites used for cloning purposes are underlined.  
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VII.5 Plasmids 
 
Figure 44 pTRA(k)t-based antibody expression vectors for N. benthamiana plants. 
Binary plant expression vectors based on pTRA(k)t encoding human IgG1-heavy chain (A), kappa-light chain 
(B) or IgA2m(2)-heavy chain (C) are shown, respectively.  
p35SS: 35S promoter of the Cauliflower mosaic virus with duplicated enhancer region; 5’ UTR: 5’ untranslated 
region of the Tobacco Etch virus; SP: murine immunoglobulin heavy chain signal peptide targeting to the 
extracellular space (plant apoplast). Vh: variable heavy chain region.; Vl: variable light chain region; Ch: 
constant region of a human IgG1 (allotype m17.1) or IgA2m(2) (without tailpiece for dimerization) heavy chain; 
Cl: constant region of a human kappa light chain (allotype Km3); pA35S: polyadenlytion signal of the 
Cauliflower mosaic virus; SAR: scaffold attachment region; RB: right border; RK1 ori: origin of replication (A. 
tumefaciens); AmpR/CarbR: Gene for ampicillin (E. coli) or carbenicillin (A. tumefaciens) resistance; ColE1 ori: 
origin of replication (E. coli); LB. left border; nptII: gene for kanamycin resistance in stably transformed plants 
(only pTRAkt vectors). Restriction sites enabling in-frame insertion of the V genes are highlighted in coloured 
boxes: purple: AgeI; grey: SalI; green: NheI; yellow: BsiWI. 
Ch- and Cl-domains were codon-optimized for N. benthamiana. 
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Figure 45 pTT5-based IgG1 expression vectors for HEK293-6E cells. 
Expression vectors based on pTT5 [80] encoding human IgG1-heavy chain (A) or kappa-light chain (B).  
pCMV: Promoter of the Cytomegalie virus; TPL and enh MLP: Adenovirus tripartite leader and enhancer of the 
major late promoter, both effective enhancer of translation; SP: murine immunoglobulin heavy chain signal 
peptide targeting to the extracellular space; Vh: variable region of a heavy chain.; Vl: variable region of a light 
chain; Ch: constant region of a human IgG1 (allotype m17.1) or IgA2m(2) (without tailpiece for dimerization) 
heavy chain; Cl: constant region of a human kappa light chain (allotype Km3); pA: polyadenlytion signal; oriP: 
origin of replication for HEK293-6E cells; AmpR: Gene for ampicillin resistance in E. coli; pMB1-ori: origin of 
replication for E. coli; Restriction sites enabling in-frame insertion of the V regions are highlighted in coloured 
boxes: purple: AgeI; grey: SalI; yellow: EcoRI; pink: XbaI; yellow: BsiWI. 
Ch- and Cl-regions were used with a mammalian codon usage except for Ch (IgA2m(2)) which was optimized 
for N. benthamiana. 
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Figure 46 pTT-o-GFPq vector for cytosolic co-expression of GFP in HEK293-6E cells. 
The pTT-o-GFPq vector (based on pTT5 [80]) was used for the co-transfection of HEK293-6E cells for the 
monitoring of transfection efficiency. The nomenclature of the vector features is as in Figure 45 except for: GFP: 
sequence for the green fluorescent protein.  
 
 
 
Figure 47 pTT5SH8Q2_EGbR201K-scFv expression vector for HEK293-6E cells. 
Expression vector based on pTT5 [80] encoding Granzyme B-scFv fusion protein. The nomenclature of the 
vector features is as in Figure 45 except for: SP: murine immunoglobulin kappa light chain signal peptide 
targeting to the extracellular space; rEK cleavage site: N-terminal protective peptide bearing an rEK cleavage 
site for activation of Gb after expression; Granzyme B (R201K): SerpinB9-resistant Gb mutant. Restriction sites 
enabling in-frame insertion of the scFvs are highlighted in coloured boxes: grey: SfiI; blue: NotI. 
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VII.6 Ordered DNA sequences 
The DNA sequences encoding for the 4G2V regions and for the human IgA2m(2) constant 
domain without the dimerization-tailpiece were ordered from GeneArt®, codon-optimized for 
expression in N. benthamiana (Table 21), as part of a pMK-RQ vector. 
 
Table 21 Ordered DNA sequences 
Name Sequence (5‘-3‘ orientation) 
4G2Vh 
(GenBank ID FJ156082) 
GAGGTTCAGCTTGTTGAATCTGGTGGTGGTCTTGTGCAGCCTGGTAGA
TCTCTTAAGTTGAGCTGTGCTGCTTCCGGTTTCACCTACAGCAATTACG
TTATGGCTTGGGTGAGGCAGGCTCCTACTAAGGGTCTTGAATGGGTGG
CATCCATCAGCACTGGTGCTTACAATACCTACTACAGGGATAGCGTGA
AGGGAAGGTTCACCATCTCTAGGGATAACGCTAAGAACACCCTGTAC
CTGCAGATGGATTCTCTGAGGTCTGAGGATACCGCAACCTACTACTGC
GCTAAGGATATTGATAACAACTACGATTACTTCGATTACTGGGGTCAG
GGAACCTCTGTGACCGTTTCTTCT  
  
4G2Vκl 
(GenBank ID FJ156083) 
TCTATTGAGCTGACCCAGTCTCCTTCTCTGCTGTCTGCTTCTGTTGGTG
ATAGGGTGACCCTTAACTGCAAGGCTTCTCAGGCTTTCTACATCAAGC
TGGCTTGGTATCAGCAGAAGTTGGGAGAGGCTCCTAAGCTGCTGATCT
ACGATTCTAACAGGCTGCAGACCGGAATCCCTTCTAGGTTTTCTGGTA
GCGGTAGCGGAACCGATTTCACCCTTACCATTTCTAGCCTGCAGCCAG
AGGATGTGGCTACTTACTTTTGCCACCAGTACCACTCTGGTTCTGGAA
CTTTTGGTGGTGGTACTAAGTTGGAGCTGAAG 
  
Signal peptide –  
project-unrelated antibody
Vh region –   
IgA2m(2) antibody constant 
domain 
(The NcoI and NheI 
restriction sites used for 
cloning are underlined.) 
 
CCATGGACTGGACCTGGAGAATCCTCTTCTTGGTGGCGGCCGCCACCG
GTGCCCACTCC –
GAGGTTAAGCTGCAAGAATCTGGTCCTGAGCTGAGAAAGCCTGGTGA
GACTGTGAAGATCAGCTGCAAGGCTTCTGGTTACACCTTCACCAACTA
CGGTATGAACTGGGTGAAGCAGGATACTGGTAAGGGTCTTAAGTGGA
TGGGTTGGATCAACACCTTCTCTGGTGAGCCTACCTACGCTGATGATT
TCAAGGGAAGGTTCGCTTTCAGCCTGGAAACTTCTGCTACCACCGCTT
ACCTGCAGATCAACAACCTGAAGAACGAGGATATGGCTACCTACTTCT
GCGTGCAGAGCGTGATCGATAATTGGGGTCCTGGTACTAGCGTGACCG
TGTCATCT –
GCTAGCCCAACCTCTCCTAAGGTGTTCCCTCTGTCTCTTGATAGCACTC
CTCAGGATGGTAATGTGGTGGTTGCTTGCCTTGTGCAGGGATTCTTTCC
ACAAGAGCCTTTGTCTGTGACCTGGTCTGAGTCTGGTCAGAATGTGAC
TGCTAGGAACTTCCCACCTAGCCAGGATGCTTCAGGTGATCTTTACAC
CACCTCTTCTCAGCTTACCCTTCCTGCTACTCAGTGCCCTGATGGTAAG
TCTGTTACCTGCCATGTGAAGCACTACACCAACTCCTCACAGGATGTT
ACTGTGCCTTGTCGAGTTCCTCCTCCTCCACCTTGTTGTCATCCTAGGT
TGTCTCTTCACAGGCCTGCTCTTGAGGATCTTCTGCTTGGATCTGAGGC
TAACTTGACCTGCACTCTTACTGGTCTTAGGGATGCTAGTGGTGCTACT
TTTACCTGGACCCCATCCTCTGGAAAGTCTGCTGTTCAAGGTCCTCCTG
AGAGAGATCTTTGCGGTTGCTACTCCGTTTCTTCTGTGCTTCCTGGTTG
TGCTCAGCCTTGGAATCATGGTGAGACATTCACTTGCACTGCTGCTCA
CCCTGAGCTTAAGACTCCTCTTACCGCTAACATCACCAAGAGCGGTAA
TACCTTCAGGCCAGAGGTTCACCTTCTTCCACCTCCATCTGAGGAACTT
GCTCTTAACGAGCTTGTGACCCTTACTTGCCTTGCTAGGGGTTTCAGCC
CTAAGGATGTTCTTGTGAGATGGCTGCAGGGTTCTCAAGAGCTTCCTA
GAGAGAAGTACCTGACCTGGGCTTCTAGGCAAGAACCTTCTCAGGGT
ACTACTACCTACGCTGTGACCTCTATTCTTAGGGTGGCAGCTGAGGAT
TGGAAAAAGGGTGAGACCTTCTCCTGCATGGTTGGTCACGAGGCTTTG
CCTCTTGCTTTCACCCAAAAGACCATCGATAGGATGGCT 
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